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foreword
Professor Jan Copeland
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The evidence base of high-quality cannabis research is building in a variety of topics, including the epidemiology of 
cannabis use, its relationship to psychosis and other mental health problems, and its respiratory-related harms, to 
name just a few. Whilst this research provides those working with cannabis users and their families with important 
material for psycho-education, there have been no expert, consensus-based clinical guidelines for the management 
of cannabis-related problems.
The present guidelines are the culmination of more than a decade of research into the screening, assessment, 
and management of cannabis-related problems. Although there is a growing literature on a range of motivational, 
cognitive-behavioural, and contingency-management interventions, there are not sufficient data to submit 
to a meta-analysis. These guidelines aim to provide clinicians with a reference point for the management of 
cannabis-related problems. Health-care practitioners may be confronted with client presentations ranging from 
occasional cannabis use through to dependence; the presentations may include mental health symptoms and 
acute behavioural disturbances, such as psychosis and aggression. This monograph is suitable for health-care 
practitioners who work with a variety of cannabis-using individuals. Readers will be made familiar with the various 
aspects of interventions, including assessment, withdrawal, and psycho-education.
I wish to thank those colleagues who have worked with me closely over the years on our cannabis intervention 
team, particularly Etty Matalon, Dr Greg Martin, and Dr Wendy Swift. Special thanks are owed to Dr Amie Frewen, 
who led this project and oversaw the work of the international experts who contributed to these guidelines.
Please visit the centre’s website, at www.ncpic.org.au, for further postings of clinical measures and summaries of 
research on interventions in cannabis-use disorder as they emerge.
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glossary of terms
AOD (alcohol and other drug) 
workers 
All those who work in alcohol- or drug-treatment settings in a clinical capacity. This 
includes, but is not limited to, nurses, medical practitioners, psychiatrists, psychologists, 
clinicians, social workers, and other workers in the sector
Bong A water pipe used to smoke cannabis (may also be used with tobacco). The section that 
contains cannabis is the cone piece. Therefore the unit of measurement is referred to as  
a ‘cone’
Brief intervention A minimal interaction with a medical or mental health professional, ranging in duration 
from several minutes up to six or more sessions. This term is used primarily in the context 
of treatment for substance use problems
Cannabinoid An organic chemical substance belonging to a group that comprises the active 
constituents of cannabis. The three main cannabinoids are: THC, CBD, and CBN
Cannabidiol (CBD) A cannabinoid found in cannabis. It is a major constituent of the plant, representing up to 
40% in its extracts. It is found in inverse ratio to THC, that is as the level of THC rises, that 
of CBD falls. Recent studies have suggested that CBD has antipsychotic properties
Cannabinol (CBN) CBN (Cannabinol) is produced as THC ages and breaks down. It is thought to potentiate 
THC's disorienting qualities
Comorbidity In these guidelines, refers to the concurrence of an alcohol and or other drug (AOD)-use 
disorder with one or more mental health conditions. Also known as co-occurring or dual 
diagnosis
Decriminalisation Drug policy whereby possession of a drug for personal use is treated as a misdemeanour 
rather than a criminal offence but remains illegal
Hashish A purified resin, prepared from the flowering tops of the female cannabis plant, that is 
smoked or chewed. It is considered to be the most potent preparation of cannabis
Joint Herbal cannabis or resin (sometimes mixed with tobacco or other plant material) rolled 
into a cigarette
Mental disorder Refers to the presence of a mental disorder (other than substance use disorders) as 
defined by DSM-IV-TR
Psychosis Any significant mental disorder that is characterised by a loss of contact with reality by 
delusions, hallucinations and/or disorder and inability to interpret information and make 
sense of the world
Stepped care Use of interventions that start at the least intensive and after a period of monitoring are 
either "stepped up" in intensity or inversely "stepped down" after treatment gains have 
been made
Tetrahydrocannabinol (THC) The cannabinoid that is responsible for the "high"
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1
introduction
The Management of Cannabis Use Disorder and Related 
Issues – A clinician’s guide, provides the knowledge 
essential to help people reduce, cease, or manage 
their cannabis-use problems. The manual aims to 
provide facts, figures, and useful techniques to assist 
clinicians in providing evidence-based treatments 
for cannabis users wishing to change the patterns 
of their use. The manual also provides a number of 
worksheets to use with cannabis clients.
The manual is divided into 12 sections: 
Chapter 1: Background information
Chapter 2:  Working with cannabis users
Chapter 3: Screening for cannabis use
Chapter 4: Assessment
Chapter 5: Withdrawal management
Chapter 6: Brief interventions
Chapter 7: Special considerations
Chapter 8: Family interventions
Chapter 9: Psycho-education and social support
Chapter 10: Treating mental health in cannabis users
Chapter 11: Screening tools
Chapter 12: Worksheets
This manual is not intended as a substitute for 
obtaining training and experience in managing 
substance use disorders or for generalist counselling 
skills. It is designed to complement your existing skills 
and to help you offer your cannabis-using clients the 
greatest therapeutic benefits.
Examples of what to say to clients appear in the 
following format:
“Here’s a suggestion you might try.”
Who are these guidelines for?
These guidelines are for all clinicians working with 
young people and adults who are experiencing 
cannabis-related problems. Throughout these 
guidelines, we refer to you as “clinician” and the 
person seeking help as the “client”. Clinicians who 
may find these guidelines useful include (but are not 
limited to) alcohol and other drug workers, nurses, 
mental health workers, youth workers, alcohol 
and other drug specialist doctors, health workers, 
psychologists, psychiatrists, child-protection workers, 
probation and parole officers, and general medical 
practitioners. These guidelines will be useful whether 
you work in a generalist health-care setting, an in-
patient unit, or an outpatient setting. They may be 
especially useful for general medical practitioners. 
General practitioners are in an ideal position to 
identify problematic cannabis use, given the high 
proportion of the population who attend primary 
health-care services each year.
Given the differences in workers’ roles, education, 
training, and experience, not every reader will be able 
to address all issues to the same extent. Workers 
should use these guidelines within the context of 
their role and scope of practice. In other words, the 
guidelines do not substitute for the need for skill, 
practice, or supervision, and expert clinical judgment 
should be used when applying them.
Core competencies
These evidence-based guidelines are not designed to 
teach core clinical skills and do not replace specialist 
training courses. To use them, you will require 
competency in the following areas:
• basic counselling skills, such as building a 
therapeutic alliance, active listening, active 
reflections
• general alcohol and other drug assessment
• knowledge of common mental health conditions, 
such as anxiety and depression
• evidenced-based interventions, such as 
motivational enhancement therapy and cognitive 
behavioural therapy
• cultural sensitivity
• skills to engage young people.
Evidence and recommendation rating system
The Australian National Health and Medical 
Research Council (NHMRC) and similar organisations 
internationally are developing a process for assessing 
evidence and formulating recommendations for clinical 
guidelines. This process involves the development of a 
new evidence hierarchy that builds upon the NHMRC’s 
“Level of Evidence” but is less restrictive, and allows 
for the grading of studies that involve diagnosis, 
prognosis, ætiology, and screening.
Details of the consultation levels and grades can be 
found at http://www.nhmrc.gov.au
The five components that are considered in judging a 
body of evidence are: 
• volume of evidence (which includes the number 
of studies, sorted by their methodological quality 
and their relevance to patients)
• consistency of study results
• potential clinical effect of the proposed 
recommendation (including the balance of risks 
and benefits, the relevance of the evidence to 
the clinical question, the size of the patient 
population, and resource matters)
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• generalisability of the body of evidence to the 
target population
• applicability of the body of evidence to the 
Australian health-care context.
For the current guidelines, the literature has been 
reviewed by at least two experts and endorsed by 
a wider panel of clinicians and researchers with 
specific cannabis knowledge and expertise. The 
recommendation is summarised at the end of each 
chapter and given a grade based on the following:
Grade Recommendation
A Body of evidence can be trusted to guide 
practice
B Body of evidence can be trusted to guide 
practice in most situations
C Body of evidence provides some support for 
recommendation(s), but care should be taken 
in its application
D Body of evidence is weak, and 
recommendation must be applied with caution
More information about the grading process can be 
found in Appendix 1. 
All URLs given were accessed in June 2009. 
chapter 1: background 
information
1.1 Cannabis prevalence
Cannabis is the most widely used illicit substance 
in the western world. During the 1990s, incidence of 
cannabis use increased, particularly among young 
people. Recent data suggest that the upward trend is 
levelling off, albeit at historically high levels (see Table 
1) (EMCDDA, 2008).
Prevalence and patterns of cannabis use in 
Australia
In 2007, of 17.2 million Australians aged 14 years or 
older, one in three (33.5%, about 5.8 million) had used 
cannabis at some point in their lives; almost one in ten 
(9.1%, 1.6 million) had used cannabis in the previous 12 
months; and more than 600,000 (3.5%) had used it in 
the week before the survey (AIHW, 2008a). Higher rates 
are noted in particular subgroups. Amongst indigenous 
populations, for example, rates of weekly cannabis use 
of up to forty-five per cent have been reported (Clough 
et al., 2004). Higher rates are noted amongst young 
people also and amongst those with mental health 
diagnoses.
Prevalence and incidence of cannabis use in the 
U.S.
In 2007, approximately 40% of Americans aged 12 
years or older reported having used cannabis at 
some stage in their life. Use in the past month was 
approximately 5.8% (14.4 million). The majority of 
current users were under age 25 (highest rates in 18- 
to 20-year-olds) and male (SAMHSA, 2008).
Prevalence and incidence of cannabis use in 
Europe
Of all Europeans aged 15–64 years, approximately 20% 
(65 million) had tried cannabis at least once in their 
lives; 1–11% had used cannabis in the previous year; 
and approximately half of the latter had used cannabis 
in the last month (EMCDDA, 2008).
Table 1: 2008 Prevalence of cannabis abuse as 
percentage of the population aged 15–64
Europe
  Western and central 0.8–11.2%
  Southeastern 0.9–4%
  Eastern 1.5–3.9%
America
  Central 1.3–6.7%
  North 3.1–17%
  South 1.6–7%
  Caribbean 1.9–10.7%
Oceania  0.1–29.5%
Africa
  East 0.2–9.1%
  North 0.05–9.6%
  Southern 2.1–17.7%
  West and central 0.9–21.5%
Asia
  Central 3.4–6.4%
  East & South-East 0.002–4.2%
   Near & Middle East/South West 
Asia
0.1–8.5%
  South Asia 1.5–3.3%
N.B. This chart contains United Nations Office of Drugs and Crime 
estimates based on local studies, studies of special population 
groups, and/or law-enforcement agencies’ assessments (UNODC, 
2008).
1.2 Dosage
The global cannabis commission report on cannabis 
(Room et al., 2008) suggests that a typical joint 
contains between 0.25g and 0.75g of cannabis plant 
matter but that the actual amount of THC absorbed 
depends on multiple factors and is difficult to quantify. 
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The proportion of THC delivered to the lungs has 
been estimated to range from 20% to 70%. The 
bioavailability of THC (the fraction of THC that reaches 
the bloodstream or brain) is reported to be from 5% 
to 24% (Hall & Solowij, 1998; Heustis et al., 2005; 
Iversen, 2007).
1.3 Potency 
Cannabis is a plant that contains at least 60 active 
chemicals known as cannabinoids , several of which 
are biologically active. The potency (or strength) 
of cannabis is known to vary widely depending 
upon the variety and growing conditions (WHO, 
1997). In relation to potency, the cannabinoids of 
greatest interest are tetrahydrocannabinol (THC ) and 
cannabidiol (CBD). THC is responsible for most of the 
psychoactive effects of cannabis, including the “high”. 
Recent studies suggest that CBD has antipsychotic and 
anxiolytic properties (Potter, Clark, & Brown, 2008) 
that may offset some of the psychoactive effects of 
THC. Morgan and Curran (2008) suggested that the 
potency of cannabis is not due simply to the amount of 
THC in the sample, but also to the ratio of THC to CBD. 
The media have claimed that cannabis potency has 
increased 20- to 30-fold in recent decades; research 
suggests, however, that cannabis potency has at least 
doubled in the past 10 years (McLaren et al., 2008).
Below is a brief summary of countries that have 
examined cannabis potency: 
Reference Location Sample size THC concentration
Advisory Council on the 
Misuse of Drugs (2008)
UK 2,921 Herbal cannabis mean = 16.2% (4.1-46)
Resin mean= 5.9% (1.3-27.8)
EMCDDA (2004) European Union 
and Norway 
(1998-2002)
59,369 Herbal cannabis mean = 7.7% 
Resin mean= 8.2%
ElSohly et al. (2000) USA (1980-1997) 35,213 Herbal cannabis=2% (1980) 4.5% (1997)
Poulsen & Sutherland 
(2000)
NZ (1976-1996) 1,066 Cannabis leaf mean = 1%, heads 3.5%
Cannabis oil mean = 13.5% (1995)
1.4 Demand for treatment
In Australia, between 2005 and 2006, 44% of all 
treatment presentations to government alcohol and 
other drug treatment services included cannabis as 
a drug of concern (AIHW, 2008b). Cannabis was the 
primary concern in 23% of these cases. It was the 
most common principal drug of concern, followed 
by alcohol, for adolescents aged 10–19 years (AIHW, 
2008b). In the United States and the European Union, 
treatment admissions are slightly less commonly for 
cannabis. Since 2001, rates of treatment admission 
for cannabis have stayed relatively stable at 15–16% 
(SAMHSA, 2009). For example, the Treatment Episode 
Data Set found that cannabis problems were involved 
in 16% of admissions to publicly funded U.S. alcohol 
and other drug treatment services (SAMHSA, 2009). 
In the European Union, cannabis was the second-most 
common illicit drug of primary concern, with 15% of 
all clients and 27% of new clients presenting with a 
primary cannabis problem (EMCDDA, 2008).
The number of client presentations for cannabis 
to alcohol and other drug treatment programs is 
increasing in all western countries. From 1996 to 
2003, cannabis treatment provision accounted for 
the greatest increase in drug of principal concern in 
the EU. Since 1993, the U.S. has seen a doubling of 
requests for treatment for cannabis use relative to its 
population (SAMHSA, 2002). Minor increases have 
been noted in Australia from 2000 to 2007 (AIHW, 
2008b).
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Though the numbers seeking treatment are high, the 
majority of cannabis users do not seek professional 
support for their cannabis use (Agnosti & Levin, 
2004). This may be for a number of reasons, 
including: believing that treatment for cannabis use is 
unnecessary; not being motivated to stop using; and 
feeling that treatment is stigmatising (Gates et al., 
2008). When cannabis users present to non-specialist 
services such as general medical practitioners, 
they usually do so for a secondary concern, such 
as anxiety or depression, rather than specifically 
for their cannabis use (Roxburgh & Degenhardt, 
2008). Additionally, cannabis dependence may be 
seen as qualitatively different from the problems of 
populations seen in conventional “drug treatment” 
agencies. An individual may, therefore, conclude that 
he or she will not have anything in common with the 
clients of those conventional agencies, and that the 
programs and services offered at those agencies will 
not be relevant to cannabis dependence. 
1.5 Cannabis-related problems 
Although the short-term negative consequences 
of cannabis use are fairly well-known, the long-
term effects of regular cannabis use are less so. 
Determining the long-term effects of cannabis has 
been difficult, due to many factors, including high 
rates of multiple drug use, a long lead time for long-
term effects to become apparent, and a lack of 
literature examining harmful use, although this is now 
changing. A summary of known health concerns is 
given in Table 2.
Table 2: Harms associated with cannabis use
Risks of acute 
intoxication
impaired attention, memory, and psychomotor performance while intoxicated•	
cannabis-induced psychosis•	
increased risk of motor-vehicle accidents•	
Most probable 
chronic effects
subtle cognitive impairment in attention, memory, and the organisation and integration of complex •	
information (of unknown reversibility, though not likely to be grossly debilitating)
increased risk of developing a dependence syndrome•	
adverse respiratory effects, such as chronic bronchitis (greater if cannabis is used with tobacco)•	
Possible chronic 
effects 
increased exposure to xerostomia (dry mouth), which can lead to tooth decay, gum disease, and other •	
oral-health issues
some evidence that cannabis may affect human female fertility (cannabis has been found to reduce •	
sperm count and testosterone levels in some male animals, but this has not been established in 
humans)
in children who have been exposed to cannabis in the womb, more difficulties with problem-solving •	
and attention, which may continue into adulthood and reduce education potential
an increased likelihood of pre-cancerous changes•	
increased rate of lung cancer •	
increased possibility of heart attack in people who have risk factors for heart disease (e.g. obesity •	
and/or cigarette smoking)
Probable risks 
amongst specific 
populations
associated with adolescent cannabis use:•	
poorer school performance and outcomes•	
lower levels of degree attainment by age 25•	
higher unemployment•	
lower levels of life satisfaction•	
leaving the family home•	
early sexual activity and teenage pregnancy •	
other illicit drug use and dependence •	
in women who continue to smoke cannabis during pregnancy, increased risk of having a low-•	
birthweight baby (which can lead to mortality, morbidity, and disability)
exacerbation of some mental health conditions such as depression , anxiety, and schizophrenia •	
Adapted from Hall & Solowij, (1998); Room et al., (2008)
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1.6 Cannabis intoxication, abuse, and 
dependence 
Assessing dependence and abuse can be an 
important clinical tool for communicating with other 
professionals, communicating the nature of the 
issue to the client, and assessing outcomes. It can 
be done using structured clinical interviews and 
questionnaires. Two major international classification 
systems exist for mental disorders: the International 
Classification of Disorders, version 10 (ICD-10) (WHO, 
1992) and the Diagnostic and Statistical Manual, 
Version IV (DSM-IV-TR) (APA, 2000). The latter is the 
most commonly used system in the U.S. and the 
former, in Europe and in Australia. The diagnostic 
criteria for cannabis intoxication, abuse, and 
dependence according to each classification system 
are listed below. Note that the DSM-IV-TR includes a 
disorder specific to cannabis use, whereas the ICD-10 
specifies only a generic diagnosis.
A) Acute cannabis use
DSM-IV-TR cannabis intoxication
The essential feature of cannabis intoxication is 
the development of behavioural and psychological 
disturbances (e.g. impaired motor coordination, 
euphoria, anxiety , sensation of slowed time, 
impaired judgment, social withdrawal) during, or 
shortly after, cannabis use. The psychoactive effects 
are accompanied by two (or more) of the following 
signs, developing within two hours of cannabis use: 
conjunctival injection (bloodshot eyes), increased 
appetite, dry mouth, and tachycardia (rapid heart 
rate). These symptoms are not due to a general 
medical condition and are not better accounted for by 
another mental disorder.
The pattern of onset and duration of cannabis 
intoxication is variable. If cannabis is smoked, 
intoxication usually occurs within minutes and lasts 
approximately three to four hours. Onset may take 
hours and the effects may be longer lasting, however, 
when cannabis is consumed orally. The DSM-IV-TR 
notes that the magnitude of effects will vary with dose, 
administration route, and personal characteristics, 
such as tolerance of and sensitivity to cannabis.
Importantly the DSM-IV-TR adds a qualifier, with 
perceptual disturbances, to cannabis intoxication in 
which the individual experiences hallucinations with 
intact reality testing or in whom auditory, visual, or 
tactile illusions occur in the absence of a delirium. In 
other words, this qualifier is noted only when the user 
realises that the perceptual disturbances are induced 
by cannabis use. This experience is distinguished from 
substance-induced psychotic disorder.
ICD-10 acute intoxication 
Acute intoxication is a transient condition that follows 
the administration of alcohol or other psychoactive 
substance and results in disturbances in level 
of consciousness; cognition; perception; affect; 
behaviour; or other psycho-physiological functions. 
The ICD-10 specifies that this diagnosis should be a 
main diagnosis only in cases in which intoxication 
occurs in the absence of more-persistent alcohol- or 
drug-related problems. When such problems exist, 
precedence should be given to diagnoses of harmful 
use (f1x.1), dependence syndrome (f1x.2), or psychotic 
disorder (f1x.5).
B) Cannabis abuse and harmful use 
ICD-10 (WHO, 2004) 
Harmful use
DSM-IV-TR (APA, 2000) 
Abuse
psychoactive substance •	
use that causes damage 
to the physical or mental 
health of the user
harmful patterns of use •	
are criticised frequently 
by others
harmful patterns of use •	
are associated frequently 
with adverse social 
consequences 
maladaptive pattern of •	
substance use leading 
to clinically significant 
impairment or distress, 
as manifested by one (or 
more) of the following, 
occurring within a 
12-month period:
recurrent failure to fulfil •	
major role obligations 
at work, school, or 
home
recurrent cannabis use •	
in situations in which it 
is physically hazardous
C) Cannabis dependence
Making a diagnosis of cannabis dependence helps 
clinicians to give feedback about the harms associated 
with their client’s cannabis use. Dependence is 
characterised by marked distress resulting from a 
recurring cluster of problems that reflect impaired 
control over cannabis use and continuing cannabis use 
despite harms arising from it. See Table 3 for a list of 
the criteria in both classification systems.
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Table 3: Cannabis-dependence criteria (ICD-10 and DSM-IV-TR)
Both classification systems state that a diagnosis is made if three of the following have occurred within a 12-month 
period:
ICD–10 (WHO, 2004) dependence criteria DSM-IV-TR (APA, 2000) dependence criteria
A strong desire or sense of compulsion to take 
cannabinoids
There is a persistent desire to use cannabis, or there has been 
one or more unsuccessful efforts to cut down or control  
cannabis use
Difficulties in controlling cannabinoid-taking behaviour  
in terms of its onset, termination, or levels of use
Cannabis is taken in larger amounts or over a longer period than 
the person intended
A physiological withdrawal state when cannabinoid 
use has ceased/reduced, as evidenced by a withdrawal 
syndrome for cannabinoid; or use of the same (or a 
closely related) substance with the intention of relieving 
or avoiding withdrawal symptoms 
Withdrawal, characterised by either of the following:
a) symptoms of withdrawal
b)  the same substance is taken to relieve or avoid withdrawal 
symptoms 
Evidence of tolerance, such that increased doses of 
cannabinoid are required in order to achieve effects 
originally produced by lower doses
Tolerance, as defined by either of the following:
a)  a need for markedly increased amounts of the substance to 
achieve intoxication or desired effect;
b)  markedly diminished effect with continued use of the same 
amount of the substance
Progressive neglect of alternative pleasures or interests 
because of cannabinoid use or an increased amount 
of time necessary to obtain or take the substance or to 
recover from its effects
A great deal of time is spent in activities necessary to get 
cannabis (e.g. using cannabis or recovering from its effects)
Persisting with cannabis use despite clear evidence of 
overtly harmful consequences (though efforts should  
be made to determine that the user was actually, or  
could be expected to be, aware of the nature and extent 
of the harm)
Continued cannabis use despite knowledge of having persistent 
or recurrent social, psychological, or physical problems that are 
caused or exacerbated by the use of cannabis
Narrowing of the personal repertoire of patterns 
of cannabinoid use has also been described as a 
characteristic feature
Important social, occupational, or recreational activities are  
given up or have been reduced because of cannabis use
1.7 Risk of dependence 
The majority of people who try cannabis do not 
become dependent on it. The adult lifetime prevalence 
rates for cannabis dependence are around 9–15% 
(Degenhardt, Hall, & Lynskey, 2001; Anthony, Warner, 
& Kessler, 1994). As with other drugs, the risk of 
developing dependence appears to be greatest 
amongst those with a history of frequent or daily 
cannabis use and those who initiate use early (Coffey 
et al., 2002).
1.8 Cannabis withdrawal syndrome
Clinical studies over the last decade have produced 
evidence for a cannabis withdrawal syndrome. 
Currently, these symptoms are not documented in 
the DSM-IV-TR or the ICD-10. The proportion of clients 
reporting cannabis withdrawal in treatment studies 
has ranged from 50% to 95% (Budney & Hughes, 
2006). Symptoms typically emerge after one to three 
of days of abstinence, peak between days two and 
six, and typically last from four to 14 days (Budney 
et al., 2003). The severity of withdrawal symptoms 
has been linked with difficulty achieving abstinence 
(Stephens, Roffman, & Simpson, 1993; Copeland et 
al., 2001; Budney et al., 2000). Discussing withdrawal 
may therefore be an important aspect of treatment. 
We recommend using psycho-education (see 
“worksheets” section) to indentify typical withdrawal 
symptoms and patterns, so that dealing with 
withdrawal can be incorporated into a treatment plan.
The most commonly experienced withdrawal 
symptoms appear in Table 4.
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Table 4: Cannabis-withdrawal symptoms
Symptom Duration Prevalence 
Anger, aggression, irritability Few days to 3 weeks Highly prevalent
Anxiety/nervousness Few days to 3 weeks Highly prevalent
Restlessness Few days to 3 weeks Highly prevalent
Sleep difficulties, including strange dreams Few days to 4+ weeks Highly prevalent
Craving Few days Common
Weight change/decreased appetite Generally in the first week Common
Depressed mood Unclear, generally 4+ weeks Less common
Physical discomfort: stomach pain, chills, sweating, or 
shakiness
Few days to 3 weeks Less common
1.9 Cannabis treatments
Attracting clients to treatment is a challenge for 
many services offering treatment for substance use, 
including those managing cannabis-related problems. 
Stephens et al. (2007) reported that of those who 
met the criteria for cannabis dependence or abuse 
in 2003, only 9.8% reported receiving treatment, a 
lower proportion than of those meeting the criteria for 
other drug types. Unfortunately, as with other drugs, 
many people resume using cannabis after they have 
completed treatment. Despite this, treatment improves 
their lives by helping them reduce the amount of 
cannabis they use and mitigating the associated 
health and social problems. As we learn more about 
cannabis and its users’ related problems, more-
effective treatment will be developed and evaluated. 
Current research into cannabis-specific interventions 
is summarised below.
A) Psychological interventions
To date, nine randomised trials for adults with 
cannabis abuse/dependence have been reported in 
the published literature (Budney & Hughes, 2006). 
Results indicate that behaviourally based outpatient 
treatments are effective for reducing cannabis 
consumption and engendering abstinence. Cognitive–
behavioural therapy (CBT) has been the cornerstone 
of most interventions (Budney et al., 2007). CBT 
includes teaching and practice of behavioural and 
cognitive skills to deal with risk factors (drug refusal, 
coping with craving, managing mood, avoiding 
environments offering high risk of drug use, finding 
alternative activities, etc.). It essentially focuses on 
how the person feels about and responds to thoughts 
and experiences and on ways of tackling negative 
thoughts.
A range of behaviour-based treatment options have 
been shown to be efficacious in the treatment of 
cannabis dependence. These include Motivational 
Enhancement Therapies (MET) and a combination of 
Cognitive Behavioural Therapy (CBT ) and Contingency 
Management (CM). These approaches will be 
discussed in detail in chapter six.
B) Pharmacological interventions
Currently, there are no approved medications 
for cannabis dependence or withdrawal-related 
symptoms. Research over the past ten years has 
begun to explore medications that may either block 
the symptoms of cannabis withdrawal or block the 
effects of cannabis. These types of medications are 
still in an experimental stage. Further information is 
included in chapter five.
C) Self-help/mutual-support groups
Whilst there are no outcome studies, cannabis users 
may find peer-support programs helpful as has 
been reported by those with alcohol and other drug 
problems. A self-help group is any group that has the 
aim of providing support, practical help, and care for 
group members who share a common problem. The 
two most widely available types of support groups are 
(1) Marijuana Anonymous/Narcotics Anonymous and 
(2) Self Management and Recovery Training (SMART) 
groups.
Narcotics Anonymous (NA) and the specifically 
designed Marijuana Anonymous (MA) are 12-step, 
spiritually-based groups. The primary purpose of MA 
is “to stay free of cannabis and to help the cannabis 
addict who still suffers achieve the same freedom”. 
No experimental studies unequivocally demonstrated 
the effectiveness of alcoholics anonymous or 12-
step approaches for reducing alcohol dependence or 
problems (Ferri, Amato, & Davoli, 2006), and none 
exist for cannabis. Clients wishing to attend such 
groups should not be discouraged from doing so.
Other mutual-support groups, not based on the 
12-step model, such as SMART (Self Management 
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and Recovery Training) groups (including online 
groups), are also available in many countries (e.g. 
http://www.smartrecoveryaustralia.com.au/). These 
groups are based on CBT principles, are practical and 
solution-focused, and teach group members to:
• enhance and maintain motivation to abstain;
• cope with urges;
• problem-solve (managing thoughts, feelings, and 
behaviours);
• balance their lifestyles (balancing momentary and 
enduring satisfactions)
To date there are no outcome data available on the 
SMART program. In an internal evaluation of Sydney 
participants, more than four out of every five (83%, or 
90) respondents indicated that they thought that the 
programme had given them “lots of help” (AER, 2006).
1.10 Policy response to cannabis harms
Australian cannabis policy currently is guided 
by the National Cannabis Strategy 2004–2009 
(Commonwealth of Australia, 2006), which 
encompasses:
• supply reduction strategies to disrupt the 
production and supply of illicit drugs and to 
control and regulate licit substances;
• demand reduction strategies to prevent the 
uptake of harmful drug use, including abstinence-
oriented strategies and treatment to reduce drug 
use; and
• harm reduction strategies to reduce drug-related 
harm to individuals and communities
A number of countries, particularly Australia and 
France, have established specialised cannabis-
treatment clinics to improve treatment access for 
those with cannabis-related problems. Cannabis 
remains illegal in all states of Australia, but it has 
been decriminalised in some states. Decriminalisation 
involves replacing penal sanctions (i.e. imprisonment) 
with civil penalties (i.e. fines and education).
States with prohibition with civil penalties 
(infringement notices) are:
• South Australia (1987)
• Australian Capital Territory (1992)
• Northern Territory (1996)
• Western Australia (2004)
States using prohibition with cautioning:
• Tasmania (1998)
• Victoria (1998)
• New South Wales (2000)
• Queensland (2001)
1.11 International approaches to criminal 
sanctions 
Drugs laws are guided by the 1988 United National 
Convention Against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances. The convention established 
a difference between the intent of trafficking and the 
possession, purchase, and cultivation of substances 
for personal consumption. In various countries, the 
possession of a quantity of cannabis for personal use 
is decriminalised, and there are many other countries 
in which it is no longer a priority for law enforcement or 
in which sentences have been reduced (Jelsma, 2008).
Decriminalisation laws exist in many E.U. countries 
(including Belgium, Italy, the Czech Republic, 
Portugal, and Denmark) and in some U.S. states. 
Some jurisdictions in Europe (Spain and parts of 
the Netherlands and Germany) maintain cannabis’s 
illegality but do not enforce it, resulting in “de facto 
legalisation” of possession in some circumstances of 
small amounts of the drug. In parts of the most well-
known example, the Netherlands, the sale of up to 5g of 
cannabis to adults in retail coffee shops is permitted.
Summary  
of laws
Cannabis remains illegal across the 
world, but a number of countries have 
lessened the penalties for possession of 
small quantities of cannabis, so that it is 
punished by a fine and/or education rather 
than imprisonment. See NCPIC Criminal 
Justice Bulletin, March 2009, for more 
details. www.ncpic.org.au
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chapter 2: working with 
cannabis users
2.1 General principles of working with cannabis 
users
Whilst treatment-outcome research suggests that 
most therapies when directly compared in randomised 
controlled trials are equally effective, research has 
demonstrated that a strong therapeutic relationship is 
a necessary, but not sufficient, condition for effective 
psychotherapy. According to Ackerman & Hilsenroth 
(2003), a strong therapeutic relationship involves 
flexibility, honesty, respect, trustworthiness, warmth, 
confidence, interest, and openness. Ultimately, 
the effectiveness of therapy relies on the ability to 
establish a therapeutic relationship and on the skills 
and specialist knowledge of the counsellor. This is 
especially true of working in the cannabis area, as the 
majority of cannabis users do not voluntarily seek help 
for their cannabis use and therefore interventions may 
be opportunistic and need to be tailored to users who 
could be ambivalent about making changes to their 
drug use. In addition, cannabis use may be secondary 
to other drug use, health concerns, or mental health 
conditions.
Working with clients who use cannabis – key tips
Given the variety of treatment settings, other than 
alcohol and other drug centres, that cannabis users may 
access, it is important that general assessments capture 
cannabis use
Assessment should be considered integral to the 
engagement and treatment process rather than an 
independent process
Engagement early in the course of using offers the 
opportunity to intervene before behaviours become 
engrained. Use of motivational interviewing approaches  
is suggested, in order to enhance engagement
Empirically-based cannabis interventions should 
be explained to the client and incorporated into a 
comprehensive treatment plan, with goals and intensity 
of the treatment individualised
When relevant, cannabis use may be addressed in the 
context of other drug use
Interventions may need to be applied repeatedly before 
significant change is achieved, because drug use, 
including use of cannabis, is a cyclical and relapsing 
condition
Some clients may have other coexisting disorders that 
affect all stages of the change process
Determine treatment goals , which involve interim, 
incremental, and even temporary steps toward 
ultimate goals
Integrate substance abuse treatment with services such 
as mental health or criminal justice ones to best meet 
complex needs
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2.2 Intensity of treatment
Stepped care involves the provision of a series of 
interventions, from the least to the most intensive, 
with each incremental step made available on the 
basis of the client’s response to the previous one. 
A stepped care approach provides a best-practice 
framework for integrating assessment, case 
formulation, and treatment planning into the treatment 
process, and is useful for determining what level 
of intervention an individual requires. For example, 
a brief motivational intervention may be sufficient 
for some but not for other users. Clients who do not 
improve after a brief intervention can be stepped up 
to the next level of care (e.g. a 12-session outpatient 
treatment). If they continue to experience problems, 
a more comprehensive treatment plan may be 
needed (e.g. treatment of comorbid conditions; family 
involvement; etc.). The level of intervention required 
for success may not necessarily relate to level of use 
(i.e., not all heavy cannabis users will require such a 
comprehensive treatment program).
Since individuals with concurring mental health 
and alcohol and other drug problems are a very 
heterogeneous group in terms of type, severity, 
and readiness to address their various problems in 
treatment, a stepped care approach to treatment can 
allow for flexibility in intervention. A graded approach 
to treatment can:
• allow for flexibility in the intervention and 
match the treatment to the client’s needs. 
That is, clients with more severe dependence 
should be encouraged to engage in more 
intensive interventions (ranging from longer and 
more frequent outpatient visits to residential 
rehabilitation). As well as linking treatment 
intensity with the severity of the problem, 
treatment matching also considers the client’s 
motivations, cognitive functioning, and other 
variables, such as age, gender, cultural issues, 
and underlying psychological issues
• increase service access by reducing unnecessarily 
intensive interventions for those with minor 
cannabis-related issues
• optimise use of resources such as practitioner 
time
2.3 General principles of cannabis interventions
There are a number of principles clinicians should 
consider when providing treatment for cannabis 
dependence: 
• client progress may be variable, therefore 
interventions (including those that are 
manualised) will need to be tailored as required
• basic counselling skills are important for engaging 
cannabis users, including empathy and using 
open-ended questions
• early dropout (i.e. attending for only one 
session) is common, therefore prioritising the 
key messages and working on establishing 
engagement and on building motivation for 
change in the first session is important
• research has not yet established the optimum 
number of sessions to offer dependent cannabis 
users. Studies do suggest that single sessions can 
be effective, but continued care may be appropriate 
and is dependent on complexity of presentation 
and on motivational issues of the client
2.4 Setting
Primary health-care interventions 
Primary health-care settings provide an excellent 
opportunity for delivering brief interventions to 
address problematic cannabis use. In most cases, 
clients will not present in these settings requesting 
help for cannabis. This is where screening tools 
and making enquiries about lifestyle issues (which 
include drug use) that may contribute to presenting 
health concerns is important. Whilst some clients 
may avoid conversations about their drug use, others 
will be relieved that they did not have to bring it up. 
In addition, clinicians and general practitioners may 
need to look out for signs that clients are making 
subtle inquiries to see whether it is safe to talk 
about cannabis use. At a minimum, such settings are 
encouraged to provide pamphlets, and basic screening 
and detection are strongly encouraged.
Outpatient/client interventions
Consistent with other substance use-disorder 
counselling interventions, the majority of episodes 
of care for cannabis will be for brief (e.g. one- to 
five-session) interventions. This is consistent with 
the evidence base and with the patterns reported in 
treatment data sets. The screening and assessment 
sections within these guidelines give suggestions for 
domains of assessment, and the brief intervention 
section provides outlines for treatment options. 
Clinicians in outpatient services should be proficient 
in assessing and delivering brief interventions. These 
guidelines will assist in the development of a resource 
guide for clients. This may include a list of local 
support groups and self-help material.
In-patient and residential services
Whilst these guidelines suggest that the first line 
of treatment for cannabis issues is outpatient 
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intervention, clients experiencing severe withdrawal, 
multiple drug dependence (more specifically alcohol 
or benzodiazepine dependence), and acute or severe 
mental health problems have the highest risk of 
adverse consequences during withdrawal and may 
require in-patient/residential treatment. In these 
settings, cannabis use may be not specifically 
targeted but dealt with in the context of a general 
drug and alcohol abstinence program. The worksheets 
provided at the back of the guidelines can be used 
to individually work with clients wanting to address 
cannabis use during in-patient treatment. Given the 
prevalence, among illicit drug users, of cannabis use 
and comorbid substance use dependence, we strongly 
recommended that in-patient and residential treatment 
services offer at least one group that specifically 
targets cannabis use.
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chapter 3: screening for 
cannabis use 
Consistent with usual best practice, the initial meeting 
with a client should focus on engagement and 
identification of cannabis-related issues. Screening is 
most relevant for generalist settings, such as primary 
health care, workplaces, and schools, where detection 
of risky use is important, interventions are typically 
brief, and referral is likely.
3.1 What is screening?
A screen is a brief method for determining whether 
a particular disorder(s) (such as substance use or a 
mental health condition such as depression) may be 
present. Screening is a process for identification of a 
possible problem and does not necessarily catch the 
presence of a disorder, nor does it make assumptions 
about the role of cannabis use in a client’s life. 
Screening can be done easily in clinical practice and 
may open a gateway to clinical care. A positive screen 
will usually trigger a more detailed assessment of the 
condition.
Screening is not assessment 
Assessment is not diagnosis
Diagnosis is not formulation
Formulation is not treatment
Lee et al. (2007)
3.2 Rationale
Routine screening for cannabis use is important for 
many reasons:
cannabis users may seek assistance for other 1. 
problems, such as poor sleep, anger, depression, 
anxiety, relationship issues, or respiratory 
problems, and not mention that they use cannabis
early detection of cannabis-related issues is 2. 
important in preventing escalating problems
only a small minority of cannabis users actively 3. 
seek some form of intervention to address their 
cannabis use. Although many cannabis users have 
only minor problems with cannabis, a significant 
proportion do experience significant dependence 
and related harms that affect them and others, but 
still do not seek treatment
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cannabis use is very common in the community, 4. 
especially among 15- to 30-year-olds and 
individuals using other illicit substances, with 
mental health conditions. Those presenting with 
new persistent respiratory conditions such as a 
wheeze or cough should be screened for cannabis 
use as a contributing factor
3.3  Who to conduct screening for cannabis  
and when
Due to the widespread use of cannabis in the 
community, the guiding principle is that all people in 
health settings should be screened for cannabis use. 
Your setting will guide the comprehensiveness of your 
screening and assessment procedures, as set out in 
Table 5.
Table 5: Opportunities for screening
Health 
Professional Opportunities for cannabis screening
GP Any routine check-up consultation 
or consultation related to smoking, 
respiratory, mental health, injury, 
reproductive health, accident, or sleep
Community 
health services
Any generalist counselling services, 
especially those serving young people
Mental health 
workers
All comprehensive assessments 
should include a general drug screen, 
especially those involving psychosis 
Hospital workers Presentations that include mental 
health, injury, or respiratory issues, 
especially in people aged 15 to 40
3.4 How to introduce screening to the client
Letting clients know why and how you will be 
screening for cannabis will assist in providing a non-
threatening context. In any setting, it is important 
to assure clients that what they tell you will remain 
confidential and that you will use the information 
for the purposes of treatment planning only. Be sure 
to discuss the limitations of confidentiality relevant 
to your service (including suicide risk and ethical 
obligations). In a setting that does not specialise in 
alcohol and other drug treatment, such as a GP surgery 
or on a hospital ward, it is important to introduce 
screening in a non-threatening manner. For example:
“I am now going to ask you some routine lifestyle 
questions. Is that o.k.? [collaborative approach]
O.k., first off, do you use alcohol or tobacco [If yes, how 
much]? Have you used any other substances [If yes, 
quantify and probe using specific drug names]?”
If you introduce standardised questionnaires, it is 
important to discuss their relevance to the assessment 
procedure. You should explain the purpose of each 
instrument, what the results will be used for, who 
will have access to them, and how long they take to 
complete. In addition, you should ask for permission 
to administer the forms after providing them with the 
above information. All of the tools to be recommended 
are brief and can be scored in session and the 
results incorporated into your feedback to the client 
immediately.
3.5 Types of screening 
Screening can be standardised or non-standardised, 
and questions can be open-ended or closed. Most 
screening tools utilise closed questions. We suggest 
that after introducing screening to the client as 
suggested in 3.4, clinicians start the screening by 
asking one general, open-ended question about 
cannabis use as suggested in Table 6.
Table 6: Examples of open-ended and closed 
questions you can use
Closed–ended questions Open–ended questions
How old were you when you 
first smoked cannabis?
Tell me about your early 
experiences with cannabis?
How often do you use 
cannabis?
How has your cannabis use 
changed over time?
How old were you when  
you began using it daily?
Describe some of your 
recent experiences with 
cannabis.
When did you first think you 
had a cannabis problem?
Can you tell me about some 
of the less positive things 
you might experience when 
using cannabis?
Adapted from Steinberg et al. (2005)
3.6 Standardised screening tools
Psychometric tools are often used as an adjunct 
to clinical assessment (see Table 7). The Cannabis 
Severity of Dependence Scale has a strong evidence 
base for use in screening; the other measures reported 
below have a developing evidence base. Please note 
that the table is not a full list of available instruments 
and that the tools mentioned are not diagnostic.
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Table 7: Screening tools
Tool
Number  
of items Description Psychometric properties
Cannabis
Severity of Dependence Scale 
(SDS)
(Gossop et al., 1995)
5 valid•	
reliable•	
tested with adolescents, adults, •	
and psychiatric populations
separate norms available for •	
adults and adolescents
sensitivity 64–86%, specificity •	
82–94% in adults (Swift, Copeland 
& Hall, 1998); and sensitivity 64% 
and specificity 94% (cut-off 4) in non-
clinical young people (Martin et al., 
2006)
Cannabis Use Disorders 
Identification Test (Adamson & 
Sellman, 2003)
10 self-report for adults•	
cut-off norms available•	
sensitivity 73%; specificity 95%•	
overall positive predictive validity 84%•	
Cannabis Use Problems 
Identification Test (Bashford, 
2007)
16 cannabis-specific tool that can •	
identify and predict problems in 
adolescents and adults
sensitivity 98%; specificity 35%•	
overall positive predictive validity 95%•	
Alcohol, Smoking and 
Substance Involvement 
Screening Test (ASSIST) (WHO 
ASSIST Working Group, 2002)
8 general alcohol and other drug •	
screen (including cannabis)
clinician-administered; includes •	
feedback
91% sensitivity, 90% specificity •	
(Humeniuk et al., 2008)
Problem Oriented Screening 
Instrument for Teens (POSIT) 
(short form) (Knight, 2001; 
Danseco & Marques, 2002)
11 identifies adolescents in need of •	
further drug-abuse assessment 
accuracy of 84%, with sensitivity •	
and specificity ratios of 95% and 
79% respectively (Latimer, Winters & 
Stinchfield, 1997)
After administrating the screening tools, it is important 
to give individualised feedback about the results. It is 
at that point that you may encounter some resistance 
from clients. The following illustrates some examples 
of client responses and how you might respond in 
a Motivational Interviewing style (See Chapter 6 for 
more information on this approach).
“Client: Smoking cannabis is not a problem for me.”
“ Clinician: You don’t believe you need to reduce your 
use right now (reflect back). You feel that you have 
control of your use.”
“Client: Cannabis is not as bad as other drugs.”
“ Clinician: You don’t think that cannabis use is as bad 
as other drugs (reflect back). Can you tell me why you 
think it’s less risky for you than using other drugs?”
“ Client: My friends all smoke more than I do.”
“ Clinician: So it sounds like you believe that because 
your friends smoke more than you, you don’t have a 
problem with cannabis. Does that sound right?”
“Client: Cannabis is not addictive.”
“ Clinician: Yes it true that not everyone who uses 
cannabis gets addicted. Let’s look at the answers from 
the screening and see whether it fits for you.”
3.7  Biochemical markers for screening and 
assessment
In some settings, the testing of urine, blood, hair, 
and oral fluid samples for a drug or drug metabolites 
is acceptable for assessing drug use. Biological 
markers should guide the nature of further assessment 
options. For example, if a patient screens positive for 
a drug, then tools such as the Severity Dependence 
Scale (SDS) (Gossop et al., 1995) may be satisfactory 
to determine the severity of use. Biochemical markers 
also can be used to validate self-reports.
There are two types of biochemical testing procedures: 
screening and confirmation.
A. Screening 
Screening tests (e.g. urine dipstick tests) tend to be 
very specific, but can lack sensitivity. Specificity refers 
to the ability to give a negative result in someone who 
has not used a particular drug recently. Sensitivity, on 
the other hand, refers to the ability to give a positive 
result in someone who has used it recently.
B. Confirmation testing
Confirmation of a positive screening result involves the 
use of a second and more rigorous detection method 
that is usually done in a laboratory. The most common 
method used for confirmation procedures is gas 
chromatography or mass spectrometry.
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Rationale for biochemical testing 
• it provides an objective measure of substance 
abuse or relapse on which to base clinical 
decisions and treatment planning
• it may be a medico-legal requirement
• it can confirm treatment progress. Local 
laboratory services that provide “emit assays” 
can quantify the cannabinoids, but what these 
quantities represent can be very difficult to 
interpret and should not be used without having 
an expert provide the range of alternative 
possible interpretations. This can be helpful in 
client feedback of falling cannabinoid levels; 
measurement of treatment outcomes; and 
research studies. It should be noted that results 
of these laboratory tests may not be available for 
some days or weeks after the sample is taken and 
that the tests may incur extra costs
• dipstick tests provide immediate confirmation of 
drug use, but cannot establish whether a patient 
has only used recently or has a chronic problem. 
That is, dipstick tests cannot assess whether 
cannabis has been used in the last 24 hours, how 
many times cannabis has been used, or how much 
cannabis was consumed
• a less intrusive method may be appropriate. 
Saliva-testing kits are increasingly used in a 
variety of settings. Release of THC from blood 
back into saliva is idiosyncratic, however, and 
saliva testing often cannot distinguish immediate 
past use from use a day or more earlier; so THC 
detection using current saliva-testing devices also 
has limitations that necessitate good knowledge 
of alternative interpretations
Clinical issues when using biochemical screening 
If you are considering the use of biological markers 
you should bear in mind the following points: 
• How relevant is objective information for feedback 
and treatment planning? 
• How important in relation to the possible negative 
effect on the therapeutic alliance if the client 
declines or is found to be under-estimating 
cannabis use?
• the cost of testing. Costs can be prohibitive for 
some individuals or services and may be an 
impediment to treatment if the client is required to 
bear it
• all the options. Select the test from the available 
options according to appropriateness, price point, 
availability, and intrusiveness
• setting. In a medico-legal; contingency-
management; or middle- or long-term residential 
treatment setting, test results may be used to 
increase privileges or to offer advancement in the 
program
Please note that if a client requires a urine drug screen 
for criminal justice or medico-legal purposes, the 
relevant chain of custody requirements needs to be 
maintained. 
Sample collection
The method of collecting a urine sample for drug 
screening is important. Techniques include measuring 
the temperature or pH of the sample immediately after 
it is procured, and using tamper-proof containers. 
Supervised specimen collection may need to be 
conducted to ensure that it is the urine of the person 
being screened.
Detection times
The window for detection of cannabis following 
the last occasion of use is subject to debate (Cary, 
2006). Detection rates are influenced by technical 
variations (e.g. differing testing methods and test 
sensitivities), pharmacological variables (duration of 
use, metabolism, route of administration), and large 
individual differences in metabolism.
Table 8: Cannabis detection times
Amount In urine* In oral fluid
Single use 3–4 days  
(50ng/ml)
7 days (20ng/ml)
4–14 hours
Oral ingestion 1–5 days Unknown
Daily use/ 
chronic use
10–36 days 4–30 hours
*Dyer, Wilkinson & Wilkinson, (2008); Cary, (2006)
NB: Individual variation and variation in sampling 
method can significantly influence the detection time. 
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3.8 Summary
Recommendation Evidence
Screening for cannabis consumption should 
be routinely undertaken across a range of 
health settings, including alcohol and drug; 
mental health; emergency department; and 
general practice
A
A positive screening is a trigger for  
further assessment 
A
There are few clinically reliable and valid 
tools suitable for cannabis screening. Of 
those listed in Table 7, only the SDS and 
ASSIST are of Grade B evidence reliability. 
The remainder are of Grade C reliability
B & C
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chapter 4: assessment 
4.1 Overview
Conducting a comprehensive assessment is an 
essential requirement of determining the most 
appropriate and potentially effective treatment 
intervention for the client (see Figure 1). In addition, 
comprehensive assessment provides information 
through which to monitor treatment progress because 
it is done both at the beginning of treatment and 
throughout.
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Health professionals experienced in health and social 
assessment should assess cannabis use and related 
problems as part of a larger assessment of a client’s 
psychosocial health functioning. In order to increase a 
client’s understanding of the purpose of assessment, 
health professionals should provide clients with 
information about the details of the assessment, how 
its results can be used to make appropriate referrals, 
and how they can be used to track the efficacy of the 
treatment services provided to the client.
assessment 
instruments
understanding  
the client
screening  
tools
clinical  
interview
observation
collatoral 
information
Figure 1: Collecting information on clients 
4.2 Rationale
Early detection of, and intervention in, cannabis-
related problems is an effective public-health strategy. 
It also increases the likelihood that an individual will 
benefit from a brief intervention and reduce the long-
term harms associated with cannabis dependence.
4.3 Assessment as an engagement strategy 
Difficulties engaging cannabis users are sometimes 
cited as a barrier to treatment. Assessment of 
readiness for treatment and monitoring the level of 
engagement, therefore, are particularly important. A 
growing evidence base suggests that a strong, positive 
relationship exists between treatment adherence and 
treatment outcome (Zweben & Zuckoff, 2002). Zweben 
and colleagues believe that readiness for change can 
be assessed by looking at problem acceptance (i.e. 
whether the change is needed, wanted, and within 
reach) and treatment acceptance (i.e. whether the 
client agrees with the pathway offered).
Once cannabis users have presented for an initial 
appointment, whether or not they perceive it to be 
related to cannabis, the challenge for the practitioner 
is to engage them in treatment. Even when directly 
seeking assistance for cannabis-related problems, 
clients may come to a consultation with a degree of 
reluctance and some anxiety about the possibility 
of being judged. This increases the likelihood that 
they will be prepared to defend any impending threat 
to one of their most useful coping tools – cannabis. 
The assessment process in itself is an opportunity to 
engage and build rapport with clients. One technique 
for developing rapport is using open-ended questions 
to explore their concerns and goals. The subject of 
a clinician’s guide
18
cannabis and drug use should be introduced as a 
natural and routine part of discussion. For example:
“Tell me about your use of cannabis.”
“What do you enjoy about cannabis?”
“ Do you have any concerns about your use of 
cannabis?”
“Where do you see your cannabis use fitting in here?”
4.4  Comprehensive drug use assessment  
(60–120 mins) 
Assessment for cannabis problems may take place 
on just a single occasion and be relatively brief. A 
comprehensive and continuing assessment process 
may, however, provide opportunities for clinicians 
to non-judgementally provide, and for clients to 
seek, information useful in assisting clients to make 
changes in their cannabis use (Beich, Thorsen & 
Rollnick, 2003). An individual’s pre-existing strengths, 
deficits, and goals, as well as the effect of cannabis 
on his or her life, need to be considered in formulating 
a treatment plan (Beich, Thorson & Rollnick, 2003). 
A comprehensive assessment therefore necessitates 
careful attention in several domains.
4.5 Domains of assessment 
Core elements of any assessment of cannabis users 
should cover their broad range of problems beyond 
cannabis abuse or dependence as well as factors 
predisposing to, precipitating, or maintaining its use. 
The extent to which you explore each of these areas 
will depend upon their relevance for your client and the 
setting in which you work.
Systematic assessments should include:
pattern of recent history of cannabis and other drug use
mental health history
psychosocial issues
treatment goals 
motivation to change
Pattern and recent history of cannabis and other 
drug use
• quantity, frequency, and pattern of cannabis use 
over time (recorded as grams or number of cones 
or joints used daily/weekly)
• duration of current pattern, and changes in 
pattern over time
• indicators of severity of dependence, withdrawal 
symptoms, significant periods of abstinence, and 
situations of/triggers for use
• identification of established or probable DSM-IV-
TR and/or ICD-10 cannabis-related diagnoses 
• other substance use issues (i.e. full drug history, 
typical/current patterns of other drug use), as well 
as ascertaining which drug is currently causing 
the most dysfunction (noting that this may not be 
relevant or possible to identify if clients engage 
in varying patterns of multiple drug use or if 
substitution is common)
• past treatment, exploring experiences and 
outcome
• biological markers 
• the five Ps: presenting issues, predisposing 
factors, precipitating factors, perpetuating factors, 
and protective factors
Examples of cannabis-history questions
“When did you last you use cannabis?”
“ Have there been any recent changes in the way you 
use?”
“ Have you ever tried to cut down or stop your cannabis 
use?”
“Do you normally smoke with others? (If yes, ask,  
“Are they friends, family members, your partner?”)
“Are you worried about your cannabis use?”
Mental health history
• previous psychiatric/mental disorders, including 
established or probable DSM-IV-TR and/or ICD-10 
diagnoses
• related admissions or treatment
• medications
• known family history of mental disorders
• current mental status (see mental status 
examination)
• current and past suicidality risk
Psychosocial issues
• collateral information from carers/family 
members/friends where possible
• indicators of problems directly or indirectly related 
to cannabis use (e.g. relationship issues; physical, 
financial, or cognitive problems; legal problems; 
absenteeism from work/school)
• cognitive screening (memory, reading skill/ability 
to participate in CBT )
• domestic violence screen (mandatory in some 
settings)
• client’s strengths and positive coping strategies 
and past successes
• current social situation and supports
management of cannabis use disorder and related issues
19
• forensic history (details of offences, charges, 
convictions, and sentences passed)
• background information (family, marital status, 
legal involvement, health, education, and 
financial, employment, and housing status)
Note: The Cannabis Problems Questionnaire can help 
raise awareness of psychosocial issues resulting from 
cannabis use (see Chapter 11).
Treatment goals 
• cannabis-specific treatment goals (abstinence or 
reduction in levels of use)
• additional treatment goals (e.g. mood 
management, vocational, relationship)
Tip It is important to assess mental health symptoms 
on a regular basis, as cannabis use may mask 
underlying conditions that may initially worsen or 
remit following cessation
Motivation to change
Despite the negative sequelae of cannabis use, many 
users are reluctant or ambivalent about change and 
may come for treatment through coercion by others 
(families, partner, courts). For this reason, it is 
important to explore individuals’ internal and external 
motivation to change their cannabis use; barriers to 
change, such as the success of previous quit attempts; 
the pros and cons of changing; and behavioural 
changes (Miller & Rollnick, 1991).
Ways to assess internal factors
“What do you want to change?
“ What are the most important changes you’ve been 
looking forward to after cut-down/quitting?
“ Based on a scale of 0 to 10, how much do you want to 
change at this moment?
“ Are your concerns about the health consequences 
related to cannabis motivating you to change?
“ Are your concerns about your relationship with 
someone important to you motivating you to change?
Ways to assess external factors
“ Have there been recent happenings that led you here 
for a change?
“ Who in your life (e.g. family, spouse, significant 
others, close friend) expects or wants you to change 
your use?”
“ Do you come here for a change because of a legal 
order?”
“ Will there be any negative consequences if you don’t 
change?”
Previous quit attempts
Nature, number of attempts, longest abstinence 
period, reason for recent lapses.
“ Have you ever attempted quitting? If yes, where and 
how?”
“Which attempt(s) were successful/unsuccessful?”
“ If you look back, what have you done (what did you 
try) to make the attempt(s) successful/unsuccessful?”
“ Can you tell me about what you have received from 
others that felt extremely supportive to you?”
“ What was your longest abstinence period? How did 
you keep it up so long?”
“ Can you tell me about the situations that led to 
relapse?”
“ What were your inner conversations/how did you feel 
right before and right after the relapse?”
“ (Rating) based on a scale of 0 to 10, how much 
confidence do you have in succeeding in the current 
attempt?”
Behavioural changes gained
Consider what the individual has done to change his or 
her cannabis use already. In addition, address what he 
or she plans to do in the future. Importantly, recognise 
and validate his or her achievements to date.
“ Since the time when you decided to change, what 
action(s) have you taken to change (e.g. avoiding high-
risk situations, staying away from drug-using friends, 
restriction on spending, etc.)?”
“ What further actions are you going to take to continue 
to change your behaviour?”
Assessing ‘stages of change’ as described by 
Prochaska and DiClemente (1983) can be achieved 
through activities such as the contemplation ladder or 
by the therapist’s working through the series of tasks 
set out in the table below.
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Stage of change Therapist tasks
Pre-contemplation identify “the problem” •	
be aware of difference between reason and rationalization•	
use MI strategies to raise awareness and doubt•	
increase the client’s perception of risks and problems with current behaviour•	
remember that the goal is not to make precontemplators change immediately, but to help •	
move them to contemplation
Contemplation consider the good and the not-so-good (from the client’s perspective) of the problem •	
behaviour, as well as the good and the not-so-good of change
gather information about past change attempts. Frame these in terms of “some success” •	
rather than “change failures”
explore options the client has considered for the change process, and offer additional options •	
where indicated and if the client is interested. Remember that our clients are rarely novices to 
the change process
elicit change statements•	
Preparation Ask key questions designed to evoke a change plan:
what do you think you will do?•	
what’s the next step?•	
it sounds like things can’t stay as they are now •	
what are you going to do?•	
Assist client in building an action plan and removing barriers 
Action Help increase client’s self-efficacy:
focusing on successful past attempts•	
highlight successful changes already made•	
reaffirming commitment•	
offer successful models with a menu of options •	
therapist acts as monitor of change•	
Maintenance explore the factors precipitating and maintaining the crisis•	
provide information•	
give feedback about progress•	
have empathy for clients•	
communicate possibility of future support•	
Assessing motivation on a contemplation ladder
Based on the “stages of change” of Miller and Rollnick 
(1991), the Contemplation Ladder (Biener & Abrams, 
1991) is a scale depicted as a ladder with the higher 
rungs representing greater motivation to change. The 
“Marijuana Ladder” developed by Slavet et al., (2006) 
for incarcerated young people has been associated 
with increased engagement with adolescents (See 
Chapter 12).
Assessing motivation through formalised 
questionnaires
Motivation to change can also be assessed using 
validated tools, including:
• importance of change (Miller & Johnson, 2008; 
Rollnick, 1998)
• confidence to change (Miller & Johnson, 2008; 
Rollnick, 1998)
• readiness to change (Miller & Johnson, 2008; 
Rollnick, 1998)
• decisional balancing (Miller & Rollnick, 2002)
• motivations for using substances amongst 
psychotic patients (Spencer, Castle & Michie, 2002)
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4.6 Adjunctive measures 
Assessment may be guided by the validated structured 
clinical interviews and self-reports. Table 9 provides 
details of adjunctive assessment tools that are 
supported by a minimum level of evidence and 
available in the public domain.
Table 9: Assessment options 
Area Tool Items Notes
Cannabis
diagnosis
Tobacco dependence 
diagnosis
DSM-IV-TR (APA, 2000)
CIDI (Kessler et al., 1998)
SCID (First et al., 1997)
SCAN (Wing et al., 1990)
GAIN (Dennis et al., 2002)
Fagerström Nicotine Dependence 
Scale (Heatherton et al., 1991)
6 items All tools are in a structured interview 
format and can provide differential 
diagnosis 
Identification and severity of nicotine 
dependence 
Severity Severity of Dependence Scale 
(Gossop et al., 1992)
5 items Assesses severity of dependence 
Consumption Timeline Followback 
(Sobell & Sobell, 1996)
— Can be used to assess cannabis use 
during the past year, but we suggest 
limiting assessment to the past 30 
days to lessen client burden
Psychosocial issues Cannabis Problems Questionnaires 
(CPQ for adults (Copeland et al., 
2005) and adolescents Martin et al., 
2006)
22 (adult)
27 (core)
Assesses a range of physical and 
psychosocial consequences of 
cannabis use
Withdrawal symptoms Marijuana Withdrawal Checklist 
(Budney, Novy & Hughes, 1999)
15 Assesses severity of withdrawal 
symptoms 
Cognitive functioning Adult/Youth Self Report 
(Achenbach & Edelbrock, 1987)
Mental Status Examination  
(Trzepacz & Baker, 1993)
126 items
10 domains
Assesses cognitions
Structured way of observing and 
describing a patient’s current state 
of mind
Readiness to change “Readiness to Change” Scale  
(Rollnick et al., 1992)
12 Designed for use in medical settings
Mental health 
symptoms
Depression Anxiety and Stress Scale 
(DASS) (Lovibond & Lovibond, 1995)
K10 (Kessler et al., 2002)
42 (mini version 21) 
questions
10 items
Rates severity of symptoms of 
depression, anxiety and stress
Scale of psychological distress
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4.7 Continuing assessment
As with other substance use disorders, clients may 
replace cannabis with other drugs, such as alcohol. 
It is important, therefore, to monitor other drug use 
for escalation and/or substitution when reducing the 
drug of primary concern. Such monitoring can assist 
clinicians in deciding whether patients need their care 
to be stepped up or down.
4.8 Post-assessment feedback
Providing the assessment results to the patient can 
assist with increasing patients’ knowledge about the 
harms associated with their cannabis use and with 
increasing their motivation to change. Recent evidence 
suggests that structured feedback can bring about 
significant change in use by some individuals, even 
without providing more intensive intervention (Wild et 
al., 2007; Doumas & Hannah, 2008).
Feedback should entail a summary of the client’s 
drug use and related problems as reported in the 
assessment. Clinicians are encouraged to couch this 
information in comparison with levels of use and 
problems evidenced in the general population and 
in treatment-seeking cannabis users. At all times, 
clinicians will want to deliver the feedback in an 
understandable, objective, culturally sensitive, and 
collaborative manner. It should be noted that many 
of the tools discussed in this manual have not been 
validated in culturally diverse groups and may not be 
appropriate for use in some groups. As always, clinical 
judgement should determine how much feedback the 
clinician should deliver and at what time.
In summary, clinicians need to deliver accurate 
feedback in an empathic, non-judgemental, and 
non-threatening manner. Such a context will allow 
patients to envision the benefits of changing and will 
increase their motivation for change. After feedback is 
presented, clinicians should allow clients to develop 
their own treatment goals. Such a process leads to 
a collaborative atmosphere, which is more likely 
to engender change than a coercive environment. 
Clinicians should aim to empower clients to sustain 
the changes they have decided to make.
How do I feedback dependent use?
“ The level of cannabis use you report and the problems 
you describe, such as missing work, poor sleep, 
and difficulty not using, suggest that you may be 
dependent on cannabis. How does that fit with your 
view of your use?”
4.9 Summary
• where possible, conduct a comprehensive 
assessment in parallel with building rapport
• provide feedback from assessment, with the goal 
of increasing insight that cannabis use needs 
attention
• continue to revise and monitor information 
throughout the different stages of treatment
Recommendations Evidence
A thorough assessment may include a clinical 
interview as well as structured questionnaires, 
e.g. SDS, TLFB. Tools such as the MWC do not 
meet level A evidence
A & B
Key topics of assessment include patterns of 
drug use; psychosocial functioning; general 
health; mental symptomatology; readiness to 
change; and treatment goals 
A
Routine assessment of commonly experienced 
mental health symptoms (e.g. depression, 
anxiety, and psychotic symptoms) should 
occur at assessment and be repeated regularly
A
Where possible, and with the client’s 
permission, information from other family 
members/carers should be used
C
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chapter 5: withdrawal 
management
5.1 Cannabis withdrawal
As mentioned in chapter two, the most common 
withdrawal symptoms are irritability, anxiety/
nervousness, restlessness and sleep difficulties 
(including strange dreams), anger, and aggression. 
Symptoms typically emerge after one to three days of 
abstinence, peak between days two and six, and last 
from four to 14 days (Budney et al., 2003; Budney & 
Hughes, 2006).
5.2 Assistance through withdrawal
Assisting clients with withdrawal symptoms can 
involve:
• providing verbal and written information about 
what to expect (see withdrawal handout). Please 
note that it is important to inform clients that they 
may not experience all (or any) symptoms and 
that the severity of any symptoms experienced 
depends on many factors;
• developing a coping plan;
• acknowledging clients’ fears about withdrawal 
symptoms; 
• arranging the appropriate level of support
5.3 Other influences on withdrawal
Research has indicated that withdrawal symptoms 
adversely affect quit attempts because cannabis users 
report using cannabis and/or other drugs to relieve 
symptoms (Copersino et al., 2006). Some dependent 
clients may be unaware that they are using cannabis 
to relieve withdrawal symptoms. Clients often have 
a difficult time distinguishing relief from withdrawal 
symptoms from an increase in pleasure due to 
intoxication. Table 10 indicates the variables that may 
influence withdrawal.
Table 10: Variables that may affect withdrawal 
severity
Psychiatric comorbidity, including personality disorder
Dose: amount and potency of preparation consumed
Duration of use
Past experience of withdrawal: severe anxiety, panic 
attacks, sleeplessness
Past or current other substance use
History of aggression or violence; other personality traits
Setting: outpatient withdrawal may be more severe than 
in-patient withdrawal
Context: voluntary vs involuntary
Support: professional, family, social
Population: more severe in treatment seekers
5.4 Assessment of withdrawal symptoms
At present there is no validated measure of cannabis 
withdrawal. Researchers have relied upon the 
Marijuana Withdrawal Checklist (MWC) (Budney, Novy 
& Hughes, 1999) to assess cannabis withdrawal in 
both adolescents and adults. Multiple versions of the 
MWC have appeared in the literature; most recently a 
15-item version has been used to capture the range of 
symptoms of most patients (Budney et al., 2008). To 
monitor withdrawal symptoms, clients can complete 
the MWC on a daily basis (See “Screening Tools” 
section). When possible, monitoring of withdrawal 
symptoms should commence at least one day before 
cessation, in order to obtain an accurate baseline 
value of the symptoms and behaviours associated with 
withdrawal. As most symptoms substantially remit 
within six days, a diary should be kept for at least 
seven days. As sleep-related problems may persist 
longer for some individuals, a diary may be continued 
for up to a month.
5.5  What is the most appropriate setting for 
withdrawal?
Withdrawal symptoms from cannabis can be safely 
managed in an outpatient setting, but some clients 
may request an in-patient or residential setting. The 
necessity for in-patient care needs to be assessed on 
an individual basis and to be guided by the client’s 
history of previous quit attempts in the community; 
personal and family circumstances; and any mental or 
physical health considerations.
5.6 Withdrawal from multiple drug use
We recommend that cannabis-using clients who 
present for treatment for alcohol or a substance use 
disorder other than cannabis reduce their cannabis use 
as they reduce the drug of primary concern. Evidence 
suggests, however, that you don’t necessarily have to 
reduce cannabis use to have good outcomes for the 
drug of primary concern. Clients with severe alcohol 
dependence and/or psychiatric conditions are likely to 
need additional care.
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What if cannabis 
isn’t the only 
drug my client 
uses regularly?
There is no research indicating which 
drug a client should give up first
Best-practice referral procedures 
should be followed if a clinician 
feels that the client’s other drug use 
warrants intervention (including 
medication)
Is tobacco 
withdrawal 
similar to 
cannabis 
withdrawal?
Tobacco use with cannabis is very 
common, and many of the withdrawal 
symptoms are similar
Assess whether the individual may 
be experiencing both cannabis and 
tobacco withdrawal during this period
Tobacco withdrawal symptoms
Cannabis smokers often smoke tobacco, either with 
their cannabis or separately. Clients whose tobacco 
smoking occurs only with their cannabis smoking 
should be made aware that they could be experiencing 
tobacco withdrawal as well as cannabis withdrawal 
during this period. Clinicians should monitor both 
withdrawals, and nicotine replacement therapy 
during this period should be discussed with heavy 
tobacco smokers who use tobacco in conjunction with 
cannabis only. (Table 11 gives the timing of typical 
nicotine withdrawal symptoms.) Tobacco reduction 
can also cause changes to the saliva, which may be 
managed by sipping tap water regularly.
Table 11: Symptoms, duration, and prevalence of 
nicotine withdrawal
Symptom Duration Incidence 
Irritability/aggression < 4 weeks 50%
Depression < 4 weeks 60%
Restlessness < 4 weeks 60%
Poor concentration < 2 weeks 60%
Increased appetite > 10 weeks 70%
Light-headedness < 48 hours 10%
Night-time awakenings < 1 week 25%
Constipation > 4 weeks 17%
Mouth ulcers > 4 weeks 40%
Urges to smoke > 2 weeks 70%
Source: McEwan et al. (2006). For more information about 
pharmacotherapy options for nicotine withdrawal, see Table 15.
5.7 Pharmacotherapy for cannabis withdrawal
A number of studies have examined pharmacotherapy 
for the management of cannabis withdrawal. 
Bupropion, divalproex, Iofexidine, naltrexone, 
nefazadone, mirtazapine, lithium, and oral THC have 
been evaluated in laboratory studies, but only three 
studies examined their efficacy in treatment seekers. 
A summary of the studies is found in Copeland & Swift 
(2009). As clinical trials of potential medications for 
the management of cannabis withdrawal are in their 
early stages, no recommendations can be made on 
effective pharmacotherapies.
5.8 Gradual vs sudden cessation
There have been no studies to indicate whether 
gradual reduction of cannabis can reduce withdrawal 
symptoms or give clients a better success rate than 
abrupt cessation. The literature on alcohol and other 
drugs and clinical experience in the management 
of cannabis withdrawal suggests that a period 
of abstinence from cannabis benefits those with 
cannabis dependence and makes more likely their 
management of cannabis use in the long term. Clients 
wishing to reduce it gradually should do so having 
set a quit date for some time in the following two to 
three weeks.
5.9 Symptom-focused approach to withdrawal
As cannabis withdrawal involves a range of symptoms 
and there are no medications available to reduce the 
severity of withdrawal symptoms over all, another 
approach is to consider medications that target 
individual symptoms. There is no direct evidence, 
however, for the symptom-focused treatment of 
withdrawal management. Accordingly, practitioners 
will have to assess the utility of symptomatic 
management on a case-by-case basis. For example, a 
practitioner may find it appropriate to prescribe a short 
course of sedative–hypnotic medication at a low dose 
for an individual who experiences significant trouble 
sleeping while reducing his or her cannabis use.
As some persons with cannabis dependence are 
vulnerable to developing dependence on other 
psychoactive drugs, it is recommended that a family 
member assist in distributing and/or monitoring the 
use of prescription medication whenever possible and 
that the typical regime be limited to a maximum of 
five days.
For an individual who also has signs and symptoms 
of an anxiety disorder, acute psychosis, mania, or 
agitated depression, assessment by a psychiatrist is 
recommended. Diagnosable psychiatric conditions 
may become apparent at the end of withdrawal, and 
appropriate longer-term medication regimes may be 
considered once the diagnosis has been clarified.
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CAUTION
Prescription of a benzodiazepine is not recommended 
as a routine approach for people experiencing cannabis 
withdrawal. When considering medication options, 
consultation with specialist services is recommended.  
The course should be short-term and carefully monitored.
5.10 Stepped care for withdrawal symptoms 
As with other psychoactive drugs, physiological 
withdrawal alone from cannabis is not likely to lead 
to long-term behaviour change. Withdrawal should 
be part of a continuum of care. This incorporates 
case planning for post-treatment support. If external 
support services are appropriate, good referral 
procedures should be followed and a central case 
manager should coordinate referrals. Post-withdrawal 
planning can be done formally (post-treatment plans) 
or informally (leaving the door open for clients to 
return) depending on your agency’s procedures.
5.11 Psycho-education for withdrawal symptoms
As cannabis withdrawal research is in its early 
stages, few studies have examined the efficacy of 
psychosocial interventions for dealing with cannabis 
withdrawal. Based on the wider substance-abuse 
literature, psychosocial interventions for cannabis-
withdrawal management are well-supported. These 
interventions involve both providing clients with 
accurate information about the nature and course 
of withdrawal symptoms (see psycho-education 
worksheet) and helping clients to devise management 
strategies for potential symptoms. Self-management 
strategies that have a strong evidence base in the 
general substance-abuse literature include sleep 
hygiene, progressive muscle relaxation, meditation, 
exercise, and social support.
Clients should be encouraged to keep a diary 
throughout the withdrawal period of the symptoms 
they experience. Strategies for coping with them 
appear in Table 12. The diary can be reviewed during 
treatment sessions, and can assist patient and 
clinician in determining which strategies are more 
effective and demonstrate that the symptoms are 
rapidly diminishing. It is important to explain to clients 
that withdrawal symptoms can be very individual 
and that they may not experience all of them. At each 
session, it is important to review with the client those 
symptoms that have and those that have not remitted; 
management strategies used; and their effectiveness.
Table 12: Symptoms and recommended associated treatments
Withdrawal 
symptom
Suggested psychosocial 
interventions Explanation of intervention
Sleep problems Progressive muscle relaxation 
Imaginal relaxation 
A relaxation technique designed to reduce the tension stored in the 
muscles. Particularly helpful for intrusive thoughts
A guided approach that aims to create a safe and supportive space 
in the client’s mind
Cravings Urge surfing A cognitive technique used to “ride out the (craving) waves”
Anger/irritation Challenging irrational beliefs
Physical activity
Relaxation and coping strategies
A technique for challenging beliefs that lead to unhelpful 
behavioural patterns
Mood 
disturbances 
Mood management 
Coping strategies 
Activity scheduling
Learning to effectively manage difficult emotions such as anger, 
depression, anxiety, and low self-esteem
Strategies to alleviate or cope with stressful situations in which the 
risk of relapse is high
Timetabling pleasant activities that give enjoyment and challenge 
negative perceptions
See worksheet section for examples of how to perform these interventions with clients.
management of cannabis use disorder and related issues
27
5.12 Summary
Withdrawal symptoms are common in clients who 
use cannabis regularly. Whilst the withdrawal 
symptoms are generally mild, they can make achieving 
abstinence difficult. Monitoring of symptoms and 
communicating their role in the course of cannabis 
withdrawal can be useful interventions. As yet, there 
are no approved medications available to assist in the 
management of cannabis withdrawal.
Recommendation Evidence
Regardless of agency setting, withdrawal 
symptoms should be considered in routine 
assessment 
B
A range of psychosocial interventions should 
be considered before pharmacotherapy for 
the management of individual withdrawal 
symptoms 
C
Monitoring of withdrawal symptoms and 
appropriate psycho-education can be helpful 
approaches to intervention
C
Whilst there is no current evidence to  
support the use of pharmacotherapy in 
ameliorating withdrawal symptoms,  
short-term use of appropriate medications  
for specific withdrawal-related symptoms 
may be considered
D
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chapter 6: brief interventions
6.1 Overview of brief interventions
Brief and early interventions aim to detect and 
intervene with clients who, regardless of whether 
they meet criteria for cannabis-use disorder, are 
experiencing problems as a result of their use and are 
at risk of developing long-term cannabis dependence. 
Early interventions are generally opportunistic and 
are appropriate for clients who have not specifically 
sought help for their cannabis use but whose use is 
detected as being risky. The goal of a brief intervention 
is to reduce the risk of harm from using cannabis. 
Whilst abstinence will achieve the greatest reduction 
in harm, not all clients are ready and motivated for it. 
Striving for and realising intermediate goals, such as 
decreasing use or using in less risky situations, will 
allow clients to achieve mastery. Mastery, in turn, can 
increase a client’s motivation to work on goals more 
difficult to achieve, such as abstinence. 
Brief interventions generally range from one to nine 
sessions and typically include the provision of self-
help material, a brief assessment/screen, advice and 
information, assessment of motivation for change, 
problem solving, goal setting, relapse prevention, 
harm reduction, and follow-up care (Marsh, Dale & 
Willis, 2007). A number of large-scale trials in the 
United States and Australia (see Table 13) provide 
support for four behaviourally based interventions: 
Motivational Interviewing (MI), Motivational 
Enhancement Therapy (MET), Cognitive Behavioural 
Therapy (CBT), and Contingency Management (CM). 
The treatment that has received the most evidentiary 
support has been CM in combination with Cognitive 
Behavioural Therapy (Budney et al., 2006).
Given that the optimum number of sessions is 
unknown; this chapter provides two options for 
interventions. For the first, we provide information 
regarding a brief two-session intervention for clients 
who are experiencing relatively few problems with 
their cannabis use or who are not motivated to access 
more-intensive treatment services. For the second, we 
detail common components used in various cannabis 
evidence-based interventions so that you can add 
components to the basic two-session treatment on the 
basis of a client’s needs. As most programs range from 
four to six sessions, we offer a six-week program that 
can be tailored to suit each client.
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Table 13: Randomised trials of behavioural treatments (adults and young adults)
Author N Study design Intervention Outcome
Manual 
available
Stephens  
et al., 1994
212 Adults, two 
groups, 12-month 
follow-up
CBT vs social-
support group 
(discussion 
intervention)
Both groups had significant reductions in 
cannabis use. No significant differences 
between groups in days of cannabis use, 
cannabis-related problems, or abstinence 
rates
N/A
Stephens  
et al., 2000
291 Adults, three 
groups, 12-month 
follow-up
14-session CBT 
group treatment vs 
2-session MET vs 
delayed treatment 
control (DTC)
Both treatment groups showed greater 
improvement than DTC on most cannabis-
outcome measures. No significant 
difference in outcomes between the two
N/A
Budney  
et al., 2006
60 Adults, three 
groups, 
no follow-up
4-session MET 
vs 14-session 
MET/CBT vs MET/
CBT and voucher 
incentives (MET/
CBT+V)
No significant differences in abstinence 
between MET and MET/CBT groups. 
MET/CBT+V had greater durations of 
abstinence and had more abstinent 
subjects at the end of treatment than the 
other two groups
No
Copeland  
et al., 2001
229 Adults, three 
groups, 6-month 
follow-up
6-session MET/CBT 
vs 1-session MET/
CBT vs DTC
Both treatment groups reported better 
outcomes (greater abstinence rates, 
fewer cannabis-use-related problems, 
less concern about cannabis use) than 
DTC
No
Sinha  
et al., 2003
Young adults on 
probation, two 
groups, 1-month 
follow-up 
3-session MET vs 
3-session MET and 
vouchers
Vouchers enhanced treatment 
attendance, did not affect cannabis use. 
Note that the voucher incentive was for 
attendance and not abstinence 
N/A
Cannabis 
Treatment 
Research 
Project Group, 
2004
450 Adults, three 
groups, multi-site, 
12-month follow-
up
9-session MET/CBT 
vs 2-session MET 
vs DTC
Both treatment groups showed greater 
improvement than DTC on most cannabis-
outcome measures. The 9-session 
MET/CBT reduced cannabis use and 
associated consequences more than the 
2-session MET did
Yes
Steinberg  
et al., 2005
Budney  
et al., 2006
90 Adults, three 
groups, 12-month 
follow-up
14-session MET/
CBT vs MET/CBT 
and vouchers 
(MET/CBT+V) vs 
vouchers alone
No differences on abstinence initiation 
during treatment, between MET/CBT +V 
and vouchers alone, but both superior to 
MET/CBT alone. MET/CBT+V had superior 
post-treatment abstinence to that of 
vouchers alone or MET/CBT alone
No
Carroll  
et al., 2006
136 Young adults, four 
groups, 6-month 
follow-up
MET/CBT vs  
MET/CBT and 
vouchers (MET/
CBT+V) vs vouchers 
alone vs case 
management
Vouchers enhanced treatment retention 
and cannabis abstinence, with MET/CBT 
+V showing the best outcomes.  
MET/CBT enhanced self-reports of 
decreased cannabis use at the 6-month 
follow-up
N/A
Kadden  
et al., 2007
240 Adults, four 
groups, 12-month 
follow-up
MET/CBT vs MET/
CBT and vouchers 
(MET/CBT+V) vs 
individual drug 
counselling (DC) vs 
DC and voucher
Vouchers engendered superior 
abstinence outcomes. MET/CBT +V 
showed the highest rates of abstinence at 
later follow-ups
N/A
Dennis  
et al., 2002
600 Young people 
15–16 years old
5-session MET/
CBT vs 12-session 
MET/CBT vs family 
support
All interventions demonstrated 
significant pre- to post-treatment effects 
over 12 months. No treatment was 
superior to another
Yes
Martin & 
Copeland, 
2008
40 Young people 
14–19 years old
2 session MET vs 
delayed treatment 
control
Intervention group showed significantly 
greater reductions in frequency of use 
and of dependence symptoms 
Yes
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6.2 Successful elements of brief interventions
Miller and Sanchez (1993) looked at a number of brief 
alcohol interventions and found that they have the 
following six effective components in common.
• F. Feedback  provide feedback from your 
clinical assessment 
• R. Responsibility   emphasise the person’s 
personal responsibility for 
their drug use and associated 
behaviour
• A. Advice  provide clear, practical advice 
and self-help material
• M. Menu   offer a range of behaviour-
change and intervention 
options
• E. Empathy   express non-judgmental 
empathy and support
• S. Self-efficacy  stress one’s belief in the 
person’s capacity for change
The FRAMES intervention can be divided into two 
major phases:
 (1) building motivation for change, and
 (2)  strengthening commitment to change (Miller & 
Rollnick, 1991)
Below is more information about the techniques 
showing the most promise. These techniques are 
effective in the wider substance-using area, and 
clinicians are commended to seek specific, substantial 
training in cognitive-behavioural strategies and 
motivational-enhancement techniques.
6.3 Motivational Interviewing
Motivational Interviewing (MI) is a clinical strategy 
designed to enhance client motivation for change. MI 
can be incorporated into counselling, assessment, 
and brief interventions and aims to increase the 
client’s awareness of the potential problems caused, 
consequences experienced, and risks faced as a result 
of a type of behaviour. The main goals are to establish 
rapport, elicit conversation related to change, and 
establish commitment language from the client. As 
this approach explores and resolves ambivalence 
within the client, it is appropriate for clients who 
are not voluntary treatment seekers (i.e. who are 
court-diverted) or who are contemplating change 
but not quite ready to move into the action phase. 
Ambivalence is accepted as normal.
MI is supported by more than 80 clinical randomised 
controlled trials (Hettema, Steele & Miller, 2005) 
in a range of target populations and behaviours, 
including substance use disorders, health promotion 
behaviours, medication adherence, and treatment of 
mental disorders.
• Miller and Rollnick (1991) identified characteristics 
of the clinician’s style that embody the spirit of 
motivational interviewing, on the basis that they 
are more important than any particular technique. 
They identified the most important characteristic 
as being a collaborative approach, seeking to 
understand the person’s point of view, particularly 
via reflective listening; summarising; and 
affirmation (see below)
• MI involves eliciting and selectively reinforcing the 
client’s own self-motivational statements
• MI requires monitoring the client’s degree of 
readiness to change and ensuring minimal 
resistance by matching their approach to the 
client’s stage of change
• Mi promotes the client’s autonomy
target  
behaviour
skills
principles
spirit
MI framework
Collaboration1. 
Evocation2. 
Autonomy3. 
Open questions1. 
Affirming2. 
Reflections3. 
Summarising4. 
Express empathy1. 
Develop discrepancy2. 
Roll with resistance3. 
Support self-efficacy4. 
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Miller and Rollnick (2002) have described four basic 
motivational principles underlying MI. These are to:
1.  express empathy
2.  develop discrepancy
3.  roll with resistance
4.  support self-efficacy
1. Express empathy
The MI clinician seeks to communicate great 
respect for the client. Communications that imply a 
superior–inferior relationship between clinician and 
client are avoided. The clinician’s role is a blend of 
supportive companion and knowledgeable consultant. 
The client’s freedom of choice and self-direction are 
respected. In this view, only the client can decide to 
change and carry out that choice. The clinician seeks 
ways to compliment and build the client, rather than 
to denigrate or to tear the client down. Much of MI 
is listening rather than telling. Persuasion is gentle, 
subtle, always with the assumption that change is up 
to the client. The power of such gentle, nonaggressive 
persuasion has been recognised widely in clinical 
writings, including Bill Wilson’s own advice on 
“working with others” (Alcoholics Anonymous, 1976). 
Reflective listening (accurate empathy) is a key skill 
in motivational interviewing. It communicates an 
acceptance of clients as they are and supports them in 
the process of change.
2. Develop discrepancy
Motivation for change occurs when people perceive a 
discrepancy between where they are and where they 
want to be. This approach seeks to increase and focus 
the client’s attention on such discrepancies with 
regard to drug use. In certain cases, in which the client 
is not actively engaged in thinking about change, it 
may be necessary to develop such discrepancy by 
raising the client’s awareness of the adverse personal 
consequences of his or her drug use. Such information, 
when properly presented, can precipitate motivation 
for change. As a result, the individual may be more 
willing to enter into a frank discussion of change 
options, in order to reduce the perceived discrepancy 
and regain emotional equilibrium. In other cases, 
the client enters treatment in a later “contemplation” 
stage, and it takes less time and effort to move the 
client along to the point of determination to change.
3. Roll with resistance
How the clinician handles client “resistance” is a 
crucial and defining characteristic of this approach. MI 
strategies do not meet resistance head-on, but rather 
“roll with” the momentum, with a goal of shifting 
client perceptions in the process. New ways of thinking 
about problems are invited, but are not imposed. 
Ambivalence is viewed as normal, not pathological, 
and is explored openly. Solutions are usually evoked 
from the client rather than provided by the clinician. 
This approach to dealing with resistance will be 
described in more detail later.
4. Support self-efficacy
A person who is persuaded that he or she has a 
serious problem will still not move toward change 
unless there is hope for success. Bandura (1982) has 
described self-efficacy as a critical determinant of 
behaviour change. Self-efficacy is, in essence, the 
belief that one can perform a particular behaviour or 
accomplish a particular task. In this case, the clients 
must be persuaded that they can change their drug 
use and thereby reduce related problems. In everyday 
language, this might be called hope or optimism, 
although it is not an overall optimistic nature that is 
crucial here but rather clients’ specific belief that they 
can change their drug problem. Unless this element 
is present, a discrepancy crisis is likely to resolve 
into defensive coping (e.g. rationalisation, denial) to 
reduce discomfort, without changing behaviour. This 
is a natural and understandable protective process. If 
one has little hope that things could change, there is 
little reason to face the problem.
Further details can be found in Miller (1995).
Motivational Interviewing has been adapted into 
many brief-intervention approaches, of which the 
best known is Motivational Enhancement Therapy 
(MET), employed in PROJECT MATCH to address 
drinking (Project Match Research Group, 1993). MET 
is a time-limited four-session approach that provides 
normative-based feedback and uses Motivational 
Interviewing to explore client motivation to change in 
light of the feedback. This approach of including MI in 
assessment feedback has been adopted by many brief 
interventions with good success (Miller & Rollnick, 
2002). 
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Examples of responses to clients using the above MI 
framework
“Client: I’m only here because the judge sent me.”
“ Clinician: So you were forced to come here. [reflecting 
back and no fighting]”
“Client: A good joint really relaxes me.”
“ Clinician: You notice that pot relaxes you in the 
moment. You’ve also noticed that you have had 
increased anxiety in the last 12 months, which 
is around the same time you started smoking 
more. [linking past and present and developing 
discrepancy]”
“ Client: I wouldn’t use if my parents weren’t on my back 
all the time.”
“ Clinician: Your cannabis use isn’t just the only issue for 
you. It sounds like there are some issues to work on 
with your parents. [rolling with resistance]”
6.4 Cognitive–behavioural therapy (CBT)
Cognitive–behavioural therapy (CBT ) is an evidence-
based therapy that works on the premise that 
cognitions and behaviours are often intrinsically 
linked. Drug use is many drug dependent clients’ 
primary mechanism of coping with a range of 
situations, both negative (such as distressing ones) 
and positive (such as celebrations and rewards). The 
emphasis of skills training is to help clients to unlearn 
old habits and replace those with new, more functional 
skills. CBT allows clients to develop, under clinical 
supervision, new coping skills, or to re-establish old 
skills that have become neglected.
Substance-abuse disorders, like many psychological 
disorders, are believed to be partly the result of 
faulty or irrational thought processes that have their 
manifestation in dysfunctional behaviours (such as 
drug taking). Many such thoughts are automatic, 
habitual, and resistant to change. The development 
of techniques to change or challenge such thought 
processes, together with other cognitive and 
behavioural coping responses, can lead to a reduction 
in an individual’s dependence on a drug. Thus, CBT 
is a skills-based approach, and works on helping 
clients to develop a range of therapeutic techniques 
for overcoming physiological dependence and 
habitual reliance on a drug as a coping mechanism. 
The approach is structured and goal-oriented, with 
“homework” tasks that require clients to develop 
specific skills in the context of their problem drug use 
by practising set exercises.
Advantages
The CBT approach is a relatively brief therapeutic 
intervention, especially when compared with some 
other psychological therapies. CBT for substance-
abuse disorders can be effective with one to six 
sessions (Mattick & Jarvis, 1993). Furthermore, the 
specific skills or techniques used can be varied 
according to the needs of the individual client.
Elements
A successful therapeutic outcome with CBT entails 
several important elements. Critically, clients are 
instructed in the use of drug-related coping skills. 
These include:
• techniques for managing urges and cravings;
•  recognising triggers of drug use; and
•  developing personal strategies for either 
avoiding or dealing with such triggers, managing 
withdrawal symptoms, and learning relapse-
prevention strategies.
•  techniques for managing negative affect;
•  stress-management skills;
•  assertiveness and communication skills; and
•  relaxation skills
Further information:
Australian Association for Cognitive and Behaviour 
Therapy
www.aacbt.org/
The British Association for Behavioural and Cognitive 
Psychotherapies 
www.babcp.com/
Association for Behavioral and Cognitive Therapies
www.abct.org/dhome/
The European Association for Behavioural and 
Cognitive Therapies 
www.eabct.com/
The Centre for Clinical Interventions 
www.cci.health.wa.gov.au/index.html/
The Psychological Self-Help (Mental Health Net) 
www.psychologicalselfhelp.org/
6.5 Contingency management (CM)
CM involves the systematic use of positive and 
negative consequences (reward and punishment) 
following a target behaviour (Budney et al., 2001). In 
the case of treatments for cannabis dependence, two 
types of CM have been tested to date: abstinence-
based and attendance-based vouchers. This incentive-
a clinician’s guide
32
based intervention was adapted from a program 
developed for the treatment of cocaine dependence 
(Budney & Higgins, 1998). The abstinence-based 
voucher program provides tangible incentives 
contingent on cannabis abstinence documented via a 
once- or twice-weekly drug-testing program. Vouchers 
have a monetary value that escalates with each 
consecutive negative drug test. Earned vouchers can 
be exchanged for pro-social retail items or services that 
may serve as alternatives to cannabis use.
Of the five trials published looking at CM and cannabis 
use, all report positive effects on cannabis-use 
outcomes (Budney et al., 2006). CM, however, has not 
been evaluated outside experimental trial conditions. 
Despite the lack of effectiveness studies (i.e. real-
world applications), clear and consistent evidence 
exists, throughout the substance-abuse literature, for 
the efficacy of abstinence-based incentive programs 
to engender high rates of initial and medium-term 
abstinence. 
General information
Contingency management considers drug use as 
operant behaviour, that is, behaviour that is maintained 
in part by the reinforcing biochemical effects of 
the abused substance and in part by reinforcing 
environmental influences (e.g. social reinforcement by 
peers). CM, in the form of vouchers, has been found 
to assist cannabis users to achieve extended periods 
of continuous cannabis abstinence during treatment 
(Petry & Simic, 2002). Contingency management seeks 
to provide alternative incentives contingent upon 
abstinence from a particular target drug. There are four 
primary methods of providing incentives:
• voucher-based reinforcement: clients receive 
vouchers with various monetary values (usually 
increasing in value after successive periods of 
abstinence) for providing biological samples 
(usually urine) that are negative for the tested 
drugs. These vouchers are withheld when the 
biological sample indicates recent drug use. 
Once earned, vouchers are exchanged for goods 
or services that are compatible with a drug-free 
lifestyle
• prize-based reinforcement: participants receive a 
set number of draws, for example from a number 
of slips of paper kept in a fishbowl, for providing 
a negative biological specimen. Provision of a 
specimen indicating recent drug use results in the 
withholding of draws. Each draw has a chance 
of winning a “prize”, the value of which varies. 
Typically, about half the draws say “good job!” and 
the other half result in receiving a prize of varying 
value
• privileges: participants receive privileges for 
providing a negative biological sample
• monetary incentives: there have been a few 
studies from America in the cannabis field that 
have assessed the use of monetary incentives. It 
appears that low-value (US$3) incentives are as 
effective as higher-value (US$20) ones
If considering offering CM incentives, be aware that 
the following issues need to be agreed upon:
• the target behaviour (i.e., attendance or drug use)
• the type of reward (cash, voucher, or products)
• schedule (cumulative, behavioural)
• principles of application (consistency, agreement/
contract/tangible)
• program details (duration, objective, consequences 
[including magnitude], schedule of delivery, 
practical logistics of costs, acceptability, training 
considerations, etc.)
• whether there is sustainable funding
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Screening 
• screening/assessment can be done with open-
ended questions and/or formalised tools
• questionnaires/screens should be scored in 
session and fed back, taking into consideration 
the client’s individual answers
• invite reflections by asking, “What do you make  
of this?”
Psycho-education 
• this includes reflecting back the harms associated 
with cannabis use that were raised by the client 
in his or her assessment. Provide the client with 
additional psycho-educational materials (see 
worksheets and booklets such as “Guide for 
Quitting”, available from www.ncpic.org.au)
Self-monitoring of cannabis use/withdrawal 
symptoms and/or mood
• if a client expresses motivation to modify 
cannabis use, encourage him or her to monitor 
changes for at least seven days. For clients with 
co-morbid mood disorders, a diary can incorporate 
cannabis use, withdrawal symptoms, and links 
with changes in mood state (see cannabis diary in 
worksheets section)
Readiness to change 
• if clients are ambivalent about changing their 
cannabis use, employ MI techniques to create a 
desire and resolution to commit to change
• complete the “pros and cons” sheet (see decision 
balance sheet in worksheets section)
• if the client is committed to change, set a 
quit date and discuss relapse prevention (see 
worksheet)
• if the client is not interested in modifying use at 
this time, offer educational material (see psycho-
education section) and negotiate a follow-up 
session
Negotiate continuing treatment/referral or a 
follow-up session
• the length and intensity of an intervention should 
be discussed from the outset
• discussing the follow-up procedures of your 
agency is an important aspect of engagement
• suggested two- to six-session interventions can be 
found in the next section, but more experienced 
clinicians may prefer to pick and choose from the 
evidence base as set out in Table 14
psycho 
-education
60 – 90 mins
setting goals
readiness  
change/
motivational  
interviewing
screening
monitoring
6.6 Outline of a single-session intervention
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6.7 Two- to six-session interventions
In the absence of evidence for the optimum number 
of sessions and which components of treatment are 
most successful, elements that have been included 
in successful cannabis-treatment trials are detailed 
below. Experienced clinicians may choose to tailor 
these components to the client’s needs based on 
the assessment or case formulation. This includes 
a negotiable number of sessions and the order you 
deliver the components in. There is no evidence to 
suggest which components may be more important 
than others.
Table 14: Components of evidenced-based 
interventions for cannabis
General Behavioural Cognitive 
Self monitoring Activity 
scheduling
Urge surfing/craving 
management
Goal setting Indentifying 
coping 
strategies
Mood management/
cognitive awareness/
coping strategies
Problem-
solving skills
Drug-refusal 
skills
Relapse prevention
Psycho-
education 
Mood 
management 
Challenging irrational 
beliefs
Sleep hygiene Urge surfing/craving 
management
*Note: client-based activities on all of these topics are located in 
the worksheet section
Alternatively clinicians may wish to follow the session 
outlines used in treatment trials. As an example, 
we have provided below the session outline from A 
Brief Cognitive–Behavioural Intervention for Cannabis 
Dependence: Therapists’ Treatment Manual (Rees, 
Copeland & Swift, 1998). Other manuals are available 
for no cost (see Table 13).
session 1: assessment session
• setting the scene and introduction to motivational 
enhancement training 
• explain privacy policy of the service, and outline 
of type of treatment the service provides
• clients to attend all six sessions for best 
results
• outline the rationale of CBT, i.e. CBT’s 
provision of specific tools that will assist in 
making desired changes
• outline the plan for therapy
• feedback from completed screening tools
• feedback level of dependence (from SDS scale)
• high-risk situations and triggers (from 
Cannabis Smoking Situations Scale)
• identify reasons for smoking and its pros and 
cons
• motivational-enhancement strategies
• establish client’s attitude and confidence to 
change and tailor your intervention to their 
stage of change
• setting goals 
• consider goals based on conversations about 
reasons for reducing/quitting
• introduction to behavioural self-monitoring
• explain that keeping tabs on smoking 
behaviour can help identify unhelpful patterns 
of thinking and behaviour
session 2: planning to quit
• review of the week and homework exercise 
• check or complete homework 
• review of personal triggers and high-risk 
situations
• review urge and trigger diary and examine any 
patterns emerging
• summarise triggers or cues
• introduction to coping with urges
• establish strategies to overcome urges
• understanding urges including their time-
limited nature
• urge surfing, non-reinforcement of urges, 
delay/distraction
• planning to quit
• setting a quit day (*see 6.8)
• information and discussion of withdrawal 
symptoms 
• examine social support systems (who, what, 
how)
• dealing with slips or lapses
• optional section: drug refusal skills
• practising making confident statements about 
having “given up”
• concluding: goals and homework
session 3: managing withdrawal, and cognitive 
restructuring
• review of the previous week
• review success of quit attempt
• review high-risk situations and triggers
• reviewing withdrawal symptoms 
• review diary, and reinforce time-limited nature 
of symptoms
• cognitive restructuring: cognitive issues in quitting 
cannabis
• outline ABC model
• challenge automatic thoughts
• discuss and challenge automatically arising 
expectations of the results of cannabis use
• ending the session
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session 4: review of cognitive strategies and skills 
enhancement 
• review of previous week
• review negative thoughts and automatic 
thoughts
• introduce seemingly irrelevant decisions
• development of personal skills
• depending on client’s need:
   i) problem-solving skills (recognising problems 
and generating solutions)
   ii) management of insomnia (principles of good 
sleep hygiene)
  iii) progressive muscle relaxation 
session 5: reviewing and consolidating
• review of previous week
• review overall progress and effectiveness of 
strategies
• coping-skills training
  i) assertiveness skills/understanding of self-
esteem
 ii) communication skills
 iii) stress/anger management
• concluding the session
session 6: relapse prevention and lifestyle 
modification 
• overview of previous week’s homework 
• relapse prevention
• outline main ideas to be covered
• discuss awareness of rationalisations
• discuss the client’s past relationship with 
cannabis
• discuss feelings of loss or anxiety related to 
stopping cannabis
• dealing with lapses/relapses
• identifying personal rewards
• looking to the future
• reviewing positive changes
• after the therapy has ended
• identify post-treatment support
6.8 Setting a quit day
Clinical experience has also suggested that clients 
benefit from nominating a quit day (i.e., a day when 
they will cease to smoke cannabis). As not all users 
have abstinence as a goal, clinicians may need to 
tailor the quit date to a reduction date. Reduction 
dates allow users to cut down their use over time.
When trying to set a quit date, clinicians should 
discuss:
• client goals: as mentioned above, not all clients 
will be aiming for abstinence
• dependence severity: as recommended in the 
alcohol field, those more severely dependent 
are encouraged to spend some time away from 
cannabis
• self-efficacy for cannabis refusal: client confidence 
can be amplified by discussing past successes 
either in achievement of abstinence or change or 
in other endeavours that highlight their resources/
strengths
• employment/educational requirements and legal 
or parenting responsibilities: mandated orders 
may influence the need to quit or cut down and 
the time limits set by the client in which to achieve 
his or her goals 
6.9 Summary
Recommendation Evidence
Results from treatment trials have indicated 
that interventions using CBT/MET and CM are 
effective treatment for cannabis use
A
Clinicians should train in Motivational 
Interviewing techniques, in order to 
appropriately intervene with clients at 
different stages of readiness to change 
A
As there is no evidence to guide the optimum 
number of sessions, clinicians should develop 
the skills to offer one to nine sessions, 
depending on clients’ needs or goals and the 
agency setting
C
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chapter 7: special 
considerations
7.1 Young people
Working with young people requires an understanding 
of the developmental issues as well as of the risk 
and protective factors associated with adolescent 
issues. It has been suggested that working with young 
people requires unique approaches that consider 
developmental processes, physical differences, and 
differences in belief and value systems (Winters, 
1999). Typically, young people do not seek treatment. 
Of those who present for treatment, many have been 
coerced, under direction of the courts or pressure from 
family or schools, and may be unmotivated to change. 
Often not completing treatment, young people need 
to be given up-to-date accurate information, including 
harm reduction strategies, early in treatment: 
assessment and psycho-education should be 
combined during the first few sessions.
Brief motivational interventions have been demonstrated 
to be effective in reducing cannabis use and cannabis-
related problems in both treatment-seeking and non-
treatment seeking young people (Dennis et al., 2004; 
Martin & Copeland, 2008). It has been suggested 
that the motivational approach may be particularly 
appropriate for young people given its emphasis on 
acceptance, absence of labelling, and avoidance of 
argumentation or hostile confrontation (Tevyaw & Monti, 
2004). This accepting approach also means that the 
young person need not identify themselves as having 
a substance use problem (or potential problem) in 
order to participate in the intervention, which may aid 
the engagement of young people who do not see their 
behaviour as problematic, nor self-identify as having a 
problem (Tevyaw & Monti, 2004).
There are many factors that may reduce the likelihood 
of young people seeking treatment:
• young people’s belief in their invincibility;
• adolescence being a natural time of 
experimentation;
• executive function not being fully developed;
• their not yet being socialised into seeking help;
• concern about the consequences should their 
cannabis use become known to schools/police/
parents
The literature provides increasing evidence that 
involving families in drug treatment for youth is “best 
practice”. Involvement of families in the assessment 
and treatment of young people’s drug-use issues is 
outlined in chapter 8.
Group interventions need to consider matching of 
young people according to key variables such as age, 
developmental stage, intensity of drug use, peer 
affiliation, and youth subculture.
The majority of the evidence supporting brief 
interventions with adolescent substance users 
comes from the “check-up” model. This intervention 
is designed for and tailored to the non-treatment 
seeker, with the intention of promoting a “taking 
stock” experience designed to increase motivation 
for change. Walker et al. (2006) note that check-up 
models have five elements in common:
1)   The prospective participant is helped to 
understand the nature of the check-up as 
something other than treatment: something that 
may be helpful to the individual who is questioning 
his or her own current behaviour or who has 
concerns, and something during participation in 
which he or she has the choice to accept or reject 
feedback offered.
2)   Each “check-up” involves an assessment that 
captures information about behavioural patterns, 
positive and negative consequences as perceived 
by the client, and attitudes regarding changing or 
not changing the behaviour.
3)   Check-ups offer personalised feedback to the 
participant. Commonly, personalised feedback 
reports (PFRs) are created from the client’s 
assessment responses and include: normative 
comparison data (e.g. how the individual’s drinking 
frequency compares with the average frequency 
of drinking by the general population); graphics 
that are used to enhance self-appraisal of the 
behaviour; risk-related indices; and the positive 
and negative consequences from changing that the 
client anticipates.
4)   A style of interviewing that facilitates a candid 
taking stock of one’s own behaviour (i.e., 
motivational interviewing) is essential to this type 
of experience.
5)   Interventions are based on harm reduction 
principles and the “stages of change” model, 
both of which support tailoring interventions to 
meet individuals “where they are” in order to both 
reduce stigma associated with help-seeking and 
to encourage low-threshold access to services as a 
means of supporting steps (however big or small) 
toward change.
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Check-up models have also been shown to be helpful 
in adult cannabis-using populations. For more 
information and training on check-up models, see 
Walker et al. (2006), Martin & Copeland (2008), and 
www.ncpic.org.au
Websites for young people and mental health 
issues
The following websites are well designed, with young 
people in mind. They offer information including a wide 
range of self-rating scales, activities, evidence-based 
factsheets and interactive opportunities, including a 
web-based CBT program (www.moodgym.anu.edu.au) 
that operates as an e-couch and has been described in 
the literature (Burns et al., 2007). 
http://www.reachout.com.au
http://www.headspace.org.au
http://www.somazone.com.au
http://www.ybblue.org.au 
OR http://www.beyondblue.org.au
http://www.moodgym.anu.edu.au
7.2 Gender
Alcohol and other drug services have typically failed 
to meet the special needs of substance-dependent 
women. Given the dearth of cannabis-specific 
services, it is not surprising that there are a limited 
number with gender-specific programs. It should 
be remembered that women have some special 
constraints on accessing treatment. These include a 
particular sensitivity to the stigma associated with 
dependency in women, especially while pregnant 
(Zeese & Lewin, 1999); higher rates of trauma 
and of comorbid mental health rates (especially 
for depression, anxiety, somatic, and personality 
disorders ); and difficulties with physical access 
because of parental responsibilities. In recent 
decades, the number of women using cannabis 
increased, subsequently reducing at a slower rate than 
the number of males such that they now converge for 
14- to 19-year-olds. Motives for use may differ between 
men and women, males more motivated by mood 
enhancement and women using to cope with chronic 
stress or tension (Chabrol et al., 2005), which may 
account for the higher rates of anxiety and depression 
reported in women cannabis users (Copeland, 2006; 
Degenhardt, Hall & Lysnkey, 2003; Poulin et al., 
2005). Higher rates of mental disorders among female 
cannabis users are already apparent in adolescence 
(Tu, Ratner & Johnson, 2008), which may suggest that 
early intervention for mental health problems may 
reduce the numbers of women seeking treatment in 
the future.
Men initiate cannabis use earlier than do women, 
make up the majority of cannabis users, and more 
commonly seek cannabis-use treatment. This 
suggests that drug education programs aimed at 
prevention and identification of problem use should 
be developed specifically for boys and provided to 
them earlier than programs are presented to girls. 
Specific issues facing men include links between drug 
use and anger and/or violence, and higher rates of 
completed suicides. These are important issues to be 
addressed in treatment. It should be noted that men 
respond better to concrete, action-oriented treatment 
approaches (such as CBT) and perform better in 
mixed-gender groups (Marsh & Dale, 2006).
7.3 Culturally and linguistically diverse 
populations
People from culturally and linguistically diverse (CALD) 
backgrounds are less likely to access drug-treatment 
services than are those from the predominant 
culture; and if they do, it is after a longer period 
of time spent coping alone with their drug issues 
(Reid, Crofts & Beyer, 2001). Research has identified 
several contributing factors. These include lack of 
knowledge about the services available; lack of 
trust in the services; an unfamiliarity with seeking 
help outside the family or community unit for any 
problem; and great stigma and shame surrounding 
drug use, which makes seeking help for this problem 
particularly difficult (Donato-Hunt, 2007). Developing 
an effective therapeutic relationship needs to take into 
account these factors if a treatment approach is to be 
successful.
When working with people from CALD populations, 
it is important to consider the cultural context of 
cannabis use. Houseman (2003) recommends that, in 
order to understand the cultural context of use and to 
provide treatment in a culturally secure way, clinicians 
develop an understanding of a client’s cultural 
experience and beliefs in three core domains:
• migration experience and context of migration
• ethnic subgroup membership
• beliefs in relation to the dominant culture – 
ascertaining whether the client’s beliefs are 
traditional, acculturated, or a blend of the two
The Drug and Alcohol Multicultural Education Centre 
(DAMEC) recommends that clinicians be aware 
of a client’s degree of English comprehension. 
Importantly, comprehension will affect clients’ ability 
to communicate their expectations for treatment, 
which can have a serious effect on the therapeutic 
relationship and treatment outcome; furthermore, it 
will affect a client’s participation and understanding 
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in a group-treatment setting. Avoiding jargon and 
minimising reliance on written information and written 
homework will ease communication. The use of an 
interpreter in some cases can be helpful but can 
result in numerous problems. Dale, Marsh, and Willis 
(2007) recommend that clinicians be aware of the 
potential problems of using an interpreter: primarily in 
confidentiality and accurate translation.
It is recommended that referral to ethnospecific 
services is ideal; and that in lieu of the availability 
of treatment services for every cultural group in the 
community, using cultural consulation in colloboration 
with an AOD-treatment service is likely to provide the 
best treatment outcomes (Dale, Marsh & Willis, 2007) 
It is useful to meet with a cultural consultant prior 
to meeting with a client. Cultural consultation can 
provide assistance and guidance in the following:
• gaining knowledge about the client’s cultural 
background
• tailoring manualised treatments
• tailoring any written material provided to the client
• assessing the understanding of homework tasks
• providing guidance in utilising the community
• providing guidance in the role of gender in 
treatment
If a cultural consultant is unavailable, ascertain the 
client’s preferred approach.
7.4 Indigenous populations
Cannabis use by Indigenous Australians is common 
and presents a significant health concern (Clough 
et al., 2004). For example, the Western Australian 
Aboriginal Child Health Survey (2005), which surveyed 
the emotional and social wellbeing of 5289 young 
Aboriginal people aged up to 17 years and living in 
Western Australia Blair et al. (2005), indicated the 
following:
• thirty per cent of young people in the sample had 
used cannabis at some time in their lives
• forty-five per cent of males and 21% of females 
used cannabis at least weekly
• seventy-five per cent of those sampled who drank 
alcohol and smoked cigarettes also regularly 
used cannabis, in comparison with eight per cent 
of those who neither drank alcohol nor smoke 
cigarettes
Similarly, Clough and colleagues have reported a 
lifetime prevalence of cannabis use of 77% of males 
and 61% of females in a random sample of 190 people 
(17–36 years) from two communities in Arnhem Land.
In providing treatment to Indigenous clients, the 
following are recommended for culturally secure 
service provision:
• given the prevalence of cannabis use, include 
screening for cannabis use in all primary  
health-care and general-counselling settings
• develop an awareness of the terms and non-
verbal gestures denoting cannabis in the local 
community
• recognise that questionnaires and other 
assessment methodologies may not be 
appropriate. When providing feedback on any 
measures, be aware that scores in relation to the 
general population may have little significant 
meaning to a client
• if possible, give the client the opportunity to 
choose to have an Indigenous worker present 
of the same sex or to have a referral made to an 
Indigenous-specific service
• get to know the local history of colonisation, and 
work within that knowledge
• receive cultural-awareness training
• ensure that treatment occur within the Indigenous 
definition of health
• in consultation with the client, aim to include 
family and community systems. Maintain 
confidentiality while doing so
• consult with an Indigenous cultural consultant, 
or attain Indigenous supervision, to discuss 
treatment appropriateness and any matters 
concerning shame and confidentiality
• be aware of the intensity of the grief and loss that 
continue to affect many Indigenous communities, 
and consider this in formulations and treatment 
approaches (Dale, Marsh & Willis, 2007)
• provide clinical services in a flexible manner; 
cultural and family obligations will often take 
precedence over appointments (Dale, Marsh & 
Willis, 2007)
• have an awareness of a client’s English-language 
comprehension and literacy, and reduce clinical 
jargon and reliance on written information and 
homework tasks accordingly
Existing styles of practice are not always sensitive to 
the cultural beliefs and family systems of Aboriginal 
people. Strong Spirit Strong Mind (Casey & Keen, 
2005) is one example of an alcohol and other drug 
intervention that applies CBT in a culturally secure 
way. The Strong Spirit Strong Mind resources outline 
how the inner spirit can be applied in a therapeutic 
context and incorporates culturally secure CBT. 
The model provides a structure for understanding 
the effects and implications of colonisation and of 
the introduction of alcohol and other drugs, and is 
consistent with ‘social learning theory’.
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Useful resources:
Casey, W. & Keen, J. (2005). Strong Spirit Strong Mind, 
Aboriginal alcohol and other drugs worker resource: 
A guide to working with our people, families and 
communities. Aboriginal Alcohol and other Drugs 
Program, WA Drug and Alcohol office.
Dudgeon, Garvey & Pickett’s (2000) Working With 
Indigenous Australians: A Handbook for Psychologists 
(Perth: Gunada Press, Curtin Indigenous Research 
Centre).
http://www.hc-sc.gc.ca/fniah-spnia/substan/ads/
nnadap-pnlaada-eng.php
7.5 Clients who are diverted to treatment or are 
otherwise involuntary
Involuntary referrals are very common in cannabis 
treatment with the introduction of diversion strategies 
within several jurisdictions internationally. There 
are, however, other types of coercion. These include 
referral of parents in relation to child protection; 
requirements by employers; referral of adolescents by 
parents or school; and coercion by somebody close.
There is limited research assessing the efficacy of 
legally coerced treatment, despite a third of referrals 
to alcohol and other drug treatment agencies across 
Australia being recorded as being from the criminal 
justice system. A recent evaluation of the NSW Drug 
Court (Weatherburn et al., 2008) found positive 
outcomes, as did a review of police drug-diversion 
programs in Australia (Ogilvie & Willis, 2009). A study 
of adults attending drug treatment in Texas reported 
that those legally coerced into treatment had less 
psychological distress, were more likely to complete 
treatment, and were less likely to be using cannabis 
at 90 days post treatment than were voluntary clients 
(Copeland & Maxwell, 2007).
In session:
• discuss expectations at point of referral
• acknowledge why they are there, and validate 
their feelings about being diverted/coerced into 
treatment
• acknowledge that there may be a formal 
monitoring of progress, and any other limits to 
confidentiality 
• engagement and motivation enhancement therapy 
is more important than assessment 
• many coerced clients are not interested in 
modifying their use. In this case, carefully 
consider harm minimisation strategies (depending 
on criminal justice status or goals of abstinence/
reduction in use)
7.6 Reducing use in those not seeking treatment
In common with users of other drugs, the majority of 
cannabis users do not seek professional treatment. 
It is, therefore, important that a range of activities 
including health promotion occur in a variety of 
contexts to raise the profile of treatment options.
There are opportunities to be proactive to provide early 
intervention to prevent cannabis use from becoming 
problematic. General information about cannabis use 
and treatment options can be disseminated through 
settings such as health services, GPs, community 
settings, youth services, and schools. Initiatives may 
include:
• health promotion activities in various settings, 
including community education about the health, 
social, and legal consequences of cannabis use 
and about how interventions can be accessed if 
required;
• programs of peer education, by present and 
former cannabis users, about the harms of 
cannabis, harm reduction strategies, and the 
treatments and services available
7.7 Individual vs group treatment
The cannabis intervention studies reported in the 
literature include group and individual interventions. 
Whilst many clients prefer an individual approach, 
evidence shows that CBT can be beneficial when 
offered in a group setting (Stephens et al., 1994; 
Stephens et al., 2000; Marques & Formigoni, 2001). 
In order to deliver CBT effectively in a group setting, 
clinicians need to be proficient in group processes.
Considerations 
Things for agencies to consider when developing group 
or individual programs include:
• the skill of clinicians in delivering group-based 
CBT or other intervention;
• the ability of the organisation to conduct pre-
assessments to match group members on key 
variables such as age, peer affiliation, youth 
subculture, degree of dependence, developmental 
stage, and gender balance;
• the interest of clients to engage in-group work. 
Generally speaking, it is harder to attract people 
to groups, due to stigma and embarrassment;
• group dynamics, which may either negatively or 
positively affect group cohesion; The greatest risk 
is when the membership is diverse, with limited 
common experiences;
• that services may be able to respond more quickly 
to client needs (through reduced waiting lists) 
through groups but dropout may be higher
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For clinicians wishing to consider groups for cannabis, 
we recommend the Cannabis Youth Treatment manual, 
available on line at http://ncadi.samhsa.gov/govpubs/
bkd384/OK
7.8 Treatment settings
Although cannabis treatment rarely requires in-patient 
care, a client’s immediate environment may interfere 
with his or her ability to achieve abstinence in an 
outpatient setting. There is a lack of well-conducted 
studies assessing the efficacy of residential in 
comparison with community-based treatment of 
substance use disorders and the efficacy of specific 
types of residential treatment. Residential treatment 
may be considered for those clients who are seeking 
abstinence and who have significant comorbid 
physical, mental health or social (for example, 
housing) problems. The client should typically have 
attempted a community-based psychosocial treatment 
first. Any additional benefit that might accrue from a 
period in residential rehabilitation over and above that 
obtained from the initial period of detoxification is 
likely to be related to the chronicity of the dependence 
and/or comorbid psychosocial problems. When 
symptomatic medication for withdrawal symptoms 
seems appropriate, links between prescribers and 
treating agencies are important.
When considering an in-patient or residential setting 
with clients, the relevant issues include:
• whether the home environment is an appropriate 
setting for detoxification (i.e. whether 
supports are available; availability of stable 
accommodation; number of failed outpatient 
attempts);
• whether the client has comorbid physical ill health 
or mental health issues;
• whether the client is withdrawing from multiple 
substances;
• the client’s preference
7.9 Early termination of treatment
Even after intake and acceptance into treatment, 
individuals are often ambivalent about going on to 
begin it, and the risk of dropout at this point is high. 
It is common for even those seeking treatment to 
not stay long enough to benefit (Hser et al., 1997). 
Pre-treatment dropout of people with cannabis 
dependence is associated with a range of social 
instability and socioeconomic factors. These include 
being unemployed, unmarried, less educated, and 
young (Vendetti et al., 2002). Individuals who do not 
perceive themselves to be “dependent” on cannabis 
have been found to be almost four times as likely to be 
pre-treatment dropouts than those who acknowledged 
their cannabis dependence.
What if an 
adolescent 
drops out of 
treatment?
Young people should be more 
assertively followed up.
Follow-up tips:
use a phone call (minimum) followed •	
by a letter (handwritten letters on an 
official agency letterhead may lead to 
better re-engagement)
research suggests that confirming •	
appointments by text/SMS increases 
attendance
7.10 Continuing care
Follow-up sessions or booster sessions are also good 
clinical practice in the management of cannabis-
use disorder. The timing of a follow-up session 
may depend on issues such as the magnitude of 
the problem, the skills the client needs to practise 
between sessions, and the capacity of the clinician 
and of the service. Studies have examined a number 
of styles of continued care. There is still much to learn 
about:
• the usefulness of more frequent or even 
continuous monitoring in improving outcomes;
• the effect of less formal types of care (e.g. 
recovery coaches and faith-based interventions); 
and
• modes of service delivery such as mail, telephone, 
Internet, and e-mail
All clinicians are encouraged to develop their own 
models that consider resource issues and capacity 
limits, as the research indicates that regardless 
of what method you use, if you do it well, positive 
client outcomes increase. Two such methods are 
discussed below.
Telephone-based continuing care
The use of telephone-based interventions is novel 
and gaining popularity as a low-cost option. Results 
suggest that weekly telephone delivery of continuing 
care after in-patient/residential care can lead to 
improved outcomes (Cacciola et al., 2008). The 
authors recommended that follow-up procedures 
be explained to clients in detail from the time of 
admission. This raises participation rates and 
lowers rates of unplanned discharges. Procedures 
for the number of attempted calls and for increasing 
the intensity or frequency of contact attempts 
following missed phone sessions need to be clearly 
documented.
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Assertive continuing care (ACC)
In order to reduce relapse rates, a structured plan for 
following up clients who have recently left treatment 
(regardless of setting) is important. Assertive 
continuing care is care in which the clinician takes 
an active role in supporting the client to receive 
continuing support. A study of young people leaving 
residential rehabilitation for continuing-care services 
showed that they were more likely to be abstinent from 
cannabis three months later than those not receiving 
ACC (Godley, Godley & Dennis, 2002).
The process generally starts with the clinicians 
meeting the client before discharge. Subsequently, 
the clinician provides outpatient or phone support and 
help to negotiate additional treatment services, which 
may include school support, probation, and other 
services to support recovery. Continuing-care plans 
may include brokerage of links to local outpatient 
treatment programs and self- or mutual-help groups.
Considerations
The following guidelines are recommended as the 
minimum for continuing care:
• despite the difficulty of following up clients, it 
should be given high priority
• the format for follow-up procedures should be 
explained to clients before discharge. They should 
have the option of not participating in follow-up, 
but its importance should be emphasised to them
• the first follow-up session should be scheduled 
before the client completes treatment
• advise the referring agency of the outcome of 
treatment and of your intentions regarding  
follow-up
• preference should be given to face-to-face 
(individual or group) or telephone follow-up, 
although even written contact has benefits
• follow-up should be arranged at periodic intervals 
after completion, at a frequency within your 
resources
7.11 Other therapies
Whilst the evidence regarding cannabis-use disorder 
supports the use of CBT and MET, there may be 
reasons to consider other modes of therapy (e.g., 
complexity, resistance to CBT, or your previous 
clinical training). The following therapies were found 
by the NSW Health Drug and Alcohol Psychosocial 
Interventions Professional Practice Guidelines (NSW 
Department of Health, 2008) to be supported by at 
least level 2 or 3 research and clinical opinion.
• mindfulness-based stress reduction (developed by 
Segal, Williams & Teasdale, 2002)
• this is a meditative practice with Buddhist 
origins
• attention is focused on physical, emotional, 
and cognitive experiences in the present 
moment
• dialectical behavioural therapy (DBT) (developed 
by Linehan, 1993)
• this is adapted from treatments with 
borderline personality disorder. It involves 
CBT and mindfulness approaches to include 
group skills training, behavioural and cognitive 
modification of problem behaviours, reflection, 
empathy, and acceptance
• DBT has been adapted to specifically target 
problematic alcohol and other drug use, and 
improved outcomes have been reported
• acceptance and commitment therapy (ACT) 
(developed by Hayes & Strosahl, 2004)
• this approach teaches people to explore 
painful events such as thoughts, memories, 
feelings, and bodily sensations rather than 
avoid them
• research suggests that ACT is effective with 
stress management, depression, pain, chronic 
illness, and drug dependence 
• solution focused brief therapy (SFBT) (developed 
by de Shazer, 1985)
• this approach assumes that the client is willing 
and motivated to change, and treatment helps 
him or her imagine what would he or she would 
like to be different and what can be done to 
bring about that change
• a meta-analysis of SFBT approaches found a 
positive treatment effect (Kim, 2008)
• psychodynamic approaches
• these focus on the effects of external stimuli
• treatment is generally long-term (lasting from 
16 weekly sessions to several years)
7.12 Internet approaches
Self-help strategies offer a promising solution to the 
accessibility difficulties of face-to-face treatment, 
and the Internet provides an excellent delivery mode 
for such strategies. Studies have demonstrated the 
efficacy of web-based treatment in reducing the 
use of alcohol (e.g. Doumas & Hannah, 2008; Kypri 
et al., 2008; Riper et al., 2008) and tobacco (e.g., 
An et al., 2008). No published study has tested the 
effectiveness of web-based specialist treatment for 
cannabis use.
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7.13 Concurrent drug use
Tobacco use 
For clients who smoke cannabis and use tobacco 
(independently and/or mixed with cannabis), the 
evidence for quitting simultaneously is mixed. One 
study found that smoking cessation did not disrupt 
alcohol abstinence and suggested that quitting both 
may enhance the likelihood of longer-term sobriety 
(Gulliver, Kamholz & Helstrom, 2006). A further 
study found that symptoms of withdrawal were more 
severe during simultaneous cessation, but that the 
differences were of short duration and not robust; 
substantial individual differences were noted (Vandrey 
et al., 2008). Sullivan and Covey’s (2002) review of 
clinical trials found that continued smoking adversely 
affects treatment for cannabis dependence. 
A client’s inability or unwillingness to cease tobacco 
use should not, however, be a barrier to accessing 
or continuing cannabis treatment. Clients who 
mix tobacco with their cannabis may not identify 
themselves as tobacco smokers, so careful 
assessment of comorbid nicotine dependence and 
feedback of the risks of using tobacco are warranted.
“ Difficulty in tobacco cessation might be considered one 
of the most important adverse effects of marijuana use” 
(Ford, Vu & Anthony, 2002, p. 247).
Overview
• tobacco use has been associated with increased 
cannabis dependence (Ream et al., 2008; Okoli 
et al., 2008) and makes quitting cannabis more 
difficult (Patton et al., 2006)
Steps
• assess nicotine dependence by clinical interview 
or the Fagerström Nicotine Dependence 
Questionnaire
• assess readiness to change tobacco use 
concurrently
• if the client is ready, discuss and/or refer him or 
her for pharmacotherapy options such as Nicotine 
Replacement Therapy (NRT), buproprion (Zyban), 
or varenicline (Champix). Various options appear 
in Table 15
• in Australia, Champix has superseded Zyban
• note: clinicians are encouraged to monitor the 
results of clinical trials of nicotine replacement-
therapy options, as this field is rapidly expanding
NB: The Fagerström Nicotine Dependence 
Questionnaire may not be appropriate for those who 
do not smoke tobacco independently of their cannabis.
Review of nicotine-replacement therapy (NRT)
A Cochrane review (Stead et al., 2008) of 132 trials of 
NRT, with over 40,000 people, found that all forms 
of NRT made it more likely that a person’s attempt to 
quit smoking would succeed. The chances of stopping 
smoking were increased by 50 to 70% (based on a 
15-cigarette-a-day habit).
Other results include that:
• there are no overall differences in the 
effectiveness of different forms of NRT, nor a 
benefit from using patches beyond eight weeks
• NRT works with or without additional counselling
• heavier smokers may need higher doses of NRT
• people who use NRT during a quit attempt are 
likely to further increase their chance of success 
by using a combination of the nicotine patch and a 
faster-acting form
• preliminary data suggest that starting to use NRT 
shortly before the planned quit date may increase 
the chance of success
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Table 15: Options for nicotine-replacement therapy
Preparation Method Possible side effects Dosing
Transdermal patches 16 hr and 24 hr patches are available
They are placed on a relatively hairless 
part of the body between neck and ankle
Local irritation may occur 1 patch per day
Sublingual tablets A microtab is placed under the tongue 
and absorbed
Some burning sensation in 
mouth
15–20 tablets/day
Lozenges A lozenge is placed in the mouth Some burning sensation in 
mouth
10–15/day
Chewing gum Chew gum for a few minutes then rest in 
mouth
Repeat, changing sides 
Limit time per piece to 20 minutes
Some burning sensation in 
mouth
Aching jaw
1–15/day
Nasal spray One squirt per nostril Some burning sensation in 
nostrils 
Sneezing and eyes may water
2 squirts regularly 
throughout day
Inhalator Puffed on as with a cigarette N/A 3–6 cartridges
Adapted from McEwen, Hajek, McRobbie, & West (2006), Manual of Smoking Cessation: A Guide for Counsellors and Practitioners.
CAUTION
Caution should be taken when prescribing buproprion 
(Zyban) during cannabis withdrawal, as it may exacerbate 
withdrawal symptoms. 
There is no evidence base for NRT among young people.
NRT is available over the counter at pharmacies but 
is not subsidised by the Pharmaceutical Benefits 
Scheme (PBS). Champix and Zyban are available 
only by prescription from a medical practitioner and 
are subsidised by the PBS. At this time, there are no 
published clinical trials of the use of NRT and Champix 
for use in either cannabis dependence or nicotine and 
cannabis dependence. There is one published clinical 
trial of the use of Zyban in cannabis dependence 
with poor outcomes because of the significant side 
effects of the bupropion’s exacerbation of cannabis 
withdrawal.
Concurrent benzodiazepine use
For cannabis users seeking treatment for their 
cannabis use and also either using benzodiazepines 
for a recognised condition or dependence on 
benzodiazepines, the following is recommended:
Steps Recommendations for medical management
1 Stabilise benzodiazepine use: this can be 
achieved by a reduction regime and capping 
the number of tablets consumed each day at 
a number that you and the client are agreed is 
manageable
2 Selective detoxification from cannabis: clients 
reduce their cannabis use while maintaining 
the current dose of benzodiazepines
3 Monitor and maintain benzodiazepine use: 
check with client regularly to ensure that there 
is no escalation of benzodiazepine use
4 After the cannabis use has ceased (or 
been reduced and stabilised), consider the 
options for withdrawal from or reduction of 
benzodiazepines with medical supervision
7.14 Dealing with time constraints
Throughout these guidelines we have talked about 
shaping interventions to the needs of the client. 
Interventions will also be shaped, however, by the 
setting in which you work and, realistically, by the time 
you have available. The following is a guide for shaping 
your interventions (adapted from Shand et al., 2003). 
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Table 16: Settings with time constraints 
No time provide pamphlets about quitting •	
cannabis (www.ncpic.org.au)
30 mins screen•	
give simple advice about the harms •	
associated with cannabis use
offer a follow-up appointment•	
60–90 mins assessment of cannabis and other issues •	
and personalised feedback
discuss self-management and treatment •	
options
provide self-help material•	
offer follow-up appointments•	
7.15 Summary
Recommendations Evidence
In most instances, cannabis dependence can 
be treated in an outpatient setting, using MI/
CBT interventions
A
Whilst not tested outside research trials, the 
addition of CM to MI/CBT has been shown to 
improve outcomes
A
Comorbid dependencies are common and 
can be treated simultaneously, e.g. nicotine 
dependence with NRT
C
Whilst there is no research to guide the 
optimum number of sessions, courses of 
one to nine sessions have been tested with 
positive outcomes
C
Continued care and assertive follow-up are 
important aspects of treatment
B
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chapter 8: family interventions
8.1 Families
Children may experience the negative consequences 
of their parents’ drug use. A recent report noted that 
approximately 10% of children live in households in 
which there is parental alcohol or other drug abuse 
or dependence. In addition, 24 out of every 1000 
Australian children under the age of 12 years will be 
exposed to at least one individual who uses cannabis 
on a daily basis (Frye et al., 2008).
Considering families is an important aspect of 
treatment, particularly in relation to adolescent 
clients. This chapter considers engaging family 
members, regardless of whether the cannabis user is 
the parent or the child. The interventions mentioned 
in this chapter can be implemented at any stage 
of treatment as deemed appropriate. Clinicians 
and settings will vary in their practices and in their 
capacity to provide interventions to family members. 
Clinicians are encouraged to do their own formal 
assessment of an individual family’s willingness and 
capacity to undergo family-oriented treatment. A 
comprehensive assessment should include a mental 
health and drug-use assessment of the parents, and 
potential referral for individual treatment of these 
issues. Below are listed principles and varying levels 
of intervention by which to support families that 
clinicians can consider. These interventions can be 
implemented at any stage of treatment as deemed 
appropriate. Please note that these interventions are 
recommended only for clinicians with prior training 
and experience in working with families.
8.2 Principles of family-inclusive practice
• involving families in treatment services can lead 
to better outcomes for the individual
• clients are the best judges of who their family is, 
and of the extent to which their family should be 
involved in treatment
• families are capable and often willing to change to 
support the individual in treatment
• staff members need to be adequately trained and 
equipped to work with families
(Patterson & Clapp, 2004)
8.3 Confidentiality
When working with more than one family member, 
clinicians often face the dilemma of breaching client 
confidentiality. Family-inclusive practice supports 
the rights of all clients to a confidential service. It is 
the right of the client to determine to whom he or she 
a clinician’s guide
48
or others will disclose details of their treatment. No 
information regarding a person’s treatment should 
be given without the client’s explicit (we recommend 
written) consent.
The following are worth clinicians’ consideration:
• discussing the clinician’s limits of confidentiality 
(such as in dealing with child protection or self 
harm);
• developing “release of information” forms that 
detail the specifics of what information is to be 
released;
• establishing confidentiality guidelines with all 
parties prior to commencing joint sessions;
• discussing with clients what information is 
recorded in their case notes
8.4 “Level of engagement” 
Patterson and Clapp (2004) have described 
different “levels of engagement” in working with 
families, depending on the family’s coping skills and 
involvement with the cannabis user.
Level 1: considering families when working with clients
At the point of contact, clinicians may ask clients 
questions that relate to family and significant others.
Examples could include:
“Who is important in your life at this moment?”
“How do they support you?”
“Do they know you are attending the service?”
“ Would you like them to be involved in treatment and in 
what way?”
It is the clinician’s role to keep the concept of family 
alive in all continuing client work and to take into 
consideration any changes in circumstances or in 
intensity of support. Genograms (pictorial displays of 
family relationships) may assist clinicians to explore and 
conceptualise family relationship and potential alliances.
Level 2: telephone support to families
Telephone support generally involves providing 
information and support over the phone to family 
members. It differs from telephone counselling in 
that it often involves a single contact with the client 
and focuses more on information-giving than on 
therapeutic support.
Family members may be offered:
• validation of concerns;
• information about cannabis withdrawal and what 
to expect;
• information on the general treatments available 
for cannabis dependence; 
• referral information;
• crisis intervention;
• problem-solving
Level 3: effective referral of families to other support 
services
Organisations or clinicians offering effective referral 
should keep an up-to-date list of agencies offering 
services in their local area. Services may include 
support groups, community health centres, family-
support agencies, and allied health professionals.
In intervention of this type, it is recommended that:
• any databases be updated at least six-monthly;
• you make direct contact with services or people to 
gather information about the referral processes, 
referral criteria, the type of service they offer, the 
length of the treatment, and treatment costs;
• you conduct active referral: calling the family 
members to see whether they have made contact 
with the referred service, or supporting the family 
to make contact
Level 4: establishment of facilitated support groups for 
families
If you or your organisation has the capacity, facilitated 
support groups for family members are a forum for 
providing access to information about cannabis 
and its effects. Groups are generally developed and 
facilitated by experienced clinicians who have skills at 
managing complexity in groups. They differ from self-
help groups in that they are time-limited, participants 
are registered as clients, and the organisation has 
responsibility for facilitation.
Facilitated support groups can provide support and 
safety for members to normalise reactions, decrease 
feelings of isolation, and increase coping skills in 
relation to the client’s drug use. They provide a forum in 
which clients can ask questions and receive responses 
from skilled and experienced practitioners and in 
which family members can learn from others present 
the resources and supports available in the wider 
community.
Level 5: single-session family therapy
Single-session therapy is a consultation aimed at 
taking best advantage of the organisation’s existing 
resources and of clients’ readiness to change, using 
the principles and ideas of family therapy and brief 
solution-focused therapy. A single session can include 
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the client and family members or can be undertaken 
with a single family member.
Interested clinicians are encouraged to seek training 
for single-session therapy.
Single-session therapy has three discreet phases:
 Intake: the family members complete an intake 1. 
questionnaire aimed at focusing their thinking on 
the problem to be addressed; existing resources or 
strengths; and change that has already occurred.
Counselling session: the elements of this session 2. 
should include setting a context; finding a focus; 
investigating attempted solutions; investigating 
constraints; reflecting; giving the client feedback; 
addressing last-minute issues; assessing 
communication in the family and family dynamics; 
and discussing what is next.
Follow-up: the family is followed up with a letter 3. 
or phone call approximately three weeks after the 
session. Another single session may be arranged, 
or files may be closed if no further intervention is 
required.
Additionally, Copello and colleagues (2009) found 
that working with users and families leads to positive 
substance-related outcomes. They have outlined a 
brief five-step family-member-focused model that can 
be delivered in a single session.
Step 1:  Listen non-judgementally to the family 
member’s concerns.
Step 2:  Provide information and education about drug 
misuse.
Step 3:  Discuss ways of responding to the family 
member’s drug use and associated behaviours.
Step 4: Explore sources of support for the family.
Step 5: Arrange further help if needed.
Level 6: providing counselling (individual and joint) to 
families
Counselling with families may include joint counselling 
or separate sessions for the family members, with 
the purpose decided by the client and family before 
commencement. Clients with drug-related problems 
often face complex issues that can lead to alienation 
from family and social support. Attempting to deal with 
these issues in isolation can be extremely difficult. 
Family members can be recruited to be on the client’s 
“team” to act as part of the solution. There are no studies 
to guide the use of one modality of family therapy over 
another. The three modes of family therapy for which the 
most evidence has been collected include functional 
family therapy (Waldron et al., 2001), multidimensional 
family therapy (MDFT) (Liddle et al., 2001), and 
multisystemic therapy (Henggeler et al., 2002).
Functional family therapy has been shown to be 
efficacious with high-risk and juvenile-justice-involved 
youth. It is a highly structured program consisting of 
several phases. Each phase includes specific goals, 
assessment foci, specific techniques of intervention, 
and therapist skills necessary for success. It works 
first to develop family members’ inner strengths and 
sense of being able to improve their situation. This 
provides the family with a basis for change and for 
future functioning that extends beyond the direct 
support of the therapist and other social systems.
Multidimensional family therapy (MDFT) is a family-
based treatment developed for adolescents with drug 
and behaviour problems and for prevention of early 
adolescent substance use. The goal is to significantly 
reduce or eliminate the adolescent’s substance use 
and other problem behaviour, and to improve overall 
family functioning. MDFT is recognised internationally 
as amongst the most effective treatments for problems 
relating to adolescent substance use (e.g. Brannigan 
et al., 2004; Rigter, Gageldonk & Ketelaars, 2005). 
Support for its effectiveness in reducing cannabis 
use comes from two large randomised trials, the 
first comparing MDFT with adolescent group therapy 
and multifamily educational intervention (Liddle 
et al., 2001), the second comparing, among 600 
cannabis-dependent adolescents, the effectiveness 
of MDFT with that of an Adolescent Community 
Reinforcement Approach and of a range of other 
interventions, including MET/CBT and community 
reinforcement (Dennis et al., 2002). Results from 
the first trial showed improvement among young 
people in all treatments, with MDFT showing superior 
improvement over all in relation to drug use (primarily 
cannabis) and psychosocial functioning more 
generally, including family function and academic 
performance. The positive findings suggest that MDFT 
may be particularly useful for young people with co-
existing behavioural problems. In the second trial, all 
treatment groups showed improvements, and MDFT 
was not considered the most cost-effective treatment.
For more information about interventions using MDFT, 
see: Howard A. Liddle (2002), Multidimensional Family 
Therapy for Adolescent Cannabis Users (Cannabis 
Youth Treatment Series vol. 5), Rockville, MD: 
SAMHSA. (http://ncadistore.samhsa.gov/catalog/
productdetails.aspx?Productid=15872)
Multisystemic therapy (MST) takes a comprehensive 
approach to adolescents’ difficulties, as it involves the 
young person and his or her family, peer group, school, 
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and community. MST has broad application and has been 
used to treat chronic and violent criminal behaviour; 
substance abuse; sexual offending; psychiatric 
emergencies (e.g. homicidal, suicidal, psychotic); child 
maltreatment; and serious health-care problems, such 
as poorly controlled Type I diabetes and HIV. A four-year 
follow-up (n = 118) of a randomised trial comparing 
MST with usual community services found that self-
reported cannabis use did not differ between groups, 
but biologically confirmed abstinence was significantly 
higher in the MST group (55% vs 28%) (Henggeler et al., 
2002). It is not suggested that all clinicians be trained in 
these modes of therapy, but clinicians with an interest in 
family therapy may wish to seek further training in them. 
8.5 Summary
Recommendations Evidence
Clinicians with the training and resources to 
conduct family interventions given suitability 
of the client’s circumstances should do so
A
Because families are affected by the client’s 
cannabis use, family members should, when 
possible, be involved in treatment plans
B
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chapter 9: psycho-education 
and social support 
9.1 Overview of psycho-education
Psycho-education is a specific form of education that 
aims to help clients with a problem related to substance 
use to access clearly and concisely presented facts about 
a broad range of issues. Psycho-education and self-help 
material (e.g. books, information pamphlets, computer 
programs) have been used as an adjunct to face-to-
face treatment and as a stand-alone intervention since 
the 1970s (Finfgeld, 2000). Psycho-education should 
be delivered in a manner consistent with motivational 
interviewing (MI) principles, which assume that the client 
can make better choices when equipped with adequate 
knowledge, self-awareness, and decision-making skills. 
Research has shown that the more that people are aware 
of their condition and how it affects their own lives and 
that of others, the more control they have over their 
condition (Lincoln, Wilhelm & Nestoriuc, 2007).
Education may be delivered with or without personal 
contact, and in an individual or group setting. One 
of the key factors is linking the information with 
the client’s personal experience. Psycho-education 
provides the opportunity for the development of 
a good therapeutic relationship and empathic 
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response to clients’ own stories of cannabis use. It 
can encourage personal exchange of experiences and 
stimulate hope and reassurance. Psycho-education 
reinforces the health messages that clients receive 
from their GP, psychologist, psychiatrist, or counsellor; 
educates clients; and supports the value of treatment 
or therapy. Clinicians should deliver psycho-education 
in a timely and strategic way in order to maximise 
the positive effect on behavior. It ideally involves the 
client’s family or carers.
9.2 Purposes of psycho-education
Different purposes exist for psycho-education. Psycho-
education for action has been found to have the 
greatest effect. (See Table 17.)
Table 17: Summary of psycho-education options
Purpose of  
psycho-education Example
Psycho-education for 
knowledge
Cravings come in waves
The time between cravings 
gets longer as the number of 
days without use increases
Psycho-education for  
useful knowledge
Lack of sleep can be a  
relapse risk
Psycho-education for  
action
Reduce stress by using 
breathing technique
It is recommended that all psycho-education be 
offered in a manner consistent with MI principles, 
using the following format:
• elicit clients’ current understanding of condition/
treatment, and discuss their concerns, such as by 
addressing myths, fears, sources, and strength of 
belief
• ask permission to provide further information
• provide information
• elicit new understanding based on the material 
provided
Psycho-education is more than providing brochures or 
lectures, especially with clients with comorbid mental 
health conditions. The effect of both mental illness 
and drug use upon clients’ cognitive, motivational, 
and attentional functioning requires that clinicians 
be highly flexible, and at times creative, in the 
presentation of information (Carey et al., 2000). 
Psycho-education is a continuing process, with 
different information being relevant at different times 
in the course of treatment/recovery.
Psycho-educational materials should be engaging. To 
do so, they will ideally:
• be accurate – including about what we do NOT 
know!;
• be multi-modal, to grab the recipient’s attention 
using different learning modalities, especially for 
adult learners;
• use references from popular culture where 
appropriate;
• use consumer stories;
• be appropriate to the person’s gender, age, 
and educational level, and present the material 
in novel and engaging formats (e.g. with good 
layout, in attractive and easy-to-read fonts, 
using appealing graphics with attention-grabbing 
colour);
• be positive in tone and visual presentation. 
Consumers are less likely to embrace information 
with “stop” signs and “no” symbols being used;
• be realistic and honest – consumers will discount 
information if it is exaggerated;
• repeat – like all effective promotional messages;
• elicit client-relevant examples;
• consider clients’ interests and offer them a chance 
to tell their story
9.3 Stage-dependent psycho-education
Engagement assess knowledge about cannabis •	
use and dependence and, if relevant, 
mental health
provide relevant information about •	
effects of cannabis
avoid overwhelming them•	
Persuasion provide knowledge of mental illness •	
and cannabis
use interactive teaching methods•	
Active 
treatment
give focused information related to •	
clients’ goals 
use interactive teaching methods•	
Relapse 
prevention
provide information related to health, •	
wellbeing, and lifestyle change
help them learn how to get information •	
themselves
Self-help materials are an important addition to 
treatment interventions, as they may address a 
portion of the population who do not usually receive 
treatment. They should be well-distributed to cannabis 
users and accessible by those with non-English 
speaking backgrounds and by people with low 
reading ability. Below is a list of resources available 
in the cannabis area. (Please note that whilst most 
resources have been peer-reviewed or have had 
consumer feedback, they have not been evaluated for 
their effects on cannabis-use behaviours or treatment 
outcomes). Before deciding which booklet is most 
appropriate for your clients, consider their reading age 
and skills. Some booklets perform best when worked 
through together with a clinician.
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9.4 Resource guide
The following is a guide to some of the psycho-educational material available for cannabis. Most of these resources 
are developed in Australia and are available for download or ordering from the relevant website (see Table 18).
Table 18: Resource guide
Resource Description and link
What’s the deal 
x 4
A series of easy to read step-by-step guides that include quitting cannabis and 
information for parents and young people
Available from http://ncpic.org.au:
What’s the deal on quitting? A do-it-yourself guide for cannabis users
What’s the deal? Cannabis facts for parents
What’s the deal? Cannabis facts for young people
What’s the deal? Talking with a young person about cannabis
Mulling it over Health information for people who use cannabis
http://www.mdecc.org.au/resources.htm
Trimming the 
grass
http://www.mdecc.org.au/resources.htm
Fast facts on 
cannabis and 
mental health
http://ncpic.org.au/
Fast facts on 
cannabis
http://ncpic.org.au/
The mix 
(alcohol and 
cannabis)
http://ndarc.med.unsw.edu.au/ 
Cannabis: facts 
for teens
Educational brochures that NIDA publishes on cannabis
http://ncadistore.samhsa.gov/catalogNIDA/
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Resource Description and link
Cannabis: facts 
parents need to 
know
Educational brochures that NIDA publishes on cannabis
Available in English and Spanish
http://www.drugabuse.gov/MarijBroch/MarijIntro.html
A guide to 
cutting down 
and stopping 
cannabis
11-page booklet
http://www.knowcannabis.org.uk/
Cannabis and 
your body 
(leaflet)
http://www.adf.org.au/store/article.asp?ContentID=Cannabisandbody753
Others Downloadable fact sheets about cannabis from www.ncpic.org.au:
What is cannabis?
Cannabis and the law
Cannabis and mental health
Cannabis potency
Cannabis and driving
Cannabis and dependence 
Cannabis and prescribed medications
Cannabis and aggression
Cannabis and motivation 
Cannabis and tobacco use
Cannabis in the workplace
Cannabis use and reproduction
Looking after a friend on cannabis
Mixing cannabis and alcohol 
People at risk of developing problems with their cannabis use
Cannabis and young people
Cannabinoids and appetite
Cannabinoids
Cannabis contamination
9.5 Self-managed change
The majority of those with alcohol and other drug 
problems successfully give up or manage their use 
without treatment. There are now a number of general 
and cannabis-specific psycho-education and brief 
intervention materials available in hard copy and 
online. While few have been rigorously evaluated, 
below (Table 19) is a list of examples of online psycho-
education links that are commonly used by clinicians.
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Table 19: Key sites for online psycho-education 
Site Description 
NCPIC
www.ncpic.org.au
information for health 
professionals, families and users
Turning Point 
online counselling 
service http://www.
counsellingonline.
org.au/en/
Counselling Online is a service 
where you can communicate with 
a professional clinician about 
an alcohol- or other drug-related 
concern, using text-interaction
this service is free for anyone 
seeking help with their own 
drug use or the drug use of a 
family member, relative or friend. 
Counselling Online is available 24 
hours a day, 7 days a week, across 
Australia
Know cannabis
http://www.
knowcannabis.org.
uk/
this website can help you assess 
cannabis use, its impact on your 
life and how to make changes
E toke
http://www.e-toke.
com/info/index.php
cannabis-specific brief assessment 
and feedback tool designed to 
reduce cannabis use among college 
students
Somazone www.
somazone.com.au
a website developed by young 
people for young people. The 
website provides fast, free, 
anonymous access to quality 
assured health information on a 
range of issues, including alcohol 
and other drugs, body image, mind 
health, relationships and sexual 
health
9.6 Social-support or mutual-aid groups 
A self-help or mutual-help group is any group that has 
the aim of providing support, practical help, and care 
for group members who share a common problem 
(Baldacchino & Rassool, 2006). Two of the most widely 
available self-help groups are Marijuana Anonymous 
(MA) and SMART Recovery. There are many peer-
run groups available to service users, however, at 
alcohol and other drug treatment centres and other 
community agencies. Whilst these groups have not 
been evaluated for their effectiveness, they form 
an important component of social support for some 
clients and are well accepted by them.
Marijuana Anonymous http://livingaid.org/maa/
SMART Recovery www.smartrecoveryaustralia.
com.au
Marijuana Anonymous (MA) provides a 12-step 
program based on the Alcoholics Anonymous program. 
MA is self-supporting through user contributions and 
is not affiliated with any religious or secular institution 
or organisation. The primary purpose is to stay free of 
marijuana (abstinence-based approach) and to help 
current users cease.
The SMART Recovery 4-Point Program employs a 
variety of CBT tools and techniques to help individuals 
change faulty thinking in order to gain independence 
from addictive behaviours. By managing the beliefs 
and emotions that lead them to drink or use drugs, 
participants are encouraged to learn how to use 
these techniques as they progress toward achieving a 
healthy life balance.
Groups are “open”, so participants can attend for 
as long or as little as they like. Sessions provide an 
opportunity for participants to discuss difficulties, 
challenges, accomplishments, and successes and to 
focus on goals.
9.7 Summary
Recommendations Evidence
Psycho-education is a continual process that 
involves delivery of written or oral material 
about the harms associated with cannabis 
use, and should be offered to all clients
B
Clinicians should familiarise themselves with 
the appropriate print and Internet resources 
available
B
Clinicians should offer self-help books and 
details of support groups alongside standard 
therapy
C
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chapter 10: treating mental 
health in cannabis users
A higher proportion of cannabis users than of non-
users have a mental disorder, and higher proportions 
of those with mental disorders than of those without, 
use cannabis. This association makes it likely that 
clients seeking either type of treatment are at higher 
than average risk for the other disorder. Even very 
experienced mental health clinicians may fail to 
recognise a concurrent substance use disorder. 
Similarly, many clinicians treating substance use 
disorders struggle to recognise, or respond to, the 
presence of concurrent mental disorders in their 
clientele. Early recognition of concurring disorders 
contributes to the planning, before either condition 
becomes established, of treatment effective for and 
suitable to the comorbidity.
10.1 Considerations
Clinicians should actively and meaningfully assist all 
people with concurrent disorders to obtain appropriate 
treatment from within the service system to which 
they present (the “no wrong door” service system 
approach). Non-mental health practitioners may need 
to provide “psychological first aid” to cannabis users, 
which may include monitoring mental health, providing 
support and practical assistance, encouraging use 
of existing social supports, and, on rare occasions, 
ensuring the client’s safety. 
When possible, clients should receive integrated 
treatment of concurrent mental health and substance 
use disorders. Integrated treatment occurs when 
a clinician provides treatment for both a client’s 
substance use and mental disorders. Integrated 
treatment also occurs when separate practitioners 
(sometimes from separate agencies) work together 
to formulate and implement an individual treatment 
plan. This integration needs to continue beyond acute 
intervention and through recovery by way of formal 
interaction (Mueser, Birchwood & Copello, 2002).
10.2 Mental health problems associated with 
cannabis
10.2.1 Cannabis, psychosis, and schizophrenia
A meta-analysis examining the link between cannabis 
and psychosis found seven relevant, high-quality 
studies (Moore et al., 2007). Results consistently 
showed that cannabis use increased the risk of 
developing psychosis. The pooled data showed 
that in people who had ever used cannabis the 
risk of psychosis increased by 40%. Evidence for a 
dose–response relationship between an increasing 
frequency of cannabis use and risk of psychosis has 
also emerged. For heavy cannabis users the risk 
increased by 50–200%. Based upon these data, 
Moore suggested that approximately 14% of the 
psychotic episodes noted in young adults in the U.K. 
would not have occurred if cannabis had not been 
used.
Cross-sectional national surveys from the U.S., 
Australia, and The Netherlands found that rates of 
cannabis use among people with schizophrenia were 
approximately double those of the general population 
(Arseneault et al., 2004). Whilst cannabis use roughly 
doubles the risk of psychosis, the absolute risk is 
small [increasing from around 7 to 14 cases per 1000 
(Saha et al., 2005)].
There is still doubt that cannabis is sufficient to 
cause schizophrenia that would not otherwise have 
occurred in its absence, as rates of schizophrenia 
appear to have remained stable or decreased, 
despite substantial increases in cannabis use over 
the past few decades. Cannabis could be considered 
a “cumulative causal factor”, acting in synergy with 
other factors (genetic or early environmental factors 
known to be risk factors for schizophrenia, such as 
obstetric complications) to result in schizophrenia’s 
manifestation. One study looking at biological 
underpinnings has identified a particular gene (known 
as COMT Val 158Met) that may be implicated in the 
relationship between cannabis use and psychosis 
(Caspi et al., 2005). This study is yet to be replicated.
Recent clinical and population studies (Moore et 
al., 2007; Raphael et al., 2005; Degenhardt, Hall & 
Lynskey, 2001; Arseneault et al., 2004a; D’Souza et 
al., 2008; Fergusson, Horwood & Swain-Campbell, 
2003) may be summarised as follows:
• a number of well-designed longitudinal studies 
have found that adolescent cannabis use was 
associated with an increased likelihood of 
psychotic symptoms
• there is consistent evidence from several 
large, well-designed longitudinal studies that 
cannabis precipitates symptoms of psychosis 
and schizophrenia in people who are vulnerable 
because of a personal or family history of 
schizophrenia
• nevertheless, rates of schizophrenia generally 
appear to have remained stable or declined 
despite substantial increases in cannabis use
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• cannabis may act in synergy with genetic or 
other environmental factors to result in the 
manifestation of psychotic symptoms and/or 
schizophrenia
• one study has identified a gene that may mediate 
the relationship between cannabis use and 
schizophrenia
An excellent summary can be found in McLaren, 
Lemon, Robins, and Mattick’s (2008) Cannabis and 
Mental Health: Put into Context, available from 
www.ncpic.org.au
10.2.2 Cannabis and depression 
A recent analysis of the National Comorbidity Survey 
(NCS) data set found that a higher risk for having a 
major depressive episode was associated with greater 
cannabis use (Chen et al., 2002). Similarly, an earlier 
study reported that individuals meeting criteria for 
DSM-IV-TR cannabis abuse or dependence were 6.4 
times as likely to meet criteria for major depression 
than were individuals not meeting disorder criteria 
(Grant et al., 2005). This finding of elevated rates of 
depression in cannabis users has been repeated in a 
number of studies of youth (Rey et al., 2002) and of 
young adults (Patton et al., 2002), and in international 
longitudinal cohort samples (Fergusson & Horwood, 
1997; Angst, 1996). A dose–response relationship was 
found in four of five studies, indicating that a higher 
frequency of cannabis use was related to an increased 
risk for depression (Moore et al., 2007).
There is mounting evidence of an association between 
cannabis use and depression that is dose-related, though 
there is currently insufficient evidence to establish a 
causal link.
10.2.3 Cannabis and anxiety
Whilst there is an elevated rate of anxiety disorders 
among cannabis users, there is little evidence of a 
causal link to date (Moore et al., 2007). Only two of 
seven studies reviewed by Moore and colleagues 
found a significant association between cannabis use 
and anxiety independent of potential confounding 
variables. Due to the complex nature of cannabinoids, 
there is evidence that cannabis can both relieve and 
create anxiety, depending on the amounts of THC and 
CBD (Hall & Solowij, 1998).
10.2.4 Long-term cannabis dependence; 
depression; and anxiety  
Over a period, the effects of cannabis dependence can 
lead to symptoms of depression and anxiety. These 
symptoms often cease once the client has completed 
the withdrawal process. If symptoms persist, however, 
the client should be referred for a full mental health 
assessment. For some people with depression 
or anxiety, the withdrawal process increases the 
symptoms of these mood disorders, and therefore the 
person is more likely to relapse into cannabis use. This 
can cause a merry-go-round effect of use, reduction, 
depression or anxiety, and relapse into use.
10.2.5 Cannabis and suicide
A small number of studies have found a relationship 
between cannabis use and suicide among young 
people (see Hillman et al., 2000 for a review). It is 
unclear, however, whether this increased risk is better 
explained by other risk factors. At this stage, the 
studies conducted are too heterogeneous to make firm 
conclusions about the links.
10.2.6 Other mental health issues
Problems of conduct in childhood and early 
adolescence appear to be associated with the onset 
of cannabis use and to meet criteria for cannabis-
use disorder in a manner consistent with the self-
medication hypothesis, although this association is 
more likely the result of underlying common factors 
that increase the risks for both disorders (e.g. 
impulsiveness).
10.3 Screening for cannabis use in a mental 
health setting
Clinicians assessing a cannabis user should be alert 
to the possibility that the client has a mental illness. 
For this reason, it is important to screen and re-screen. 
See Table 21 for examples of validated screening tools. 
• all individuals receiving mental health or 
substance use treatment should be screened or 
assessed for a concurrent disorder
• routine screening represents an efficient method 
for services to increase their recognition of 
concurrent disorders. Screening should not be 
necessary, however, where comprehensive routine 
“dual diagnosis” assessment (one assessing both 
mental health and alcohol and other drug status) 
is provided
• screening and/or assessment for a concurrent 
disorder should take place at or near the time of a 
person’s first contact
• screening and assessment should not be 
attempted when the client is intoxicated, 
distressed, in pain, in need of emergency 
treatment, or acutely psychotic
• younger people should receive some level of 
screening at each contact for a concurrent disorder
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Table 20: Validated tools for identifying cannabis 
use
Tools
Use in population with  
mental health issues
Alcohol, Smoking and 
Substance Involvement 
Screening Test 
(ASSIST)
(WHO ASSIST Working 
Group 2002)
The World Health Organization 
(WHO), which developed the 
ASSIST for use in primary and 
general medical care settings 
worldwide, reports that 
screening questions can be 
answered by most individuals in 
around ten minutes
Severity of Dependence 
Scale (SDS)
(Gossop et al., 1995)
The SDS has also been shown 
to be reliable in mental health 
patients
Modified Simple 
Screening
The MSSI-SA is a very slightly 
modified version of the Simple 
Screening Instrument for 
Substance Abuse (SSI-SA) and 
can be self-administered or 
administered as an interview in 
10 minutes or less
The screen has good internal 
psychometrics and very good 
sensitivity, specificity, and 
overall accuracy
Urine drug screen It can be used as an outcome 
measure or for confirmation  
of use
CAUTION:
Please note that tools such as the SDS may use lower 
cut-off scores for clients with mental illness, reflecting 
that they can experience problems with cannabis at lower 
levels of use than do other clients.
10.4 Assessment and treatment of cannabis use 
in a mental health setting 
Due to the high prevalence of mental health issues 
in cannabis users, it is important that cannabis 
use be assessed as part of standard assessment 
procedures. The language of the assessment must be 
understandable and should communicate confidence 
and a collaborative approach. The following clinical 
recommendations are made with regard to the 
assessment and treatment of cannabis use among 
people with mental health problems:
• all clients with mental health problems who 
present in primary care or specialist mental health 
settings should be screened for cannabis and 
other drug (including tobacco) use
• clinicians should be alert to the possibility of 
cannabis use by clients with any mental health 
conditions, not only those with psychosis 
• due to the high prevalence of cannabis use in 
mental health settings, it is important that any 
cannabis use be comprehensively assessed as 
part of standard assessment procedures
• a stepped-care approach, from brief to more 
intensive interventions, following guidelines 
developed by Hides et al. (2006), may be helpful 
• furthermore, the well-established association 
between cannabis use and relapse of symptoms 
in individuals with psychosis (Linszen et al., 1994; 
Gleeson, 2004) highlights the need to provide 
continuing monitoring of cannabis use and 
symptoms of psychosis to detect lapses and to 
help prevent relapse in this vulnerable population
Feedback 
Feedback to individuals with psychosis is helpful 
in reinforcing that the client’s individual story has 
been heard and in allowing each client to correct 
any inaccuracies (Prochaska et al., 1993). Graphical 
feedback, such as a simple ladder or bar chart that 
compares a client’s use with that of others in their age 
range or in the general population, can allow clients 
to review and assimilate the information following 
the session. Feedback can summarise data gathered 
on the practical aspects of cannabis use, such as 
on the cost or the time spent procuring, using, and 
being intoxicated with cannabis, as well as on the 
relationship between use and relapse patterns, and 
can be powerful (see worksheet in Chapter 12).
Treatment
Cannabis use has been found to co-exist with a 
range of mental health symptoms and disorders (a 
concurrence referred to hereafter as comorbidity). 
Large-scale epidemiological surveys have found 
higher rates of psychotic, affective, anxiety, and 
behavioural disorders among individuals with 
substance use disorders than in the general 
population (Degenhardt, Hall & Lynskey, 2001; Farrell 
et al., 2001; Merikangas et al., 1998). The majority of 
individuals seen at publically-funded mental health 
services have psychosis (including schizophrenia), 
bipolar disorder, or severe personality disorder, 
especially borderline personality disorder. Though 
there has been a dearth of studies on the latter, there 
have been several attempts to develop treatments 
for cannabis use for the former conditions (Edwards 
et al., 2006; Barrowclough et al., 2001; Baker et 
al, 2006; Kavanagh et al., 2002). Recent Australian 
studies have found cannabis use in individuals 
with psychosis to be significantly greater than have 
comparable international studies (Wade et al., 2006; 
Wade et al., 2007; Hinton, Edwards & Elkins, 2008) 
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in a similar population of patients with recent-onset 
psychosis. See Table 21 for an overview of phases of 
and strategies for treatment.
Studies suggest that cannabis use among people with 
severe mental disorders is amenable to treatment.
• as a minimum intervention, give advice about 
quitting or reducing cannabis use and about its 
effects on mental health symptoms, delivered 
using MI
• treatment is as outlined in Chapter 6, but includes 
MET/CBT, which integrates mental health issues 
with those relating to cannabis use
• treatment of cannabis use in a mental health 
population does work, and studies show that 
cannabis consumption can be reduced by 30–50% 
on average (Wade et al., 2006; Johnsson et al., 
2004; Addington & Addington, 2001)
• the earlier the treatment, the better are the 
outcomes
• discharge planning should include continuing 
monitoring of cannabis use and, potentially, 
referral to alcohol and other drug services
• consider the role that cannabis may play in the 
life of a person with psychosis, especially in cases 
in which there may be many incentives to keep 
smoking post-recovery
Table 21: Phases of and strategies for treatment of mental health issues
Phase Goals Clinical strategies
1: Entry Engage
Gain commitment to treatment
Raise the issue of problematic 
cannabis use
Case formulation
Feedback from assessment 
Exploration of explanatory model of mental health diagnosis
Exploration of views of interaction of cannabis and diagnosis
Exploration of readiness to change cannabis use
Psycho-education: exploration of and problem-solving barriers 
to future attendance
2: Commitment Set a goal of reduced or no  
cannabis use
Motivational Interviewing (MI) 
Harm reduction
Psycho-education about cannabis and mental health diagnosis
3: Goal setting Reinforce commitment to change
Set a goal of reduced use that may 
include abstinence
Develop goal-achievement strategies
MI revisited
Goal setting
Psycho-education
4: Challenges Adopt a sound approach to all potential 
challenges to cannabis-reduction goals 
Withdrawal counselling
Problem-solving
Relapse prevention
Psycho-education
5.  Relapse 
prevention
Examine factors that are “rewards” 
for the short-term achievement and 
long-term maintenance of reduced/no 
cannabis use
Consider positive lifestyle changes to 
support cannabis goals 
Relapse prevention
Cannabis-refusal skills
Time management
Psycho-education
6. Maintenance Maintain motivation to a commitment 
of reduced/no cannabis use
Continually consider positive lifestyle 
change to support cannabis goals 
Relapse prevention
Coping skills
Time management
MI revisited
Reinforcement of psycho-education
Exit Conclude episode of care Reassurance that client can return if required, by mutual 
agreement, or can be referred to another clinician/service
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Psychosis
With respect to early psychosis, consideration should 
be given to the age and developmental stage of the 
client, including age at illness onset. You may need 
to provide assistance with attainment of basic skills 
(e.g. problem-solving), because normal developmental 
achievements may have been interrupted by the onset 
of psychotic illness and/or long-term cannabis use.
Take into account the role and influence of the client’s 
family and social circles and of their attitudes to 
cannabis and other drug use. As with other substance 
users, there may be elevated levels of acceptance 
and use of cannabis in the client’s family. Poor insight 
is common in both disorders; clients may have not 
initiated help-seeking for psychosis or for cannabis 
use; and they may need time to understand their 
need for treatment for each condition. Thus, clinicians 
should regularly provide feedback from their re-
assessment of drug use, readiness to change, and 
mental state, as the clinical picture is complex and 
frequently in flux.
You need to consider that clients who experience 
psychosis often face many losses and that these 
individuals may experience reducing cannabis use as 
another loss. Changing cannabis use may represent 
loss of pleasure, of social activity, or of routine, and 
returning to use may be seen as a sign of returning 
to usual activities. Such an understanding on the 
clinician’s part can help in engaging.
It is important to explore the cognitive difficulties that 
can arise from heavy cannabis use, illness course, and 
medication, and to adapt interventions accordingly. 
Seize the window of opportunity afforded in the 
presentation for treatment by assertively offering early 
treatment.
CAUTION
Mental health symptoms can complicate withdrawal, and 
may lead to overmedication for symptom management.
There is even greater likelihood of comorbid nicotine 
dependence among clients with comorbid psychiatric 
illness.
There is a well-developed literature showing that 
quitting tobacco can lead to increased blood levels of 
antipsychotic medication. Medications should be carefully 
monitored during withdrawal and cessation. Dose 
reduction may be needed if side-effects become apparent.
Psycho-education for comorbidity
Psycho-education for individuals with comorbid 
mental health and substance use problems is 
“critical as there is much to learn regarding mental 
health, substance use and the interaction between 
them” (Mueser et al., 2002). Clinicians need to equip 
themselves with knowledge and access to information 
on the range of disorders that may present in cannabis 
users and on their treatments. Psycho-educational 
approaches have been shown to be highly effective 
in mental disorders (Pekkala & Merinder, 2002). In 
a recent study with young people with first-episode 
psychosis who abused cannabis, those receiving 
10 sessions of psycho-education reduced their 
cannabis use and maintained reductions over six 
months equivalent to those who received integrated 
motivational interviewing and CBT (Edwards et 
al., 2006). There are a wide range of well-written 
resources that have been developed to provide useful 
information on cannabis and mental health. See Table 
22 for details.
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Table 22: Resource guide for cannabis and mental health
Resources for professionals Link
Back to reality (cannabis and 
psychosis)
http://orygen.org.au/shoppingcategory.asp?Categoryid=21
ISBN 1-920718-17-6  
Format: DVD
Cannabis and psychosis: An early 
psychosis treatment manual
http://orygen.org.au/shoppingcategory.asp?Categoryid=20 
ISBN 1 920718 02 8 
Format: manual
Prevention of coexisting mental 
health and substance use problems
http://druginfo.adf.org.au/downloads/Prevention_Research_
Quarterly/PRQ_07Nov_Prev_mental_health_sub_use.pdf
What is coexisting mental illness 
and substance misuse?
http://druginfo.adf.org.au/downloads/fact_sheets/FS_5.10_
What_is_coexistant.pdf
Resources for consumers Links
Cannabis & psychosis fact sheet http://www.health.vic.gov.au/drugservices/downloads/
cannabis_psychosis 
Double trouble: Drugs and  
mental health
http://www.adf.org.au/store/article.asp?Contentid=product_61211
Cannabis and mental health http://druginfo.adf.org.au/druginfo/fact_sheets/cannabis_
factsheets/cannabismentalhealth.html
Mind your head http://www.adf.org.au/store/article.asp?Contentid=Mindyour 
head7551
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Resources for consumers Links
Your guide to: Mental health and 
alcohol and other drug problems
http://www.adf.org.au/store/article.asp?Contentid=Yourguideto
mentalh735
What young people should know 
about mental illness and drug use
http://druginfo.adf.org.au/druginfo/fact_sheets/mental_health_
substance_use_factsheets/mental_health_substance_use_
youngpeople.html
10.5 Mental health symptoms in alcohol and 
drug settings
All specialist alcohol and other drug workers are 
encouraged to assess and intervene with mental 
health issues at the non-severe end of the spectrum.
10.5.1 Screening 
After selecting a single screening instrument (see 
Table 23), become familiar with that instrument and 
with its use and scoring. You should be aware that 
the validity of the screening can be affected by such 
circumstances as the manner in which instructions 
are given; what the client believes about how the 
information will be used; privacy; trust; and the 
rapport with the client. It is important to be sensitive 
to the ways in which culture may influence responses 
to screening questions and to know that many of the 
recommended screening instruments are available in 
languages other than English.
You should have a protocol for assessing individuals 
who screen positive. This should include a protocol for 
responding immediately to urgent needs identified in 
the screening, including suicidal thoughts or levels of 
substance use that may require medical attention.
Table 23: Tools for detecting mental health symptoms in cannabis users
Tool Description
Kessler 10 (K10) or Kessler 6 (K6) 
(Kessler, 2003)
Discriminates cases of serious mental illness from non-cases
Screens for general distress in the last 30 days
A score of 13 or higher indicates serious mental illness
A score of 8–12 indicates an anxiety-mood disorder that does not meet the severity 
threshold for a diagnosis of serious mental illness
Mental Health Screening Form III 
(Carroll & McGinley, 2001)
17-item screen that examines lifetime history
Initially designed as a rough screening device
For clients seeking admission to substance abuse treatment programs
The screen can be administered in approximately 15 minutes (positive responses 
should be followed up by questions regarding the duration, intensity, and 
concurrence of symptoms. A qualified mental health professional should determine 
whether a follow-up assessment and treatment recommendations are needed)
The Psychosis Screener (Australian 
National Survey of Mental Health and 
Well-Being) (Degenhardt et al., 2005)
Seven-item screener
 Modified MINI Screen 
(MMS) (Sheehan et al., 1997)
22 Yes/No items that screen for anxiety and mood disorders, trauma exposure and 
PTSD, and non-affective psychoses
The MMS can be administered in five to 10 minutes and scored in less than five 
minutes
For more information on screening for concurring disorders, see:
http://www.omh.state.ny.us/omhweb/resources/providers/co_occurring/adult_services/screening.html
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After screening, all clients should be given feedback 
about the results. If the screen is positive, then a 
further assessment of the client’s mental state is 
needed. If it is negative, then discuss the potential 
effect of drug use on mental health symptoms and 
continue to monitor mental health as well as drug use.
10.5.2 Assessment
• a comprehensive assessment by appropriately 
trained clinicians is warranted for all individuals 
identified through screening as potentially having 
comorbidity. The screening processes are the 
same as those described earlier
• when working in alcohol and other drug settings, 
also investigate whether the client’s mental 
health is already being addressed by another 
professional
• consider referral to mental health specialists for 
high-risk clients and any clients with psychosis or 
other low-prevalence disorders such as anorexia 
nervosa or obsessive-compulsive disorder
10.5.3 Treatment
• strive for integrated care where possible
• if you are not able to provide integrated care, 
strive to adopt parallel communication and 
processes. This includes regular communication 
about attendance, medication update, changes in 
mental state, etc
• you should strive to develop skills in the disorders 
commonly comorbid with cannabis use, such as 
anxiety and depression 
• motivational interviewing techniques are 
paramount to establishing and maintaining 
engagement
• the key behavioural task is to monitor high-risk 
situations, such as via mood monitoring for 
depression, suicidality, etc
• relapse into both conditions is common, so 
relapse prevention should feature prominently in 
treatment plans
• if symptoms do not improve, then referral or 
secondary consultation may be required
• you may benefit from including mental health 
aspects of clients’ care in your clinical supervision
• maintain liaison with mental health teams and GP 
where appropriate
• make referrals for medication to address mental 
health symptoms
• suicidal clients should be referred to specialist 
clinicians
10.6 Summary 
Recommendations Evidence
Due to links between cannabis use and 
mental health, screening for both is 
recommended
A
Interventions that include MET/CBT /PSYCHO-
EDUCATIONAL approaches are effective for 
individuals with comorbid mental health 
issues
A
Integrated approach should be provided 
when possible
B
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chapter 11: screening tools
Severity of Dependence Scale (SDS) – information sheet
The Severity of Dependence Scale (SDS) is a five-item questionnaire that provides a score indicating the severity 
of dependence on cannabis. Each of the five items is scored on a four-point scale (0–3). The total score is obtained 
through the addition of the five item ratings. The higher the score, the higher is the level of dependence. 
Score range 
Adolescents: SDS score of 4+ may indicate dependence 
Adults: SDS score of 3+ may indicate dependence
Screens for
Dependence on cannabis
Time to complete and score
Less than 1 minute
Public domain? 
Yes 
Can client complete it? 
Yes
Where can I get it?
http://ncpic.org.au/
http://eib.emcdda.europa.eu/html.cfm/index7343EN.html (generic form that does not specify the drug)
Strengths:
• brief
• very easy to use
• well-known
• useable as an outcome measure
For further information:
Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The Severity of Dependence 
Scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and 
amphetamine users. Addiction 90(5), 607–614.
Swift, W., Copeland, J. & Hall, W. (1998). Choosing a diagnostic cut-off for cannabis dependence. Addiction 93, 
1681–1692.
Martin, G., Copeland, J., Gates, P., & Gilmore, S. (2006). The Severity of Dependence Scale (SDS) in an adolescent 
population of cannabis users: Reliability, validity and diagnostic cut-off. Drug and Alcohol Dependence 83, 90–93.
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Severity of Dependence Scale (SDS)
Over the last three months:
1.  Did you ever think your use of cannabis was out of control?
 Never or almost never 0
 Sometimes  1
 Often  2
 Always or nearly always  3
2.   Did the prospect of missing a smoke make you very anxious or 
worried?
 Never or almost never 0
 Sometimes  1
 Often  2
 Always or nearly always  3
3.  Did you worry about your use of cannabis?
 Not at all  0
 A little  1
 Quite a lot  2
 A great deal  3
4.  Did you wish you could stop?
 Never or almost never 0
 Sometimes  1
 Often 2
 Always or nearly always  3
5.  How difficult would you find it to stop or go without?
 Not difficult 0
 Quite difficult 1
 Very difficult  2
 Impossible  3
 
SDS score                                                     / 15
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K10 – information sheet
The K10 is a screening tool that can also be used as a 
rating scale/outcome measure.
The K10 was primarily designed to detect high-
prevalence mental disorders, but there is also an 
argument that high K10 scores may be an indicator of 
possible serious mental illness.
The K10 is now in widespread Australian and 
international use – for example, as a Victorian Service 
Coordination Tool, as a NSW mental health routine 
outcome measure, and by organisations such as 
the Armed Forces and Beyond Blue and by doctors 
in general practice. The K10 was used in the 1997 
Australian National Survey of Mental Health and 
Wellbeing.
Score Range
K10 score 
Inferred risk 
of anxiety or 
depressive 
disorder
SCT K10 version 
recommended responses
10 to 15 Low or no risk — 
16 to 29 Medium risk Refer for primary-care 
mental health assessment 
30 to 50 High risk Refer for specialist mental 
health assessment 
Screens for
Distress
Time to complete and score
10 items: two minutes
Can client complete it?
Yes. The K10 can also be interviewer-administered to 
people with poor reading ability.
Where can I get it?
Service Coordination Tool Templates (SCTT) version: 
http://www.health.vic.gov.au/pcps/downloads/
coordination/tool_profile_psychosocial_may02.pdf
Online electronic version and scoring: http://www.
beyondblue.org.au/index.aspx?Link_id=1.237
Public domain?
Yes
Strengths:
• brief
• very easy to use
• well-known
•  possible for client to complete
•  (SCTT version) inclusive of graduated guidelines 
about need for mental health assessment 
•  able to be used as an outcome measure
Possible limitations: 
•  as a non-specific measure of psychological 
distress only, it still requires clinician judgment 
as to whether a person needs mental health 
treatment
•  most specialist mental health services are 
oriented primarily toward serious mental illness, 
in which the K10 is less sensitive
General information
About 13% of the adult population, and about one in 
four patients seen in primary care, will score 20 or 
over. This is a screening instrument, and practitioners 
should make a clinical judgement as to whether a 
person needs treatment. Scores usually decline with 
effective treatment. Patients whose scores remain 
above 24 after treatment should be reviewed, with 
specialist referral considered.
For further information
Andrews, G. & Slade, T. (2001). Interpreting scores 
on the Kessler Psychological Distress Scale (K10). 
Australian and New Zealand Journal of Public Health 
25(6), 494–497.
Croton, G. (2007). Screening for and assessment of co-
occurring substance use and mental health disorders 
by alcohol & other drug and mental health services. 
Victorian Dual Diagnosis Initiative Advisory Group. 
Available on line: http://www.wanada.org.au/files/
comorbid/ScreeingAndAssessmentCo-occurringSubsU
seandMHDisordersbyAODandMHServicesVICDDI.pdf
Kessler, R., Andrews, G., Colpe, L., Hiripi, E., Mroczek, 
D., Normand, S., Walters, E., & Zaslavsky, A. (2002). 
Short screening scales to monitor population 
prevalences and trends in nonspecific psychological 
distress. Psychological Medicine 32(6), 959–976.
Furukawa, T.A., Kessler, R., Slade, T., & Andrews, G. 
(2003). The performance of the K6 and K10 screening 
scales for psychological distress in the Australian 
National Survey of Mental Health and Well-Being. 
Psychological Medicine 33(2), 357–362.
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Kessler 10 (K10)
For all questions, please fill in the appropriate response circle.
In the past 4 weeks: None  of 
the time
A little of 
the time
Some of 
the time
Most of 
the time
All of the 
 time
1.  About how often did you feel tired out for no good 
reason?
2. About how often did you feel nervous?
3.  About how often did you feel so nervous  
that nothing could calm you down?
4. About how often did you feel hopeless?
5.  About how often did you feel restless or fidgety?
6.  About how often did you feel so restless you could 
not sit still? 
7. About how often did you feel depressed?
8.  About how often did you feel that everything is  
an effort?
9.  About how often did you feel so sad that nothing 
could cheer you up?
10. About how often did you feel worthless?
Source: Kessler, R.C., Andrews, G., Colpe, L.J., Hiripi, E., Mroczek, D.K., Normand S.L.T., et al. (2002). Short screening scales to monitor 
population prevalences and trends in nonspecific psychological distress. Psychological Medicine 32(6), 959–976. 
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The Modified Simple Screening Instrument for 
Substance Abuse (MSSI-SA) – information sheet
Screens for
Substance consumption, preoccupation and loss of 
control, adverse consequences, problem recognition, 
and tolerance withdrawal.
Time to complete and score
Two minutes
Can client complete it?
Yes
Where can I get it?
http://www.nyc.gov/html/doh/html/qi/qi_
samhpriority.shtml
Public domain?
Yes
Strengths
• brief
• client- or clinician-completed
Administration
The MSSI-SA can be administered either in the form 
of a clinical interview or as a self-administered test. In 
order to minimise clinical or administrative burden, we 
recommend that providers give individuals the self-
administered form.
Questionnaire
The screen contains 16 questions. The individual’s 
name and the date the form is completed should be 
entered on the top. Questions 1–13 ask about the 
previous six months, and questions 14–16 ask about 
lifetime experience.
Scoring
Although the MSSI-SA is a 16-item scale, only 14 
questions are scored. The total possible score ranges 
from 0 to 14. Neither question 1a or 1b nor question 
15 is scored. In both instances, “yes” responses 
provide important background information, but it is 
too general to be useful for scoring. To the remaining 
questions, the number of “yes” answers is assigned 
one point. Any tick for question 5 counts as a “yes” 
and should be added to the score; but even if there 
are multiple checkmarks for question 5, only one point 
is assigned.
Score Degree of risk for substance abuse
0–1 None to low
2–3 Minimal
> 4 Moderate to high: indicates need for 
further assessment
Interpretation
The currently recommended interpretation is that a 
score of 4 or more indicates moderate to high degree 
of risk for alcohol and other drug abuse. 
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Modified Simple Screening Instrument for Substance Abuse (MSSI-SA)  
self-administered form 
Name:
Date: 
Directions: The questions that follow are about your use of alcohol and other drugs, including prescription 
and over-the-counter medication/drugs. Your answers will be kept private. Mark the response that best fits for 
you. Answer the questions in terms of your experiences in the past six months. Filling out this form assists us 
in identifying your needs and providing you with services. Your answers on this form will not exclude you from 
services, care, or treatment at this program.
During the last six months…
YES NO
1a.  Have you used alcohol or other drugs (such as wine, beer, hard liquor, pot, coke, heroin or other 
opiates, uppers, downers, hallucinogens, or inhalants)?
1b.   Have you used prescription or over-the-counter medication/drugs (such as sleeping pills, pain 
killers, sedatives, or anti-anxiety medication like Valium, Xanax, or Ativan)?
2.   Have you felt that you use too much alcohol or other drugs (other drugs also include 
prescription or over-the-counter medication more than recommended)?
3.  Have you tried to cut down or quit drinking or using alcohol or other drugs?
4.   Have you gone to anyone for help because of your drinking or drug use (such as Alcoholics 
Anonymous, Narcotics Anonymous, clinicians, or a treatment program)?
5.  Have you had any health problems? Please tick if you have:
   Had blackouts or other periods of memory loss
   Injured your head after drinking or using drugs
   Had convulsions or delirium tremens (“DTs”)
   Had hepatitis or other liver problems
   Felt sick, shaky, or depressed when you stopped
   Felt “coke bugs” or a crawling feeling under the skin after you stopped using drugs
   Been injured after drinking or using
   Used needles to shoot drugs
6.  Has drinking or other drug use caused problems between you and your family or friends?
7.  Has your drinking or other drug use caused problems at school, or at work?
8.   Have you been arrested or had other legal problems (such as bouncing bad checks, driving 
while intoxicated, theft, or drug possession)?
9.   Have you lost your temper or gotten into arguments or fights while drinking or using other 
drugs?
10.   Are you needing to drink or use drugs more and more to get the effect you want?
11.   Do you spend a lot of time thinking about or trying to get alcohol or other drugs?
12.  When drinking or using drugs, are you more likely to do something you wouldn’t normally do, 
such as break rules, break laws, sell things that are important to you, or have unprotected sex 
with someone?
13.  Do you feel bad or guilty about your drinking or drug use?
The next questions are about your lifetime experiences.
YES NO
14.  Have you ever had a drinking or other drug problem?
15.   Have any of your family members ever had a drinking or drug problem?
16.  Do you feel that you have a drinking or drug problem now?
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Psychosis Screener – information sheet
Score range
Score of 1 or more provides a liberal definition of psychosis
Screens for
(using elements of the Composite International Diagnostic Interview [CIDI]) the presence of characteristic psychotic 
symptoms
Time to complete and score
One minute
Can client complete it?
No
Where can I get it?
Degenhardt, L., Hall, W., Korten, A., & Jablensky, A. (2005). Use of a Brief Screening Instrument for Psychosis: 
Results of an ROC analysis. NDARC Technical Report no. 210. Sydney: National Drug and Alcohol Research Centre.
Public domain?
Yes
Strengths:
• brief
• good sensitivity and specificity for detecting psychosis in clinical and non clinical populations
General information
The first six items cover the following features of psychotic disorders: delusions of control, thought interference, 
and passivity (Question 1 and 1a); delusions of reference or persecution (Question 2 and 2a); and grandiose 
delusions (Question 3 and 3a).
Psychosis screener 
1.   In the past 12 months, have you felt that your thoughts were being directly interfered with or controlled by another 
person?
1a.   Did it come about in a way that many people would find hard to believe, for instance through telepathy?
2.   In the past 12 months, have you had a feeling that people were too interested in you?
2a.  In the past 12 months, have you had a feeling that things were arranged so as to have a special meaning for you, or even 
that harm might come to you?
3.   Do you have any special powers that most people lack?
3a.   Do you belong to a group of people who also have these special powers?
4.   Has a doctor ever told you that you may have schizophrenia?
a clinician’s guide
72
Mental health Screening Form – information sheet
This is a (17 item screen) lifetime mental health history. Questions 1–4 are about client’s history of psychiatric 
treatment. Each of questions 5—17 is associated with a particular mental health diagnosis. A positive response 
to any of these items suggests the need for more-intensive assessment or consultation with a mental health 
professional.
Time to complete and score
About 10 minutes
Can client complete it?
Yes (not scoring)
Where can I get it?
Versions available at:
http://www.asapnys.org/Resources/mhscreen.pdf
http://pathwayscourses.samhsa.gov/bully/pdfs_bully/bully_supps_pg40.pdf
Connecticut Department of Mental Health and Addiction Services: http://www.dmhas.state.ct.us/cosig.
htm#screening
(English and Spanish versions are paired with Simple Screening Instrument for Alcohol and Other Drugs)
Public domain? 
Yes
Reference:
Croton, G. (2007). Screening for and assessment of co-occurring substance use and mental health disorders by 
alcohol & other drug and mental health services. Victorian Dual Diagnosis Initiative Advisory Group. Available on 
line: http://www.wanada.org.au/files/comorbid/ScreeingAndAssessmentCo-occurringSubsUseandMHDisordersbyA
ODandMHServicesVICDDI.pdf
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Mental health screening form III
Instructions: In this program, we help people with all their problems, not just their addictions. This commitment includes 
helping people with emotional problems. Our staff is ready to help you to deal with any emotional problems you may have, 
but we can do this only if we are aware of the problems. Any information you provide to us on this form will be kept in strict 
confidence. It will not be released to any outside person or agency without your permission. If you do not know how to answer 
these questions, ask the staff member giving you this form for guidance. Please note, each item refers to your entire life 
history, not just your current situation, this is why each question begins “Have you ever ....”
1)   Have you ever talked to a psychiatrist, psychologist, therapist, social worker, or counsellor about 
an emotional problem?
YES NO
2)   Have you ever felt you needed help with your emotional problems, or have you had people tell 
you that you should get help for your emotional problems?
YES NO
3)   Have you ever been advised to take medication for anxiety, depression, hearing voices, or for any 
other emotional problem?
YES NO
4)   Have you ever been seen in a psychiatric emergency room or been hospitalised for psychiatric 
reasons?
YES NO
5)   Have you ever heard voices no one else could hear or seen objects or things which others could 
not see?
YES NO
6)   a) Have you ever been depressed for weeks at a time, lost interest or pleasure in most activities, 
had trouble concentrating and making decisions, or thought about killing yourself?
YES NO
 b) Did you ever attempt to kill yourself? YES NO
7)  Have you ever had nightmares or flashbacks as a result of being involved in some traumatic/
terrible event? For example, warfare, gang fights, fire, domestic violence, rape, incest, car 
accident, being shot or stabbed?
YES NO
8)   Have you ever experienced any strong fears – for example, of heights, insects, animals, dirt, 
attending social events, being in a crowd, being alone, being in places where it may be hard to 
escape or get help?
YES NO
9)   Have you ever given in to an aggressive urge or impulse, on more than one occasion, that 
resulted in serious harm to others or led to the destruction of property?
YES NO
10)   Have you ever felt that people had something against you, without them necessarily saying so, 
or that someone or some group may be trying to influence your thoughts or behaviour?
YES NO
11)   Have you ever experienced any emotional problems associated with your sexual interests, your 
sexual activities, or your choice of sexual partner?
YES NO
12)   Was there ever a period in your life when you spent a lot of time thinking and worrying about 
gaining weight, becoming fat, or controlling your eating – for example, by repeatedly dieting or 
fasting, engaging in much exercise to compensate for binge eating, taking enemas, or forcing 
yourself to throw up?
YES NO
13)   Have you ever had a period of time when you were so full of energy and your ideas came very 
rapidly, when you talked nearly non-stop, when you moved quickly from one activity to another, 
when you needed little sleep, and believed you could do almost anything?
YES NO
14)   Have you ever had spells or attacks when you suddenly felt anxious, frightened, uneasy to the 
extent that you began sweating, your heart began to beat rapidly, you were shaking or trembling, 
your stomach was upset, you felt dizzy or unsteady, as if you would faint?
YES NO
15)   Have you ever had a persistent, lasting thought or impulse to do something over and over that 
caused you considerable distress and interfered with normal routines, work, or your social 
relations? Examples would include repeatedly counting things, checking and rechecking on 
things you had done, washing and rewashing your hands, praying, or maintaining a very rigid 
schedule of daily activities from which you could not deviate.
YES NO
16)   Have you ever lost considerable sums of money through gambling or had problems at work, in 
school, with your family and friends as a result of your gambling?
YES NO
17)   Have you ever been told by teachers, guidance counsellors, or others that you have a special 
learning problem?
YES NO
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Print client’s name:
Program to which client will be assigned:
Name of admissions counsellor:
Date:
Reviewer’s comments:
Total score:                 (each yes = 1 pt.)
Source: Carroll, J. & McGinley, J. (2001). A screening form for identifying mental health problems in alcohol/other drug dependent persons. 
Alcoholism Treatment Quarterly 19(4), 33–47.
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Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST) – information sheet
Screens for
• substances ever used (lifetime use)
• substances used in past three months
•  problems related to substance use
•  risk of harm (current or future) and dependence 
•  intravenous drug use
Time to complete and score
An experienced clinician can conduct an ASSIST 
screen and deliver the integrated brief intervention in 
10 to 20 minutes
Can client complete it? 
No. This tool is clinician-administered.
Where can I get it?
http://www.who.int/substance_abuse/activities/
assist/en/index.html
(Versions in English, German, Hindi, Portuguese)
Manual: ASSIST: Guidelines for Use in Primary Care
Manual: Brief Intervention for Substance Use: A Manual 
for Use in Primary Care
Manual: Self-Help Strategies for Cutting Down or 
Stopping Substance Use: A Guide
(Assist is not produced here due to its length)
Public domain?
Yes
The ASSIST can:
•  warn people of their risk of developing problems 
related to their substance use
•  provide an opportunity to start a discussion about 
substance use
•  identify substance use as a contributing factor to 
the presenting illness
•  be linked to a brief intervention to help high-risk 
substance users to cut down or stop their drug 
use and avoid its harmful consequences
The ASSIST can distinguish between three main 
groups:
•  low-risk substance users or abstainers
•  those whose patterns of use put them at risk 
of problems or who have already developed 
problems or are at risk of developing dependence 
•  those who are dependent on a substance
Strengths:
•  it indicates both likely abuse and dependence 
•  it generates some assessment information
•  it has a linked brief intervention that is likely to 
be effective for people with problematic or risky 
substance use (rather than dependence)
Possible limitations:
•  it requires some concentrated effort to incorporate 
into routine practice
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Cannabis Problems Questionnaire – information sheet
Screens for
• general measure of cannabis-related problems
• modified from the Alcohol Problems Questionnaire to measure cannabis-related problems
Time to complete and score
One to two minutes
Can client complete it?
Yes
Where can I get it?
http://www.ncpic.org.au
Public domain?
Yes
Strengths:
• brief
• simple
• available in adolescent and adult versions
• both versions include optional additional questions for more-comprehensive assessment
Further information:
Copeland, J., Gilmore, S., Gates, P., & Swift, W. (2005). The Cannabis Problems Questionnaire: Factor, structure, 
reliability and validity. Drug and Alcohol Dependence 80, 313–319.
Martin, G., Copeland, J., Gilmour, S., & Swift, W. (2006). The Adolescent Cannabis Problems Questionnaire: 
Psychometric properties. Addictive Behaviors 31, 2238–2248.
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Cannabis Problems Questionnaire (Adult)©
All the questions apply to your experiences from smoking cannabis in the last three months.
Please answer all the questions by ticking yes or no. 
In the last three months: Yes  No
1. Have you tended to smoke more on your own than you used to?  
2. Have you worried about meeting people you don’t know when stoned?  
3. Have you spent more time with smoking friends than with other kinds of friends?  
4. Have your friends criticised you for smoking too much?  
5. Have you sold any of your belongings to buy cannabis?  
6. Do you find yourself making excuses about money?  
7. Have you been in trouble with the police due to your smoking?  
8. Have you been physically sick after smoking?  
9. Have you passed out after a smoking session?  
10. Have you had pains in your chest or lungs after a smoking session?  
11. Have you felt paranoid after a smoking session?  
12. Have you been neglecting yourself physically?  
13. Have you failed to wash for several days at a time?  
14. Have you felt depressed for more than a week?  
15. Have you been so depressed you felt like doing away with yourself?  
16. Have you given up recreational activities you once enjoyed for smoking?  
17. Do you find it hard to get the same enjoyment from your usual interests?  
18. Has your general health been poorer than usual?  
19. Have you felt more antisocial after smoking?  
20 Have you been concerned about a lack of motivation ?  
21. Have you worried about feelings of personal isolation or detachment?  
22. Do you usually have a smoke in the morning, to get yourself going?  
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Cannabis Problems Qusetionnaire – Adolescent (CPQ-A)
• We would like to find out if you have experienced any of the difficulties that other people who use cannabis 
sometimes complain of.
• Read each question carefully and answer either YES or NO by putting a tick in the appropriate place.
• Some questions specifically ask about problems associated with using cannabis, while others ask about 
general problems that may have occurred.
Please answer all the questions that apply to you. All the questions apply to your experiences in the 
last three months.
Core CPQ-A items
In the last three months: Yes No
1. Have you tended to smoke more on your own than you used to?  
2. Have you worried about meeting people you don’t know when you are stoned?  
3. Have you spent more time with smoking friends than other kinds of friends?  
4. Have your friends criticised you for smoking too much?  
5. Have you had any debts?  
6. Have you pawned any of your belongings to buy cannabis?  
7. Have you found yourself making excuses about money?  
8.  Have you found yourself worried about the amount of money you have been  
spending on cannabis?  
9. Have you been caught out lying about money?  
10. Have you been in trouble with the police due to your smoking?  
11. Have you been physically sick after smoking?  
12. Have you passed out after a smoking session?   
13. Have you had pains in your chest or lungs after a smoking session?   
14. Have you had a persistent chest infection or cough?  
15. Have you felt paranoid or antisocial after a smoking session?   
16. Have you lost any weight without trying to?   
17. Have you been neglecting yourself physically?  
18. Have you felt depressed for more than a week?  
19. Have you felt so depressed you felt like doing away with yourself?  
20. Have you given up any activities you once enjoyed because of smoking?  
21. Have you had less energy than usual?  
22. Have you found it hard to get the same enjoyment from your usual interests?  
23. Has your general health been poorer than usual?   
24. Have you worried about getting out of touch with friends or family?  
25. Have you been concerned about a lack of motivation?  
26. Have you felt less able to concentrate than usual?   
27. Have you worried about feelings of personal isolation or detachment?   
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Additional CPQ-A Items 
If you have lived with a parent (or guardian) in the past three months, answer these questions.  
Otherwise, go to question 33.
28. Do your parent(s) use cannabis on a regular basis?  
29. Have your parent(s) complained about your smoking  
30. Have your parent(s) tried to stop you from having a smoke?  
31. Have you argued with them about your smoking?  
32. Have you tried to avoid your parents(s) after you have been smoking?  
If you have had any regular boyfriend(s)/girlfriend(s)/partner(s) in the past three months, answer these 
questions. Otherwise, go to question 38.
Thinking about the partner that you spent the most time with over the past 3 months:  
33. Does he/she use cannabis on a regular basis?  
34. Has he/she complained about your smoking?  
35. Have you argued with him/her about smoking?  
36. Has he/she threatened to leave you because of your smoking?  
37.  Have you avoided him/her after you have been smoking?  
If you have been enrolled in school or any courses of study in the last three months, answer these 
questions. Otherwise, go to question 47. 
38.  Have you been less interested or motivated in schoolwork/study?  
39.  Have you been unable to attend classes because of smoking?  
40.  Have your school/course marks dropped?  
41.  Have you gone to classes stoned?  
42.  Have you been less able to concentrate on your schoolwork/study?  
43.  Have you smoked on school premises?  
44.  Have you been unable to complete homework because of your smoking?  
45.  Have you had complaints from teachers about your work?  
46.  Have you been disciplined or suspended from school because of cannabis?  
If you have been employed, either part-time or full-time, in the past three months, answer these questions.
47.  Have you found your work less interesting than you used to?  
48.  Have you been unable to arrive on time for work due to your smoking?   
49.  Have you missed a whole day at work after a smoking session?  
50.  Have you been less able to do your job because of smoking?  
51.  Have you gone to work stoned?  
52.  Has anyone at work complained about your being late or absent?  
53.  Have you had any formal warnings from your employers?  
54.  Have you been suspended or dismissed from work?  
55.  Have you had any accidents at work after smoking?  
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Cannabis Withdrawal Checklist  
– information sheet
Screens for
Cannabis-related withdrawal symptoms
Time to complete and score
One to two minutes
Can client complete it?
Yes
Where can I get it?
Budney, A.J., Novy, P. & Hughes, J.R. (1999). Marijuana 
withdrawal among adults seeking treatment for 
marijuana dependence. Addiction 94, 1311–1322.
Public domain?
Yes
Strengths: 
• brief
• simple
• can be used to track symptoms weekly or daily
Limitations:
• reliability and validity data unavailable
Cannabis Withdrawal Checklist
Name:  
Date:  Day:
Please answer based on your experience each day for the first five days of your recent quit attempt. 
   none mild moderate severe
1)  Shakiness/tremulousness 0 1 2 3
2)  Depressed mood 0 1 2 3
3)  Decreased appetite 0 1 2 3
4)  Increased appetite 0 1 2 3
5)  Nausea or stomach pains 0 1 2 3
6)  Irritability  0 1 2 3
7)  Trouble sleeping (insomnia) 0 1 2 3
8)  Oversleeping (hypersomnia) 0 1 2 3
8)  Sweating 0 1 2 3
9)  Craving to smoke cannabis 0 1 2 3
10)  Restlessness 0 1 2 3
11)  Nervousness/anxiety  0 1 2 3
12)  Increased anger or aggression 0 1 2 3
13)  Headaches 0 1 2 3
14)  Strange/wild dreams 0 1 2 3
15)  Fatigue/tiredness/yawning 0 1 2 3
16)  Trouble concentrating 0 1 2 3
17)  Chills  0 1 2 3
Source: Budney, A.J., Novy, P. & Hughes, J.R. (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence . 
Addiction 94, 1311–1322.
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Cannabis Use Problems Identification Test 
(CUPIT) – information Sheet
Screens for
• cannabis use in past 12 months (frequency, 
intensity)
• cannabis use in past three months
• cannabis-induced problems
• risk of harm (current or 12-month) and 
dependence 
Time to complete and score
Approximately eight to 10 minutes
Can client complete it?
Yes. The CUPIT can be self- or other-administered
Where can I get it?
http://www.ncpic.org.au
Public domain?
Yes
The CUPIT can:
• raise cannabis users’ awareness of their risk of 
developing problems related to their cannabis use
• identify cannabis use as contributing to, or as the 
cause of, users’ presenting illness, complaints, or 
social problems
• be linked to a brief intervention to help high-risk 
cannabis users to cut down or stop their cannabis 
use in order to avoid or reduce its harmful 
consequences
The CUPIT can distinguish between three main 
groups:
• currently low-risk cannabis users
• those whose patterns of cannabis use renders 
them vulnerable to developing problems in the 
future (at risk), or who have already developed 
problems and are at risk of developing full-
blown dependence (abuse, pre-clinical stage, or 
“diagnostic orphans”)
• those who are dependent on cannabis
Strengths
• it is simple and brief
• interviewers require minimal “training”
• its major strength is the ability to detect users 
currently with cannabis-use disorder and those 
heading toward developing it
General information
The original CUPIT developmental analyses showed 
that a cut-off point of 20 (of a possible 82) was 
statistically optimal (89% sensitivity, 76% specificity, 
98% PPV) in the combined adolescent–adult 
community sample. A more liberal cut-off point of 16 
(95% sensitivity, 53% specificity, 96% PPV) performed 
better, however, in capturing a greater number of 
the pre-clinical (“diagnostic orphans”) users, and an 
even more liberal cut-off point of 12 (98% sensitivity, 
35% specificity, 95% PPV) was most sensitive in the 
sample.
Scoring
A simple score plan applies:
Item 1 scores from 1 to 8
Item 2 scores from 0 to 8
Item 3 scores from 1 to 6
Item 4 scores from 0 to 6
Item 5 scores from 0 to 5
Item 6 scores from 0 to 4
Item 7 scores from 1 to 9
Items 8 to 16 score from 0 to 4 *
*Item 9 is reverse scored.
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Cannabis Use Problems Identification Test 
(CUPIT)
Some people can use cannabis without developing 
any serious problems. Others can experience health 
problems, or other kinds of problems. If you answer 
the questions below, it can help you to work out if you 
are having any problems with cannabis. There are no 
right or wrong answers. If you have any difficulties, ask 
your counsellor for help.
For each question, tick  the answer closest to your 
cannabis use 
Over the past 12 months…
1.   On how many days have you used cannabis 
during the past 12 months?
  (If there was no pattern to your cannabis use, 
please make your best estimate.)
	  1–6 days      (less than one day a month)
	   7–12 days      (an average pattern of one day 
a month)
	   13–36 days      (an average pattern of 2–3 days 
a month)
	   37–52 days      (an average pattern of one day 
a week)
	   53–104 days     (an average pattern of 2 days a 
week)
	   up to 208 days    (an average pattern of 3–4 days 
a week)
	   up to 312 days    (an average pattern of 5–6 days 
a week)
	   up to 365 days   (daily/most days)
2.   Now please think about your recent cannabis 
use.
  On how many days have you used cannabis over 
the past three months (90 days)?
	   no days
	   1–2 days  (less than one day a month)
	   3–4 days   (an average pattern of one day 
a month)
	   5–9 days   (an average pattern of 2–3 days 
a month)
	   10–15 days   (an average pattern of one day 
a week)
	   27–52 days   (an average pattern of 3–4 days 
a week)    
	   53–78 days   (an average pattern of 5–6 days 
a week) 
	   79–90 days  (daily/most days)
3.   How many times would you use cannabis on  
a typical day when you were using? (Note:  
at least one hour between each new “use”)
	   once
	   twice
	   3–4 times
	   5–6 times
	   7–9 times
	   10 or more time
4.   How often have you used cannabis first thing in 
the morning?
	   never
	   once or twice
	   less than monthly
	   monthly
	   one day a week
	   several days a week
	   daily/always
Over the past 12 months
5.   How much of the average day do you spend/or 
feel stoned?
	   0 hours
	   1–2 hours
	   3–4 hours
	   5–6 hours
	   7–8 hours
	   9 or more hours
6.   How difficult do you think you would find it to 
stop using or go without cannabis altogether?
	   not at all difficult
	   a bit difficult
	   quite difficult
	   very difficult
	   impossible
7.   What was the longest time you went without 
using cannabis?
	   6 months or longer
	   3–5 months
	   1–2 months
	   2–3 weeks
	   one week
	   4–6 days
	   2–3 days
	   one day
	   no days at all
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8.  Have you felt that you needed cannabis?
	   never
	   sometimes
	   quite often
	   very often
	   always/all the time
9.   Have you been able to stop using cannabis 
when you wanted to?
	   never/at no time
	   sometimes (not often)
	   quite often (half the time)
	   very often (usually)
	   always/all the time
10.  Have you found it difficult to get through a day 
without using cannabis?
	   never
	   sometimes
	   quite often
	   very often
	   always/all the time
11.  Did your use of cannabis ever interfere with 
(get in the way of) your work at school, your 
job, or your home life?
	   never
	   sometimes
	   quite often
	    very often
	   always/all the time
12.  Have you lacked the energy to get things done 
in the way you used to?
	   never
	   sometimes
	   quite often
	   very often
	   always/all the time
13.  Have you given up things you used to enjoy 
or were important because of cannabis (e.g., 
work, school, sports, hobbies, being with 
family and friends, etc.)?
	   none at all/nothing
	   one or two things
	   quite a few things
	   lots of things
	    everything
14.  Has anything you had planned, or were 
expected to do, not happened after using 
cannabis (e.g., a family outing, chores, taking 
care of children, homework, an assignment, 
an appointment, a job interview, training, 
attending school or work, etc.)?
	   never
	   sometimes
	   quite often
	   very often
	   always/all the time
15.  Have you had problems concentrating and 
remembering things?
	   never
	   sometimes
	    quite often
	   very often
	    always/all the time
16.  Did you ever use cannabis after you had 
decided not to?
	   never
	   sometimes
	   quite often
	   very often
	   always/all the time
© Jan Bashford, Massey University, Palmerston North,  
New Zealand.
a clinician’s guide
84
Readiness to Change Questionnaire (RTCQ) – 
information sheet
This questionnaire is used for assessing drinker’s 
readiness to change drinking behaviours. It has been 
adapted to include cannabis behaviours.
Screens for
(12-item questionnaire) the patient’s readiness to start 
to change, or for actual changes in current drinking 
habits (adapted to include cannabis), suggesting one 
of three stages:
• precontemplation – not considering making any 
changes
• contemplation – thinking about changes, may 
have started a few
• action – already actively making changes
Target population
Adults/adolescents
Time to complete and score
12 items, three subscales 
Pencil and paper, self-administered 
Time required to adminiser: Two to three minutes 
No training required for administration 
Time required scoring: One minute 
Scored by administrator 
Norms available based on excessive drinkers 
identified in general medical practice at general 
hospital
Research applicability
In research of brief, opportunistic intervention, 
especially in matching studies
Source
Center for Alcohol and Drug Studies 
Plummer Court, Carliol Place, Newcastle upon Tyne 
NE1 6UR, UNITED KINGDOM 
Tel: 44(0)191219 5648 Fax: 44(0)191219 5649
Supporting references:
Rollnick, S., Heather, N., Gold, R., & Hall, W. (1992). 
Development of a short “readiness to change” 
questionnaire for use in brief, opportunistic 
interventions among excessive drinkers. British Journal 
of Addiction 87, 743–754.
Heather, N., Rollnick, S. & Bell, A. (1993). Predictive 
validity of the Readiness to Change Questionnaire. 
Addiction 88, 1667–1677.
Heather, N., Gold, R. & Rollnick, S. (1991). Readiness 
to Change Questionnaire: User’s manual. Technical 
Report no. 15. Kensington, Australia: National Drug 
and Alcohol Research Centre, University of New South 
Wales.
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Readiness to Change Questionnaire – Cannabis revision
Name:
Date: 
The following questions are designed to identify how you personally feel about your cannabis right now. Please 
read each question below carefully, and then decide whether you agree or disagree with the statements. Please tick 
the answer of your choice to each question.
Strongly
disagree Disagree Unsure Agree
Strongly
agree
Office  
use
1  I don’t think I use too much cannabis P
2  I am trying to use less cannabis than I used to A
3   I enjoy using cannabis, but sometimes I use too 
much
C
4   Sometimes I think I should cut down my cannabis C
5   It’s a waste of time thinking about my cannabis 
use  
P
6   I have just recently changed my pattern of 
cannabis use
A
7   Anyone can talk about wanting to do something 
about cannabis use, but I am actually doing 
something about it
A
8   I am at a stage where I should think about using 
less cannabis
C
9  My cannabis use is a problem sometimes C
10   There is no need for me to think about changing 
my cannabis use
P
11   I am actually changing my cannabis-using habits 
right now
A
12   Using less cannabis would be pointless for me P
Revised by M. Hinton, from Rollnick, S., Heather, N., Gold, R., & Hall, W. (1992). Development of a short “readiness to change ” questionnaire 
for use in brief, opportunistic interventions among excessive drinkers. British Journal of Addiction 87, 743–754.
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Scoring the Readiness to Change Questionnaire
Quick method
The Precontemplation items are numbers 1, 5, 10, and 
12; the Contemplation items are numbers 3, 4, 8, and 
9; and the Action items are numbers 2, 6, 7, and 11.  
All items are to be scored on a 5-point rating scale 
ranging from:
–2  Strongly disagree
–1  Disagree
0  Unsure
+1  Agree
+2  Strongly agree
To calculate the score for each scale, simply add the 
item scores for the scale in question. The range of 
each scale is –8 through 0 to +8. A negative scale 
score reflects an overall disagreement with items 
measuring the stage of change, whereas a positive 
score represents overall agreement. The highest scale 
score represents the Stage of Change Designation.
Note: If two scale scores are equal, the scale farther 
along the continuum of change (Precontemplation–
Contemplation–Action) represents the subject’s Stage 
of Change Designation. For example, if a subject 
scores 6 on the Precontemplation scale, 6 on the 
Contemplation scale, and –2 on the Action scale, then 
the subject is assigned to the Contemplation stage. 
Note that positive scores on the Precontemplation 
scale signify a lack of readiness to change. To obtain 
a score for Precontemplation which represents the 
subject’s degree of readiness to change, directly 
comparable to scores on the Contemplation and 
Action scales, simply reverse the sign of the 
Precontemplation score (see below).
If one of the four items on a scale is missing, the 
subject’s score for that scale should be pro-rated (i.e. 
multiplied by 1.33). If two or more items are missing, 
the scale score cannot be calculated. In this case, the 
Stage of Change Designation will be invalid.
Scale scores, Readiness to Change
Precontemplation  Precontemplation  (reverse score) 
Contemplation   Contemplation (same score) 
Action   Action (same score) 
 
Stage of Change Designation
(P, C, OR A?) 
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Modified Mini Screen (MMS)  
– information sheet
Screens for
The MMS is designed to identify people in need of an assessment respecting mood disorders, anxiety disorders, 
and psychotic disorders. It is not diagnostic per se, but is intended as an indicator of when more thorough mental 
health assessment is required.
Time to complete and score
10 to 15 minutes
Scoring
• score 10+: assessment needed
• score 6–9, assessment need should be determined by treatment team
• score < 6, no action necessary unless determined by treatment team
• if there is a Yes response to Q 4, 14, or 15, assessment is needed
Public domain?
Yes 
Can client complete it?
Yes (not scoring)
Where can I get it?
OASAS – MMS Tool: http://www.oasas.state.ny.us/hps/research/documents/MMSTool.pdf
OASAS – Screening for co-occurring disorders using the Modified Mini Screen (MMS) – User’s Guide:  
http://www.oasas.state.ny.us/hps/research/documents/MINIScreenUsersGuide.pdf
Connecticut Department of Mental Health and Addiction Services:  
http://www.dmhas.state.ct.us/cosig.htm#screening
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Modified Mini Screen (MMS)
Name:
Date: 
Section A
1.   Have you been consistently depressed or down, most of the day, nearly every day, for the 
past two weeks?
YES NO
2.   In the past two weeks, have you been less interested in most things or less able to enjoy the 
things you used to enjoy most of the time?
YES NO
3.  Have you felt sad, low, or depressed most of the time for the last two years? YES NO
4.  In the past month, did you think that you would be better off dead or wish you were dead? YES NO
5.   Have you ever had a period of time when you were feeling up, hyper, or so full of energy or 
full of yourself that you got into trouble or that other people thought you were not your usual 
self? (Do not consider times when you were intoxicated on drugs or alcohol.)
YES NO
6.   Have you ever been so irritable, grouchy, or annoyed for several days, that you had 
arguments, verbal or physical fights, or shouted at people outside your family? Have you 
or others noticed that you have been more irritable or overreacted, compared with other 
people, even when you thought you were right to act this way?
YES NO
Please Total the Number of “Yes” Responses to Questions 1–6.
Section B
7.  Note: this question is in two parts.
 a.  Have you had one or more occasions when you felt intensely anxious, frightened, 
uncomfortable, or uneasy even when most people would not feel that way?
 YES NO
 b. If yes, did these intense feelings get to be their worst within 10 minutes?
 YES NO
 Interviewer: If the answer to BOTH a and b is YES, code the question YES.
YES NO
8.   Do you feel anxious or uneasy in places or situations where you might have the panic-like 
symptoms we just spoke about? Or do you feel anxious or uneasy in situations where help 
might not be available or escape might be difficult?
 Examples include:
being in a crowd•	
standing in a line•	
being alone away from home or alone at home•	
crossing a bridge•	
travelling in a bus, train, or car•	
YES NO
9.   Have you worried excessively or been anxious about several things over the past 6 months?
 Interviewer: If NO to question 9, answer NO to Q 10 and proceed to Q 11.
YES NO
10.  Are these worries present most days? YES NO
11.   In the past month, were you afraid or embarrassed when others were watching you, or when 
you were the focus of attention? Were you afraid of being humiliated?
 Examples include:
speaking in public•	
eating in public or with others•	
writing while someone watches•	
being in social situations•	
YES NO
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12.   In the past month, have you been bothered by thoughts, impulses, or images that you 
couldn’t get rid of that were unwanted, distasteful, inappropriate, intrusive, or distressing?
 Examples include:
were you afraid that you would act on some impulse that would be really shocking?•	
did you worry a lot about being dirty or contaminated, or having germs?•	
did you worry a lot about contaminating others, or that you would harm someone even •	
though you didn’t want to?
did you have any fears or superstitions that you would be responsible for things going •	
wrong?
were you obsessed with sexual thoughts, images, or impulses?•	
did you hoard or collect lots of things?•	
did you have religious-practice obsessions?•	
YES NO
13.   In the past month, did you do something repeatedly without being able to resist doing it?
 Examples include:
washing or cleaning excessively•	
counting or checking things over and over•	
repeating, collecting, or arranging things•	
other superstitious rituals•	
YES NO
14.   Have you ever experienced or witnessed or had to deal with an extremely traumatic event that 
included actual or threatened death or serious injury to you or someone else?
 Examples Include:
serious accidents•	
sexual or physical assault•	
terrorist attack•	
being held hostage•	
kidnapping•	
fire•	
discovering a body•	
sudden death of someone close to you•	
war•	
natural disaster•	
YES NO
15.   Have you re-experienced the awful event in a distressing way in the past month?
 Examples include:
dreams•	
intense recollections•	
flashbacks•	
physical reactions•	
YES NO
Please Total the Number of “Yes” responses to Question 7-15.
Section C
16.   Have you ever believed that people were spying on you, or that someone was plotting against 
you or trying to hurt you?
YES NO
17.   Have you ever believed that someone was reading your mind or could hear your thoughts, or 
that you could actually read someone’s mind or hear what another person was thinking?
YES NO
18.   Have you ever believed that someone or some force outside of yourself put thoughts in your 
mind that were not your own, or made you act in a way that was not your usual self? Or have 
you ever felt that you were possessed?
YES NO
19.   Have you ever believed that you were being sent special messages through the TV, radio, 
or newspaper? Did you believe that someone you did not personally know was particularly 
interested in you?
YES NO
20. Have your relatives or friends ever considered any of your beliefs strange or unusual? YES NO
21. Have you ever heard things other people couldn’t hear, such as voices? YES NO
22.  Have you ever had visions when you were awake, or have you ever seen things other people 
couldn’t see?
YES NO
Please Total the Number of “Yes” responses to Question 16-22.
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chapter 12: worksheets 
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Seemingly Irrelevant Decisions
from Steinberg et al. (2005)
When making any decision, large or small:
• consider the options you have
• think about the possible outcomes of each option. What positive or negative consequences can you 
anticipate, and what are the risks of relapse?
• choose an option that will minimise your relapse risk. If you decide to choose a risky option, play how to 
protect yourself while in the high-risk situation
• watch for “red flag” thinking: thoughts like “I have to (do something, go somewhere, see someone)” or “I can 
handle (a certain high-risk situation)” or “it really doesn’t matter whether (I just have a puff)”
Practical exercise
Think about a decision you made recently or are about to make. The decision could involve any aspect of your life, 
such as your job, recreational activities, friends, or family. Identify choices that are safe and choices that may 
increase your risk of relapsing.
Decision to be made:
Safe alternatives:
Risky alternatives:
a clinician’s guide
92
Cravings
from Marlatt & Gordon (1985)
What are cravings?
Cravings are a natural part of changing alcohol or other drug use and can cause some distress. Cravings are the 
result of long-term substance use and can continue long after use stops. People with a heavier history of use may 
experience stronger cravings.
A craving is like a wave at the beach. Every wave starts off small, builds up to its highest point, 
then breaks and flows away to shore. No individual wave lasts for more than a few minutes.
A craving is the same. It starts off small and builds up – and is made up of behaviours, thoughts, 
and physical symptoms. Once it reaches its peak, it eventually breaks and disappears. This whole process usually 
doesn’t last more than about 10 minutes. How long do your cravings last? How severe are they on a scale of 1-10?
What triggers cravings?
Cravings can be triggered by all sorts of things: people, places, things, feelings, situations, or anything else that has 
been associated with past alcohol or other drug use.
Be aware: sometimes, especially if you’re stressed or experience a trigger, the craving can return really strongly! 
What are your triggers? What do you notice when cravings start (thoughts, feeling & behaviours).
What if I only use once in a while?
Cravings are like stray cats: if you keep feeding them, they will keep coming back. Even if you 
use just once in a while, you will still keep those cravings alive. Cravings are strongest in the 
early parts of cutting down or quitting, but people may continue to experience cravings for the 
first few months and sometimes even years after stopping their drug use.
How do I get rid of cravings?
Cravings only lose their power if you don’t add force to them by drinking or using. Each time a person does 
something other than drink or take drugs, the craving loses its power. In time, the peak of the craving wave 
becomes smaller and the waves further apart. Quitting totally is the best and quickest way to get rid of the 
cravings.
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Coping with cravings
adapted from Hinton et al. 2002
How do you experience cravings? Describe the physical symptoms (e.g. heart racing; feeling sick), behaviours (e.g. 
fidgeting), and thoughts (e.g. “I must have a smoke”) that you experience when craving:
Physical symptoms:
Behaviours:
Thoughts:
My main craving triggers are:  How can I deal with this trigger?:
1.  AVOID or
2.  AVOID or
3.  AVOID or
4.  AVOID or
5.  AVOID or
Sometimes, when cravings can’t be avoided, you need to find ways to cope with them. Below are some options for 
you to try out, for coping with the physical symptoms, the behaviours, and the thoughts that add up to a craving. 
Put a tick () in the box next to those things you think you could do.
Behavioural coping skills:
• Eat regularly, even when you don’t feel like it. 
• Drink plenty of water – especially when you get the craving. 
• Chew gum or suck on a lolly instead of drinking alcohol or using. 
Use the “3Ds” when your craving is set off.
Delay: When you experience a craving, put off the decision to use for one hour.
Distract: Once the decision to use is delayed, do something else for that hour, like going for a walk, calling a friend 
or listening to music. This breaks the habit of immediately reaching for alcohol or other drugs when you get a 
craving. You will find that once you are interested in something else, the craving will go away.
Decide: After the craving has passed, reflect on your past successes with reducing substance use and reasons for 
stopping or reducing use, and congratulate yourself for not giving into the craving. Many people try to cope with 
their urges by gritting their teeth and toughing it out. 
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Urge surfing 
from Steinberg et al. (2005)
Some urges, especially when you first return to your old using environment, are too strong to ignore. When this 
happens, it can be useful to stay with your urge to use until it passes. This technique is called urge surfing.
Urges are like ocean waves. They are small when they start, grow in size, and then break 
up and dissipate. You can imagine yourself as a surfer who will ride the wave, staying 
on top of it until it crests, breaks, and turns into less powerful, foamy surf. The basis of 
urge surfing is similar to that of many martial arts. In judo, one overpowers an opponent 
by first going with the force of the attack. By joining with the opponent’s force, one can 
take control of it and redirect it to one’s advantage. This type of technique of gaining control by first going with the 
opponent allows one to take control while expending a minimum of energy. Urge surfing is similar. You can join with 
an urge (rather than meet it with a strong opposing force) as a way of taking control of your urge to use. After you 
have read and become familiar with the instructions for urge surfing, you may find this a useful technique when you 
have a strong urge to use.
Urge surfing has three basic steps:
Take an inventory of how you experience the craving. Do this by sitting in a comfortable chair 1. 
with your feet flat on the floor and your hands in a comfortable position. Take a few deep breaths 
and focus inward. Allow your attention to wander through your body. Notice where in your 
body you experience the craving and what the sensations are like. Notice each area where you 
experience the urge, and tell yourself what you are experiencing. For example, “Let me see – my 
craving is in my mouth and nose and in my stomach”. 
Focus on one area where you are experiencing the urge. Notice the exact sensations in that area. For example, 2. 
do you feel hot, cold, tingly, or numb? Are your muscles tense or relaxed? How large an area is involved? 
Notice the sensations, and describe them to yourself. Notice the changes that occur in the sensation. “Well, 
my mouth feels dry and parched. There is tension in my lips and tongue. I keep swallowing. As I exhale, I can 
imagine the smell and taste of cannabis.”
Refocus on each part of your body that experiences the craving. Pay attention to and describe to yourself the 3. 
changes that occur in the sensations. Notice how the urge comes and goes.
Many people notice that after a few minutes of urge surfing the craving vanishes. The purpose of 
this exercise, however, is not to make the craving go away but to experience the craving in a new 
way. If you practise urge surfing, you will become familiar with your cravings and learn how to ride 
them out until they go away easily. 
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Decisional balance sheet
adapted from Hinton et al. (2002)
This worksheet will help you:
•  to think about the costs and benefits of your 
current cannabis use
•  to understand factors that affect your smoking 
decisions
•  to decide what you want to do about it
Thinking about your smoking
Thinking about your cannabis use, ask yourself:
“What do I stand to lose and what do I stand to gain by 
continuing my current cannabis patterns?”
“What role does cannabis play in my life?”
You might be getting some benefits from your smoking 
such as relaxation or social opportunities; but you may 
be experiencing some difficulties as well.
Making Up Your Mind exercise
One of the things that can help clarify your thoughts 
about your smoking is to list all the benefits and 
the costs of changing and of continuing your current 
cannabis use.
Look at the sample below and add your own comments. 
Continuing cannabis use at  
same level Cutting down my cannabis use Quitting cannabis
Good things I don’t have to change anything I wouldn’t spend as much My mood would improve
Not so good 
things
My partner would still be on 
my back
Once I start I find it hard to 
stop
I wouldn’t see my friends as 
much
Mark the positives and negatives that are most important to you, or another way is to rate each point on a scale of 
least important (1) to most important (10) and see which column has the biggest number.
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Cannabis Ladder
adapted from Slavet et al. (2006)
10 I have changed my cannabis use and will never go back to the way I used cannabis before.
9 I have changed my cannabis use, but I still worry about slipping back, so I need to keep working 
on the changes I’ve made.
8 I plan on using cannabis, but I’ll make some changes, like cutting back on the amount of 
cannabis that I use.
7 I definitely plan to change my cannabis use, and I’m almost ready to make some plans about 
how to change.
6 I definitely plan to change my cannabis use, but I’m not ready to make any plans about how  
to change.
5 I often think about the way that I use cannabis, but I have no plans to change.
4 I sometimes think about the way that I use cannabis, but I have no plans to change it.
3 I rarely think about changing my cannabis use, and I have no plans to change it.
2 I never think about changing the way that I use cannabis, and I have no plans to change.
1
I enjoy using cannabis and have decided never to change it. I have no interest in changing the 
way that I use cannabis.
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Cannabis-use diary
Day,  
date Where and with whom did you use? How were you feeling?
How much did you 
use (approx.)? Cost ($)
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Personalised feedback summary
adapted from Hinton et al. ( 2002)
Prepared for:
This personalised feedback summary will give you a picture of your current cannabis use.
How much is a problem?
•  You reported using cannabis on                  % of days last month.
•  You reported that you had                   bongs/joints last year.
•  You also consumed                   cigarettes, if you used a 50% mix
 (most cannabis-smokers use more than this in a mix).
•  This means that you spent $                   to $                  , depending on costs.
•  You spent                  hours in activities related to smoking cannabis.
Where does your cannabis smoking fit?
High
Very high
High
Medium
Low
No problem
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Relaxation training – for clinicians
Overview
Relaxation training involves a range of procedures to 
voluntarily release tension.
These techniques can be used in everyday situations 
when stress arises.
Goals
• recognise physical and psychological tension
• learn to relax in a total sense
• use mental imagery to reduce psychological 
tension
• use specific muscle groups to release tension
Method
• explain that in response to stress we have a flight-
or-flight response wherein the muscles become 
more tense, breathing becomes more rapid and 
shallow, and we become alert
• these reactions are normal, but when someone 
experiences stress for a long time, muscle tension 
can remain high and it can be difficult to recognise 
it as it can feel “normal”
• constant tension can cause anxious feelings and 
contribute to relapse
• effective relaxation starts with unchallenging 
situations and needs to be built upon to be able to 
be used in the face of stressful situations
• basic procedures can be taught in one to three 
sessions but needs to be practised regularly for 
up to eight weeks
• more practice brings more benefits
• relaxation techniques are implemented best 
with (a) a quiet environment, (b) a comfortable 
position (not in bed), (c) a passive attitude, and 
(d) techniques that promote tension reduction
Types of relaxation 
Progressive 
muscle 
relaxation 
Involves the active tensing and relaxing of 
muscle groups in the body in an ordered 
and progressive sequence
Meditative 
relaxation 
procedures
Mental relaxation that includes silently 
repeating a work like “relax” or pleasant 
imagery
Isometric 
procedures
Involve one muscle working against 
another
Most of the exercises do not involve 
any apparent movement so can be done 
without embarrassment
Corresponding worksheets: 
Tips for better sleep1. 
Relaxing your muscles2. 
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Worksheet  – Tips for better sleep
Go to bed only when sleepy.
Do not use your bed for anything except sleep and sexual activity. Do not read, watch television, eat, or worry in 
bed.
If you find yourself unable to sleep, get up and go into another room. Stay up as long as you 
wish, preferably engaging in a boring activity. Go back to bed only when you feel sleepy. If you 
are in bed for more than 20 minutes without falling asleep, get out of bed. Repeat this as often 
as is necessary.
Set your alarm and get up at the same time each day, regardless of how much sleep you had during the night. A 
constant wake-up time helps your body to acquire a consistent sleep rhythm. If you have trouble falling asleep, try 
to miss any naps you are having during the day, and see whether this improves your sleep.
Avoid physical activity in the late evening.
Avoid stimulants like tea, coffee, cocoa, or cigarettes before bedtime. 
Avoid alcohol, especially in the evening. Although alcohol may help you fall asleep more easily, it is 
likely to lead to disrupted sleep. Sleeping pills may help initially but can be unhelpful longer term. 
If you feel angry and frustrated because you cannot sleep, do not try harder and harder to sleep. 
This can make sleeping more difficult. Get out of bed, go to a different room, and do something 
different.
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Relaxing your muscles
When you practise at home, make sure that:
• you are wearing comfortable clothes
• you minimise distractions (turn your phone off, shut the blinds)
• you sit in a comfortable chair (your goal is to be relaxed while awake)
• you never strain your muscles; just tighten enough to notice the differences between when your muscles are 
tense and when they are relaxed
Steps:
Sit in a comfortable chair and close your eyes.1. 
Clench the muscles in your face and jaw. Don’t strain the muscles; just tighten them. Now, let go slowly. 2. 
Concentrate on the release of tension.
Lift up your shoulders and put your head back. Don’t strain your muscles; just tighten them. Now, let go 3. 
slowly, releasing the tension. Let your shoulders drop, and straighten your head.
Hold your arms out straight out in front of you, and make a fist with your hands. Don’t strain your muscles; 4. 
just tighten them. Now, let go slowly, releasing the tension. Let your arms fall down gently.
Tighten your stomach muscles. Don’t strain your muscles; just tighten them. Now, let go slowly. Concentrate 5. 
on the release of tension.
Stretch your legs, and tighten your leg muscles. Don’t strain your muscles; just tighten them. Now, let go 6. 
slowly. Release all the tension. Let your feet gently fall back to the floor.
Sit for a while and enjoy the warm and heavy feeling in your muscles. When you get up, try to keep this calm 7. 
feeling.
Try to practise relaxation every day, for best results.8. 
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Cannabis withdrawal syndrome – 
client information
Many regular cannabis users are likely to experience 
some withdrawal symptoms; others may have little or 
no discomfort upon stopping use. For many users, the 
psychological symptoms are most difficult. There are 
also a number of physical symptoms, which can be 
uncomfortable but are not dangerous.
Common symptoms Less common symptoms
Anger
Aggression
Irritability
Nervousness/anxiety 
Chills
Stomach pains
Shakiness
Sweating
Appetite changes
Restlessness
Sleep difficulties
Strange dreams
Depressed mood 
Withdrawal symptoms are actually signs that the 
body is recovering and re-adapting to being cannabis 
free, so they are positive signs of recovery. Generally 
speaking, withdrawal symptoms resolve within five to 
ten days. Some symptoms, such as developing good 
sleeping patterns, generally take longer.
Quitting tobacco at the same time
Many people who smoke cannabis either smoke 
tobacco or mix tobacco in with their cannabis. If you 
mix tobacco in with cannabis, it is likely that some 
of your withdrawal symptoms are caused by tobacco 
withdrawal.
Being in withdrawal from both doesn’t mean that it 
will be twice as hard or bad, and research tells us 
that it is better to quit both tobacco and cannabis 
simultaneously. If you are worried about your ability 
to quit both tobacco and cannabis at the same time, 
discuss possible nicotine replacement treatments with 
your doctor.
Treatment options
There are a number of drug-treatment options 
available in Australia. Some treatment options 
include counselling, support groups, and education 
groups. You can also call the Cannabis Information 
and Helpline on 1800 30 40 50 or contact your local 
Alcohol Drug Information Service. At this stage, there 
are no medications available to help specifically 
with cannabis withdrawal, although your GP may 
recommend medication for other issues, such as low 
mood or sleeping difficulties. This will depend on your 
individual situation.
Monitoring withdrawal symptoms
You may like to copy and use this table to monitor your 
withdrawal symptoms over the course of one week by 
placing a tick in the space next to each symptom. You 
will see the number and severity of symptoms reduce 
quite quickly.
Managing withdrawal symptoms 
Symptoms Mild Moderate Severe
Depressed mood
Changes in appetite
Sleep difficulty 
Sweating/night sweats
Cravings for cannabis
Restlessness/irritability
Aggression/anger
Headaches
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Cannabis-withdrawal syndrome – Client information continued
Develop a withdrawal management plan with a friend, family member, or clinician. This may include:
• removing all smoking implements, to remove temptation
• making an extra effort to eat well and do some gentle exercise
• writing down the pros and cons of quitting, and displaying this somewhere where you will look at it often
• not planning too many stressful things like deadlines in the first few weeks after quitting, but planning 
enjoyable activities to distract you from use
• finding a friend or someone else who will support you and help distract you from the urges
• trying not to beat yourself up if you have a lapse
• planning a reward for yourself once you have achieved your goal
Pros of quitting/cutting down Cons of quitting/cutting down
1 1
2 2
3 3
4 4
5 5
6 6
Make an appointment to see your doctor/clinician to monitor your progress and to develop strategies to consolidate 
and build on your success.
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Problem-solving skills – for clinicians 
adapted from Steinberg et al. (2005)
Overview
• problem solving is appropriate for all drug issues and can be applied regardless of whether clients are looking 
to reduce or abstain
• these skills can be applied in group or individual settings
• the basics of these skills can be taught in session but need to be practised, refined, and reinforced to be 
effective
Goals
• recognise a problem’s existence
• generate a variety of potential solutions
• select the more appropriate options, and generate an action plan
• evaluate the effectiveness of the approach
Process Details
 Defining exactly what the  
problem is
Define the problem in terms of concrete behaviours•	
If multiple behaviours exist, ask the client to prioritise•	
Brainstorming options to deal with  
the problem
No criticism is allowed•	
Be as creative as possible•	
Number of ideas is important•	
What has worked before?•	
Choosing the best option(s) Delete impractical strategies•	
Consider pros and cons of each viable option•	
Discuss any issues that may hinder action of option•	
Generating a detailed action plan Break up actions into concrete steps•	
Decide when, where, how, and with whom•	
Putting the plan into action Practise actions in session through role plays and home practice exercises•	
Evaluating the results Does the option resolve the problem in total or only in part?•	
Does the strategy need improving, or is a new strategy needed?•	
Corresponding worksheet: Problem-solving worksheet – client worksheet
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Problem-solving worksheet —client worksheet 
adapted from Steinberg et al. (2005)
1.  A problem I would like to solve:
2.  What can I do? (Brainstorm all creative ideas):
3.  Pros and cons of each solution
Possible solution Benefits Costs
Which one will I choose?
4.  Action plan
How?
When?
Where?
With whom?
5. How did it go?
Good things Not so good things
Try this process again?
Yes No
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Relapse prevention – for clinicians 
Overview
• relapse prevention (RP) should be included in all treatment programs
• relapse is so common that it should be viewed as a normal part of the change process
• RP helps to prevent relapses and also to learn from experiences
• RP may draw on other skills such as problem solving, challenging negative thoughts, etc
Key concepts
• identifying high-risk situations and developing skills to deal with triggers
• distinguishing between some use (slip or lapse) and return to regular use (relapse)
Process Details
Enhancing the 
commitment  
to change
A high-quality resolution to change is an importance aspect of moderating use or maintaining 
abstinence
Discuss the reasons for change, and write them down so that they can be used as reminders 
and motivators
Identifying high-risk 
situations
Details: when, where, with whom, doing what, and feeling what
A diary can capture this, or questionnaires such as the Cannabis Situational Confidence Scale
Teaching coping and 
other useful skills
Clients are to implement coping skills when clients have the confidence to handle a high-risk 
situation (see problem-solving worksheet)
Other skills may include coping with social pressure, coping with mood disturbances, craving 
management (see urge-surfing worksheet)
Other helpful hints to 
avoid temptation
One of the most useful strategies for dealing with high-risk situations is planning ahead. 
Another is recognising “seemingly irrelevant decisions” (see worksheet)
Preparing for lapse Saunders and Allsop (1991) suggest you do a “relapse drill” similar to a fire drill, in which you 
create a plan for preventing a slip from becoming a full-scale relapse. This involves identifying 
emotional and situational factors
Other lifestyle issues 
important to maintaining 
change
Factors such as social networks, support networks (including self-help groups), 
communication skills, and engagement in hobbies are important aspects of treatment 
success
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Cannabis-use risk hierarchy
adapted from Hinton et al. (2002)
Degree  
of risk
(0–10) Situation Management strategies
Degree of risk            10: Severe            7: Moderate             4: Mild              0: Nil
a clinician’s guide
108
Principles of cannabis refusal skills
adapted from Hinton et al. (2002)
Refusal skills consist of six easy-to-use strategies:
1.  BE ASSERTIVE in body language and tone of voice.
  Make direct eye contact. Stand or sit at the same level as or above the person offering you cannabis. Use a strong, firm, 
confident voice. Those offering cannabis are more likely to persist when an individual doesn’t look or sound convincing.
2.  Without hesitation, SAY NO. Remember, he (or she) who hesitates is lost!
  Be firm but polite. “No” can then be expanded with a message about your intentions in the future to prevent further 
offers. For example:
No. Sorry, hadn’t you heard? I’ve quit.•	
No, thanks, doctor’s orders.•	
Sorry, but I’ve been coughing up my lungs, and I’m sick of it. Not tonight, thanks.•	
No, thanks, I’m not feeling too good.•	
Not for me, I don’t enjoy it any more.•	
No, thanks. Not today. I’m taking a break from it.•	
Thanks, but no, thanks. I’m on the straight and narrow these days.•	
No, thanks. I’m driving.•	
3.  SUGGEST AN ALTERNATIVE ACTIVITY rather than using cannabis.
It might be useful to suggest activities in non–drug-using environments: No, thanks…•	
What about getting a video?•	
Who’s up for a game of basketball?•	
Feel like phoning… to see what he’s doing?•	
What about a movie?•	
4.  When challenged, REPEAT YOURSELF, then CHANGE THE SUBJECT.
 a)  People get the message that you won’t change your mind when it is repeated, without variation, over and over.
I’d rather not go into the details, but I really can’t because of my health.•	
Not for me tonight, but you go right ahead.•	
This is hard enough – please help me stick to my guns.•	
I’d really prefer a coffee – can I make one for anyone else?•	
 b)  Change the topic to non-cannabis related topics. This gives the message that discussion is over. For example:
No, thanks. What do you want to do tonight?•	
No, thanks. How much should you pay for a reasonable car?•	
No, thanks. Do you think vampires would be scared of Buffy the vampire slayer?•	
No, thanks. Did you know there’s a sale on at the surf shop?•	
5.  AVOID EXCUSES AND VAGUE ANSWERS
  Remember the KIS principle: Keep It Simple! Stick to the point – NO. Getting involved in long, drawn-out excuses can 
backfire, resulting in equally long discussions about the positive things about using cannabis. These discussions only 
make it harder to refuse.
6.  If all else fails, LEAVE.
  If people will not take “No” for an answer, and if you feel your commitment to saying NO is wavering, avoidance is the 
best policy. Leave!
If you guys aren’t doing anything, I might catch up with you tomorrow.•	
If it’s a hassle, I can leave and catch up with you later.•	
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The “psychological squirm” worksheet – clinician
adapted from Hinton et al. (2002)
To proceed, first the client is asked:
Describe your good qualities. Describe the good things about yourself.
The client and clinician explore the more positive aspects of the client by constructing a list of qualities.
 
The clinician then asks the client:
Now how would you describe a cannabis user?
This is explored thoroughly before the clinician asks the client to compare these two lists. For example:
What do you think of these two lists: how well do they fit together?
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Pleasant activities
from Macphillamy & Lewinsohn (1982)
In stopping your cannabis use, you are giving up an activity that has taken up a great deal of your time. It is important 
that you identify other activities that bring you pleasure, and integrate them into your everyday life.
Your assignment is to do something nice for yourself every day, something you wouldn’t necessarily spend the time, 
effort, or money to do for yourself otherwise. You may need to get your partner’s, supporter’s, or someone else’s 
cooperation to do this, but don’t hesitate to ask.
It doesn’t matter whether it’s having dinner out, shopping for something you’ve been wanting, taking a hot bath, 
jogging – it should be something that makes you feel as if you’re treating yourself. You deserve it! If it involves 
spending a little more money than usual, remember that you’ll be saving money by not smoking cannabis. You’ll 
gradually find ways to treat yourself that are less expensive. Keep a record of these over the next week, and we’ll 
discuss them next time.
Some examples:
Movies; watching TV; listening to music; playing computer games; playing cards; solving a puzzle; reading; playing 
a musical instrument; yoga; exercise; drawing; painting; cooking; photography; gardening; eating; e-mailing a 
friend; massage; drinking tea or coffee; having a bath; taking a nap; visiting a beautician; meditation; swimming; 
booking a holiday; going to a market, park, or museum; shopping; watching sport; internet chat; writing in a diary; 
wearing clothes you like; hanging out with friends; dancing; riding a bike; telling a joke; surfing the internet; going 
to a garage sale; going for a drive.
Day
Plan for increasing pleasant activities
(List at least one target for each day)
Follow-up 
(What did you end up doing, each day?)
1
2
3
4
5
6
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Managing negative moods and depression 
adapted from Kadden et al. (2004) 
Use the Three As to overcome your depression.
1.  Be aware of the symptoms of depression:
•  be aware of your moods and the situations that influence them
•  be aware of your automatic negative thoughts
2.  Answer or respond to these thoughts:
•  ask questions, and challenge the assumptions behind these thoughts
•  replace the negative thoughts with positive ones
3.  Act differently:
•  increase your positive activities
•  decrease your involvement in unpleasant activities
•  reward yourself for the positive steps you’re taking
Practice exercise
Use this worksheet to become aware of the issues involved in your depression and the steps you can take to 
change your moods.
1.   What are the ways in which I show my depression in my moods, attitudes, and actions? What are my symptoms?
2.   What are the automatic negative thoughts that go along with my depression? What do I think about myself, my 
current situation, and my world in general? 
3.   What questions can I ask myself to challenge these automatic negative thoughts?
4.   What steps am I going to take to act differently? What problem-solving strategies have I come up with to cope with 
my problems? What pleasant activities might I increase? What unpleasant activities might I avoid or minimise? 
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Assess importance of making a change in cannabis use – clinicians 
To assess the importance of making a change in current cannabis use, ask clients:
“ On a scale of one to ten, how important is it for you to make a change in your substance use?”
If the importance of making a change is
Low:
“ OK, so it is not that important to you at this time. I wonder whether I can provide you with a little information about 
[substance]? Even if you don’t want to make a change in your substance use, there is some information I can give you 
on how to reduce the harms associated with use.”
If it is not important to change substance use, explore the Stages of Change diagram and discuss what stage of 
change the person is at. Advise the person that it is common to move back and forth between stages.
Medium:
“ So, about the middle. But I’m wondering, why did you say a ‘4’ and not a ‘1’? So, one reason it’s important is… What 
else?”
High: 
“ So, it’s very important for you to do something about your cannabis use. Why is that? So, one reason it’s important 
is… What else?”
Follow up those clients who see change as important by asking about their plans to make this important change, 
with a goal of eliciting change talk.
For clients with 
mental health 
problems
Assess separately the importance of making a change in substance use and in depressive/anxiety 
symptoms. The above questions should be asked first about depressive/anxiety symptoms, and then  
about substance use, as this is more likely to decrease the young person’s resistance toward substance  
use changes
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Assess confidence of making a change in cannabis use – clinicians
Assess individual’s confidence to change their cannabis use:
“ On a scale of one to ten, how confident are you that you could make a change if you wanted to?”
Explore the person’s confidence in making a change by asking:
If the importance of making a change is:
Low:
“ Pretty low. What would it take to raise that ‘1’ up to, say a ‘5’? Tell me about a change you made in the past. How did 
you go about it?”
Medium:
“ So, about in the middle. But why a ‘4’ and not a ‘1’? What else? What would it take to raise your confidence to say, an 
‘8’? How would you go about it? How can I be of help?”
High:
“ So, you’re quite confident. How would you go about it? What would it look like? What else? How can I be of help?”
Note: A lack of confidence on the scale (less than 7) indicates it may be necessary to return to Phase I motivational 
interviewing strategies or review strategies included in the change plan. 
For clients with 
mental health 
problems
Assess confidence in making a change for both anxiety/depression and substance use separately. If the 
person is low in confidence about addressing anxiety/depression but not substance use (or vice versa), 
address accordingly by returning to MI strategies or reviewing change strategies
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appendices
Appendix 1: Levels of evidence
The following five steps were implemented 
Grade each of the five components and note any 1. 
important issues arising in the discussion and 
grading on the form. 
Write an evidence statement summarising briefly 2. 
the assessment of the five separate components. 
The grades for each of the components and 3. 
the accompanying descriptor (excellent, good, 
satisfactory, poor) should be written in the 
relevant boxes. 
Determine the overall grade for the body of 4. 
evidence by summing the individual component 
grades. 
Formulate a recommendation based on this body 5. 
of evidence. The recommendation should address 
the original clinical question and ideally be written 
as an action statement.
Grading matrix
Component 
A B C D 
Excellent Good Satisfactory Poor 
Volume of evidence Several level I or 
II studies with low 
risk of bias 
One or two level II 
studies with low 
risk of bias or a SR/
multiple level III 
studies with low risk 
of bias 
Level III studies with 
low risk of bias, or 
level I or II studies 
with moderate risk 
of bias 
Level IV studies, or level I to 
III studies with high risk of 
bias 
Consistency All studies 
consistent 
Most studies 
consistent and 
inconsistency may be 
explained 
Some inconsistency 
reflecting genuine 
uncertainty around 
clinical question 
Evidence is inconsistent 
Clinical impact Very large Substantial Moderate Slight or restricted 
Generalisability Population/s 
studied in body of 
evidence are the 
same as the target 
population for the 
guideline 
Population/s 
studied in the body 
of evidence are 
similar to the target 
population for the 
guideline 
Population/s studied 
in body of evidence 
different to target 
population for 
guideline but it is 
clinically sensible to 
apply this evidence 
to target population
Population/s studied in 
body of evidence different to 
target population and hard to 
judge whether it is sensible 
to generalise to target 
population 
Applicability Directly applicable 
to Australian 
healthcare context 
Applicable to 
Australian healthcare 
context with few 
caveats 
Probably applicable 
to Australian 
healthcare context 
with some caveats 
Not applicable to Australian 
healthcare context 
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